 
 
   
 
 
CLINICAL  STUDY PROTOCOL  
 
 
A Phase Ib /II open label study to assess the safety and pharmacokinetics of 
NUC -3373, a nucleotide analogue, given in combination with standard 
agents used in colorectal cancer treatment  
 
 
IMP  NUC -3373  
Protocol Number  NuTide:[ADDRESS_430910]  2022 
Development Phase  Ib/II 
IND Number  [ADDRESS_430911]  Number  [STUDY_ID_REMOVED]  
Sponsor:  NuCana plc  
[ADDRESS_430912]  
Edinburgh, EH12 9DT, [LOCATION_006]  
Telephone: +44 (0)[PHONE_7187]  
Email: nutide302 @nucana.com  
Approval:   
 
[CONTACT_347073] , MD  
PhD  
SVP, Clinical & Medical 
Development    
 
Date  
Medical Monitor:  [CONTACT_347074] , MD  PhD 
Executive Medical Director, Global Oncology  
Clinipace  
Tel: +[PHONE_7188]  
CONFIDENTIALITY STATEMENT  
This confidential document is the property of NuCana plc. No unpublished information 
contained herein may be disclosed without prior written approval from NuCana.  
Access to this document must be restricted to relevant parties .  

NuTide:302                                                                                                                        Version 4.2, 10 Aug 2022 
Confidentia l                                                            NuCana  plc 1  
 
 
 
 
 
 
PRINCIPAL INVESTIG ATOR AGREEMENT  
AND SIGNATURE  
 
 
A Phase Ib /II open label study to assess the safety and pharmacokinetics of 
NUC -3373, a nucleotide analogue, given in combination with standard 
agents used in colorectal cancer treatment  
 
Protocol Number  NuTide:302  
Protocol Version, Date  Version 4.2, 10 Aug 2022 
IMP  NUC -3373  
Development Phase  Ib/II 
Sponsor  NuCana plc 
IND Number  [ADDRESS_430913] Number  [STUDY_ID_REMOVED]  
 
 
This study will be conducted in compliance with the clinical study protocol (and amendments), 
International Co uncil for Harmonis ation guidelines for current Good Clinical Practice 
(ICH -GCP) and applicable regulatory requirements . Compliance with ICH -GCP standards 
provides assurance that the rights, safety, and wellbeing of study patients are protected, 
consistent with t he principles that have their origin  in the Declaration of Helsinki.  
 
 
 
 
Principal Investigator’s s ignature  
 
 
  Date  (dd-mmm-yyyy)  
Principal Investigator’s n ame (printed)     
  

NuTide:[ADDRESS_430914] OF TABLES  ................................ ................................ ................................ ...... 8 
PROTOCOL SYNOPSIS ................................ ................................ ..............................  9 
OVERALL STUDY DESIGN  ................................ ................................ ....................  28 
SUMMARY SCHEDULE OF EVENTS: ARM 1A AND ARM 1B  .........................  29 
SUMMARY SCHEDULE OF EVENTS: ARM 1C AND ARM 1D  .........................  33 
SUMMARY SCHEDULE OF EVENTS: PART 2 (ALL ARMS)  ............................  37 
SUMMARY SCHEDULE OF EVENTS: PART 3  ................................ ....................  41 
SUMMARY SCHEDULE OF EVENTS: PK SUB -STUDY (PART 2 ARM  2B; 
CYCLE 1 AND CYCLE 2 DAYS 1 AND 2)  ................................ ..........  45 
ABBREVIATIONS  ................................ ................................ ................................ .... 49 
1. INTRODUCTIO N AND STUDY RATIONALE  ................................ ... 52 
1.1. Treatment Options for Recurrent Colorectal Cancer  ...............................  52 
1.2. 5-FU in Colorectal Cancer  ................................ ................................ ....... 52 
1.2.1  Adjuvant Treatment  ................................ ................................ .................  52 
1.2.2  Treatment for Metastatic Disease  ................................ ............................  52 
1.3. Limitations of 5 -FU Treatment  ................................ ................................  53 
1.3.1  Susceptibility to Breakdown  ................................ ................................ .... 53 
1.3.2  Requirement of Activation  ................................ ................................ ...... 55 
1.3.3  Dosing Administration Challenges  ................................ ..........................  55 
1.4. NUC -3373  ................................ ................................ ................................  55 
1.4.1  Non Clinical Data  ................................ ................................ ....................  56 
1.5. Clinical Data  ................................ ................................ ............................  57 
1.6. Pharmacokinetics  ................................ ................................ .....................  59 
1.6.1  Plasma Levels  ................................ ................................ ..........................  59 
1.6.2  Intracellular Levels  ................................ ................................ ..................  59 
1.7. Study Rationale  ................................ ................................ ........................  59 
2. STUDY OBJECTIVES AND ENDPOINTS  ................................ ...........  62 
2.1. Primary Objectives  ................................ ................................ ..................  62 
2.2. Secondary Objectives  ................................ ................................ ..............  62 
2.3. Exploratory Objectives  ................................ ................................ ............  62 
2.4. Primary Endpoints  ................................ ................................ ...................  63 
NuTide:302                                                                                                                        Version 4.2, 10 Aug 2022 
Confidentia l                                                            NuCana  plc 3 2.5. Secondary Endpoints  ................................ ................................ ...............  63 
2.5.1  Safety (Phase Ib and Phase II)  ................................ ................................ . 63 
2.5.2  Pharmacokinetics (Phase Ib and Phase II)  ................................ ...............  63 
2.5.3  Efficacy Endpoints (Phase Ib)  ................................ ................................ . 64 
2.6. Exploratory Endpoints (Phase Ib and Phase II)  ................................ ....... 64 
3. INVESTIGATIONAL PLAN  ................................ ................................ .. 65 
3.1. Overall Study Design  ................................ ................................ ...............  65 
3.1.1  Part 1  ................................ ................................ ................................ ........  67 
3.1.2  Part 2  ................................ ................................ ................................ ........  68 
3.1.3  Part 3  ................................ ................................ ................................ ........  70 
3.1.4  PK Sub -study  ................................ ................................ ...........................  71 
3.2. Rationale for the NUC -3373 Dose Selected  ................................ ............  71 
3.3. Study Treatment  ................................ ................................ .......................  72 
3.4. Dose Escalation Guidelines  ................................ ................................ ..... 78 
3.4.1  Definition of Dose -Limiting Toxicity  ................................ .....................  78 
3.5 Duration of Patient Participation  ................................ .............................  79 
3.6 Study Completion  ................................ ................................ ....................  79 
4 PATIENT SELECTION  ................................ ................................ ..........  80 
4.1 Inclusion Criteria  ................................ ................................ .....................  80 
4.2 Exclusion Criteria  ................................ ................................ ....................  83 
4.3 Waivers to Entry Criteria  ................................ ................................ .........  85 
5 STUDY ASSESSMENTS AND PROCEDURES ................................ ... 86 
5.1 Informed Consent  ................................ ................................ ....................  86 
5.1.1  Informed Consent for Tumour Tissue Collection  ................................ .... 86 
5.2 Patient Registration and Screening Procedures  ................................ ....... 86 
5.3 Screening Assessments  ................................ ................................ ............  87 
5.4 Re-Screening Patients who Fail Screening  ................................ ..............  88 
5.5 Evaluations to be Performed during the Study  ................................ ........  88 
5.5.1  Cycle 0 (Arm 1a and Arm 1b)  ................................ ................................ . 89 
5.5.2  Each cycle, Day 1  ................................ ................................ ....................  90 
5.5.3  Cycle 1 ONLY – Days 1, 2 & 3, and Days 15 & 16  ...............................  91 
5.5.4  Cycle 1 ONLY – Day 8 (or Day 15)  ................................ ........................  92 
5.5.5  Cycle 3 – Days 1 & 15 (C3D1 & C3D15; all cohorts)  ............................  92 
5.5.6  Each cycle, Day 8 (Q1W dosing cohorts only)  ................................ ....... 92 
5.5.7  Each cycle, Day 15 (all cohorts)  ................................ ..............................  93 
NuTide:[ADDRESS_430915] c                                                             Confidential  4 5.5.8  Each cycle, Day 22 (Q1W cohorts only)  ................................ .................  94 
5.5.9  PK sub -study (Part 2, Arm 2b): Cycle 1 and Cycle 2 D1/D2 ONLY  ...... 96 
5.5.10  Every 8 weeks (±7 days) from Cycle 1 Day 1 until disease progression,  
initiation of a new treatment or death  ................................ ......................  97 
5.5.11  End of Treatment Visit  ................................ ................................ ............  98 
5.5.12  Long -Term Follow -Up ................................ ................................ ............  99 
6 PATIENT WITHDRAWAL  ................................ ................................ .. 100 
6.1 End of Treatment  ................................ ................................ ...................  100 
6.2 Consent Withdrawal  ................................ ................................ ..............  101 
6.3 Patient Evaluability and Replacement  ................................ ...................  101 
7 SAMPLES FOR LABORATORY ANALYSIS  ................................ ... 102 
7.1 Clinical Laboratory Tests  ................................ ................................ ...... 102 
7.2 Pharmacokinetics  ................................ ................................ ...................  102 
7.2.1  PK Sub -study  ................................ ................................ .........................  104 
7.3 Pharmacodynamics (Part 1 only)  ................................ ...........................  106 
7.4 Exploratory Biomarkers  ................................ ................................ .........  106 
7.5 Tumour Tissue Sample Submission  ................................ ......................  106 
7.6 Labelling and Confidentiality of Biological Samples ............................  106 
7.7 Withdrawal of Consent for Biological Sample Collection or Retention
 ................................ ................................ ................................ ...............  107 
8 INVESTIGATIONAL MEDICINAL PRODUCTS  ..............................  108 
8.1 NUC -3373  ................................ ................................ ..............................  108 
8.1.1  NUC -3373 Description  ................................ ................................ ..........  108 
8.1.2  NUC -3373 Supplies and Study Drug Packaging  ................................ ... 108 
8.1.3  Handling and Storage of NUC -3373  ................................ .....................  108 
8.1.4  Preparation of NUC -3373  ................................ ................................ ...... 108 
8.1.5  NUC -3373 Administration  ................................ ................................ .... 108 
8.2 Other IMPs (Agents to be used in Combination with NUC -3373) ........  109 
8.3 Administration of NUC -3373 and other IMPs  ................................ ...... 109 
8.3.1  Part 1  ................................ ................................ ................................ ...... 109 
8.3.2  Part 2  ................................ ................................ ................................ ...... 111 
8.3.3  Part 3  ................................ ................................ ................................ ...... 113 
8.4 NUC -3373 Drug Destruction  ................................ ................................ . 116 
8.5 NUC -3373 Study Drug Accountability  ................................ .................  116 
8.6 Management of Overdose of NUC -3373  ................................ ...............  117 
9 DOSE MODIFICATIONS  ................................ ................................ .... 118 
NuTide:302                                                                                                                        Version 4.2, 10 Aug 2022 
Confidentia l                                                            NuCana  plc 5 9.1 Criteria for Continuation of Treatment  ................................ ..................  119 
9.2 Dose Modifications (Dose Delays and Dose Reductions)  .....................  119 
9.3 Suggested Management of Toxicity  ................................ ......................  121 
9.3.1  Nausea and Vomiting  ................................ ................................ ............  121 
9.3.2  Diarrhoea  ................................ ................................ ...............................  121 
9.3.3  Mucositis  ................................ ................................ ................................  122 
9.3.4  Palmar -Plantar Erythrodysesthaesia (hand -foot syndrome)  ..................  122 
9.3.5  Dermatologic Toxicity  ................................ ................................ ...........  122 
9.3.6  Infusion Reactions  ................................ ................................ .................  123 
9.3.7  Ocular Toxicity  ................................ ................................ ......................  123 
9.3.8  Fatigue  ................................ ................................ ................................ ... 123 
9.3.9  Combinat ion Therapi[INVESTIGATOR_014]  ................................ ................................ ..........  123 
[IP_ADDRESS]  Oxaliplatin  ................................ ................................ .............................  123 
[IP_ADDRESS]  Irinotecan  ................................ ................................ ...............................  124 
[IP_ADDRESS]  Bevacizumab  ................................ ................................ ..........................  124 
[IP_ADDRESS]  EGFR inhibitors  ................................ ................................ .....................  124 
10 OTHER TREATMENTS (NON -IMP)  ................................ ..................  126 
10.1  Support Medication  ................................ ................................ ...............  126 
10.2  Haematopoietic Growth Factor Support  ................................ ................  126 
10.3  Concomitant Medications  ................................ ................................ ...... 126 
10.3.1  Contraception Methods  ................................ ................................ ..........  126 
10.3.2  Prohibited Therapy  ................................ ................................ ................  127 
10.3.3  Therapy to be Used with Caution  ................................ ..........................  127 
10.3.4  COVID -19 Vaccinations  ................................ ................................ ....... 128 
11 TUMOUR RESPONSE ASSESSMENTS  ................................ ............  129 
11.1  Tumour Measurements and Assessment of Disease Response  .............  129 
12 SAFETY REPORTING  ................................ ................................ .........  130 
12.1  Definitions  ................................ ................................ .............................  130 
12.2  Adverse Event Reporting  ................................ ................................ ....... 131 
12.3  Assessment of Causality to Study Drug(s)  ................................ ............  132 
12.4  Assessment of Severity  ................................ ................................ ..........  132 
12.5  SAE Reporting  ................................ ................................ .......................  133 
12.6  Expedited Reporting of SAEs  ................................ ................................  134 
12.7  S[LOCATION_003]R Reporting  ................................ ................................ .................  134 
12.8  Terms and Grading of Adverse Events and Toxicities  ..........................  134 
NuTide:[ADDRESS_430916] c                                                             Confidential  6 12.9  Pregnancy  ................................ ................................ ..............................  134 
12.10  Events Exempt from being Reported as AE/SAEs  ................................  135 
12.10.1  Progression of Underlying Disease  ................................ .......................  135 
12.10.2  Death on Study Attributed to Malignancy  ................................ .............  135 
12.10.3  Elective Admissions and Supportive Care  ................................ ............  135 
12.11  Informing Investigators of New Safety Information  .............................  135 
12.12  Reference Safety Information (RSI) for Assessment of Expectedness  . 135 
12.13  Data Safety Monitori ng Committee (DSMC)  ................................ ........  136 
13 STATISTICAL CONSIDERATIONS  ................................ ..................  137 
13.1  Sample Sizes  ................................ ................................ ..........................  137 
13.2  Missing, Unused and Spurious Data  ................................ ......................  137 
13.3  Analysis Populations  ................................ ................................ .............  137 
13.3.1  Safety Population  ................................ ................................ ...................  137 
13.3.2  Full Analysis Set  ................................ ................................ ....................  138 
13.3.3  Evaluable for Response Set  ................................ ................................ ... 138 
13.3.4  PK Analysis Set  ................................ ................................ .....................  138 
13.4  Patient Disposition  ................................ ................................ .................  138 
13.5  Statistical Methods  ................................ ................................ .................  139 
13.5.1  Demographics and Baseline Data  ................................ ..........................  139 
13.5.2  Concomitant Medications  ................................ ................................ ...... 139 
13.5.3  Extent of Exposure  ................................ ................................ ................  139 
13.5.4  Safety Analysis  ................................ ................................ ......................  139 
13.5.5  Efficacy Analysis  ................................ ................................ ...................  142 
13.5.6 Pharmacodynamic Endpoints (Part 1 only)  ................................ ...........  144 
13.5.7  Primary and Interim Analyses  ................................ ...............................  145 
13.5.8  Changes to the Planned Statistical Methods  ................................ ..........  145 
14 PATIENT DATA HANDLING AND CONFIDENTIALITY  ..............  146 
14.1  Case Report Forms  ................................ ................................ ................  146 
14.2  Monitoring of the Study  ................................ ................................ .........  146 
14.3  Patient Confidentiality  ................................ ................................ ...........  147 
15 ETHICAL AND REGULATORY CONSIDERATIONS  .....................  148 
15.1  Good Clinical Practice Compliance  ................................ .......................  148 
15.2  Institutional Review Boards/ Ethics Committees  ................................ .. 148 
15.3  Regulatory Authority Approval  ................................ .............................  148 
15.4  Protocol Amendments  ................................ ................................ ...........  148 
NuTide:302                                                                                                                        Version 4.2, 10 Aug 2022 
Confidentia l                                                            NuCana  plc 7 15.5 Protocol Violations and Deviations  ................................ .......................  148 
15.6  Serious Breaches  ................................ ................................ ....................  149 
15.7  Study Reporting Requirements  ................................ ..............................  149 
15.8  Financial disclosure  ................................ ................................ ...............  149 
15.9  Investigator Documentation  ................................ ................................ ... 149 
15.10  Study Records Retention  ................................ ................................ ....... 149 
15.11  Audit and Regulatory Inspection  ................................ ...........................  150 
16 PUBLICATION POLICY  ................................ ................................ ..... 151 
16.1  Communication of Results by [CONTACT_2728]  ................................ .................  151 
16.2  Publication by [CONTACT_4718]  ................................ ................................ .. 151 
17 REFERENCES  ................................ ................................ ......................  152 
18 APPENDICES  ................................ ................................ .......................  155 
APPENDIX  1. RESPONSE EVALUATION CRITERIA IN SOLID TUMOURS 
(RECIST) VERSION 1.1  ................................ ................................ ....... 155 
APPENDIX  2. ECOG PERFORMANCE SCALE  ................................ ................  160 
APPENDIX  3. CONCOMITANT MEDICATIONS THAT MAY PROLONG QT C 
INTERVAL  ................................ ................................ ...........................  161 
APPENDIX  4. MANAGEMENT GUIDE FOR DIARRHOEA  ...........................  164 
 
  
NuTide:[ADDRESS_430917] OF FIGURES  
Figure 1  NuTide:302 study schema  ................................ ................................ ....... 65 
Figure 2  NuTide:302 Part 1 stu dy schema  ................................ .............................  67 
Figure 3  NuTide:302 Part 2 study schema  ................................ .............................  68 
Figure 4  NuTide:[ADDRESS_430918] OF TABLES  
Table 1  NuTide:301 dose escalation, treatment schedule, and enrolment  ............  58 
Table 2  NUC -3373 safety profile (Part 1 of NuTide:302)  ................................ .... 61 
Table 3  Patient populations  ................................ ................................ ...................  66 
Table 4  Part 2 expansion phase treatment arms  ................................ ....................  69 
Table 5  Part 3 treatment arms  ................................ ................................ ...............  70 
Table 6  Anticipated dose levels of NUC -3373 to be evaluated in Part 1  .............  73 
Table 7  Study treatment in Arm 2a  ................................ ................................ ....... 74 
Table 8  Anticipated dose levels of agents to be evaluated in Arm 2a  ..................  74 
Table 9  Study treatment in Arm 2b  ................................ ................................ ...... 75 
Table 10  Anticipated dose levels of NUC -3373 to be evaluated in Arm 2b  ..........  75 
Table 11  Study treatment in Arm 2c  ................................ ................................ ....... 75 
Table 12  Study treatment in Arm 2d  ................................ ................................ ...... 76 
Table 13  Study treatment in PK sub -study  ................................ .............................  77 
Table 14  Dose escalation guidance rules  ................................ ................................  78 
Table 15  PK sampling schedule (Main study ) ................................ ......................  103 
Table 16  PD sampling schedule (Part 1 only)  ................................ ......................  [ADDRESS_430919] details  ................................ .........................  133 
NuTide:302                                                                                                                        Version 4.2, 10 Aug 2022 
Confidentia l                                                            NuCana  plc 9  PROTOCOL SYNOPSIS  
Study  
Title  A Phase Ib /II open label study to assess the safety and pharmacokinetics 
of NUC -3373, a nucleotide analogue, given in combination with standard 
agents used in colorectal cancer treatment  
Protocol 
Number  NuTide:[ADDRESS_430920] 
Number  [STUDY_ID_REMOVED]  
Phase  Ib/II 
Objectives  This study consists of two phases (Phase Ib and Phase II) and includes three 
study parts (Parts 1, 2 and 3) with several treatment arms within each part. 
Phase Ib includes Part  1 (Arms 1a -1d) and Part 2 (Arms 2a -2d) and Phase  II 
includes Part 3 (Arms 3a -3g). 
Primary Objective s 
Phase Ib  
• To identify a recommended dose and schedule for NUC -3373 when 
combined with other agents commonly used in treatment of advanced 
colorectal cancer (CRC), including:  
o leucovorin (LV)  
o oxaliplatin  
o oxaliplatin and vascular endothel ial growth factor (VEGF) 
pathway inhibitors  (bevacizumab)  
o oxaliplatin and epi[INVESTIGATOR_3506] (EGFR) 
inhibitors  (cetuximab or panitumumab)  
o irinotecan  
o irinotecan and VEGF pathway inhibitors  (bevacizumab)  
o irinotecan and EGFR inhibitors  (cetuximab or panitumumab)  
Phase II  
To explore the anti -cancer activity of NUC -3373 when combined with other 
agents commonly used in the treatment of advanced CRC using Response 
Evaluation in Solid Tumours (RECIST) v1.1 criteria . 
Secondary Objectives  
• To assess the safety and tolerability of each NUC -3373 -containing 
regimen  (Phase Ib and Phase II)  
• To assess the pharmacokinetics (PK) of NUC -3373 , oxaliplatin, 
irinotecan and their metabolites  in each NUC -3373 -containing regimen  
(Phase Ib and Pha se II)  
• To make a preliminary assessment of the anti -tumo ur activity  of 
NUC -3373 alone and in each NUC -3373 -containing regimen  (Phase Ib  
only) 
• To conduct a within -patient and a between -patient analysis of the effect 
of LV when added to NUC -3373 on intracellular pharmacodynamic 
NuTide:[ADDRESS_430921] c                                                             Confidential  10 (PD) parameters and haematological parameters  and use this 
information to determine if the addition of LV to NUC -3373 -
containing regimens is required for clinical activity  (Part  1 Arm 1a and 
Arm 1b only)  
Exploratory Objective s 
• To explore predictive  biomarkers of biological activity  and possible 
relationships between  PK and PD effects  (Phase Ib and Phase II)  
• Depending on emer ging data, t o potentially conduct a within -patient 
analysis of the effect of combining NUC -3373 with irinotecan on the 
plasma PK parameters of both NUC -3373 and irinotecan  (Part 2 
Arm 2b sub -study only)  
Study 
Design  This is a three -part, open label, Phase Ib /II study of NUC -3373 administered 
by [CONTACT_33980] (IV) infusion  (weekly [Q 1W] or fortnightly [Q 2W]), either as 
monotherapy  or as part of various combinations with agents commonly used 
to treat patients with advanced CRC  (LV, oxaliplatin , irinotecan,  
bevacizumab , cetuximab , and panitumumab ). Phase Ib includes Part  1 
(Arms  1a-1d) and Part  2 (Arms 2a -2d) and Phase  II includes Part 3 
(Arms  3a-3g). 
Patients may continue treatment until radiological disease progression or 
unacceptable toxicity despi[INVESTIGATOR_346918] , or withdrawal of consent . All patients will be followed 
up until withdrawal of consent,  lost to follow -up, death or the overall end of 
study  has been reached (defined in Section 3.6) , whichever occurs first .  
Part 1  
Part 1  determined that NUC -3373 should be administered with LV (Arms 1a, 
1b and 1c) and will further assess the safety and tolerability of NUC -3373 + 
LV on a Q1W schedule  (Arm 1d) . 
Part 2 
Part 2 will assess the safety and tolerability of different doses of Q1W 
NUC -3373 +  LV when administered in combination with either oxaliplatin 
(NUFOX) or irinotecan (NUFIRI).  
Part 3 
Part 3 will assess the safety and efficacy of Q1W NUFOX and NUFIRI 
regimens administered in combination with bevacizumab  (Q2W arms may 
also be opened). NUFOX and NUFIRI regimens may also be administered in 
combination with cetuximab  or panitumumab , dependi ng on emerging data . In 
addition, Q1W NUC -3373 + LV  in combination with bevacizumab  may be 
assessed in patients qualifying for maintenance therapy.  
Different patient populations will be included in the study as follows:  
 
 
 
 
NuTide:302                                                                                                                        Version 4.2, 10 Aug 2022 
Confidentia l                                                            NuCana  plc 11 Patient Population  Criteria  Study 
Phase/ Part 
≥3rd-line patients  Received ≥[ADDRESS_430922] include a 
fluor opyrimidine plus irinotecan.  Phase Ib  
Part 1  
Part 2 (dose 
escalation)  
Combination 
chemotherapy 
ineligible patients  Considered unable to receive combination 
chemotherapy for locally advanced or 
metastatic disease and may have received 
1 prior line of fluoropyrimidine -containing 
therapy.  Phase Ib  
Part 1 
2nd-/3rd-line patients  Received at least 1 , but no more than 2, 
prior lines of fluoropyrimidine -containing 
therapy  combined with oxaliplatin and/or 
irinotecan  for locally advanced or 
metastatic disease.  3rd-line patients 
enrolled to Arms 2c and 2d should have 
received prior bevacizumab treatment, 
unless ineligible or unless bevacizumab 
was not standard of care according to 
relevant region -specific treatment 
recommendations . Phase Ib  
Part 2 
(expansion)  
Rapid progressors  
(on prior fluoropyrimidine 
therapy)  Received ≤2 prior lines of 
fluoropyrimidine -containing therapy 
combined with oxaliplatin and/or 
irinotecan for locally advanced or  
metastatic disease  and progressed 
≤[ADDRESS_430923] 
fluoropyrimidine -containing regimen .  To be 
determined. 
Cohorts of 
rapid 
progressors 
may be 
opened 
depending on 
emerging 
data.  
2nd-line patients  Received 1 prior line of fluoropyrimidine -
containing therapy  combined with 
oxaliplatin and/or irinotecan  for locally 
advanced or metastatic  disease.  Phase II  
Part 3 
Maintenance 
patients  Received ≥[ADDRESS_430924] stable 
disease and are eligible for maintenance 
therapy . Phase II  
Part 3 
Previous treatment with triplet chemotherapy -based regimens is permitted  
(i.e., FOLFOXIRI),  as long as any toxicities from the previous regimen still allow repeated 
treatment with oxaliplatin or irinotecan . 
If positive efficacy signals are observed in any of the patient populations 
included in Parts 1, 2 or 3  of the study , expansion cohorts may be opened to 
further assess efficacy in approximately 20 patients per cohort .  
A Q2W  schedule may be explored at any time, depending on emergent safety, 
efficacy and PK data . 
NuTide:[ADDRESS_430925] c                                                             Confidential  12  Part 1  
Part 1  determined that NUC -3373 should be administered with LV (Arms 1a, 
1b and 1c) and will further assess the safety and tolerability of NUC -3373 + 
LV (Arm 1d)  in pat ients with advanced or metastatic CRC .  Initially, ≥3rd-line 
patients were  randomi sed via block randomi sation to two parallel arms , each 
receiv ing NUC -3373 Q2W  either with LV (Arm  1a) or without LV  (Arm  1b). 
Upon completion of the Q2W  dose administration arms , a third arm of 
≥3rd-line patients was enrolled to a Q1W  administration schedule of NUC -
3373  (1500 and 2500 mg/m2) plus LV  (Arm 1c) . Arms 1a, 1b, and 1c are now 
complete. Following this, approximately 10 combination chemotherapy 
ineligible patients will be enrolled to a Q1W  administration schedule of 
NUC -3373 plus LV  (Arm 1d).  
In Arm 1a, patients  receive d a single dose of NUC -3373 at 1500  mg/m2. This 
visit was considered Cycle 0, Day 1 (C0D1) for the pu rposes of the study visits.  
The initial dose was followed by a 2 -week washout period, during which safety 
and PK/PD w ere monitored. The next dose of NUC -3373 was given in 
combination with LV at 400 mg/m2.  This visit was considered Cycle 1, Day  1 
(C1D1) f or the purposes of the study visits. All subsequent doses of NUC -3373 
were  given Q2W  in combination with LV  in 28 -day cycles . In Arm 1b, patients 
receive d a single  dose of NUC -3373 at 1500 mg/m2 in combination with LV 
at 400 mg/m2. This visit was considered C0D1 for the purposes of the study 
visits.  The initial combination dose was followed by a 2 -week washout period 
during which safety and PK /PD were  monitored. The next dose of NUC -3373 
was given without any LV. This visit was considered C1D1 fo r the purposes 
of the study visits. All subsequent doses of NUC -3373 were  given Q2W  
without  LV in 28 -day cycles . 
In Arm 1c, patients receive d NUC -3373 Q1W at either 1500  mg/m2 or 
2500 mg/m2 in combination with LV Q1W at 400  mg/m2.  NUC -3373 and LV 
were  administered on Days 1, 8, 15 and 22 of 28 -day cycles .  
The dose of NUC -3373 selected from Arm 1c for further exploration  was 
2500  mg/m2 in combination with LV at 400 mg/m2.  
In Arm 1d, a cohort of approximately 10 combination chemo therapy ineligible 
patients will receive NUC -3373 at 2500 mg/m2 in combination with LV at 
400 mg/m2. NUC -3373 and LV will be administered on Days 1, 8, 15 and 22 
of 28 -day cycles . 
All patients in Part 1  (Arms 1a, 1b, and 1c)  were monitored for dose -limiting 
toxicities  (DLTs)  up to Day [ADDRESS_430926] been explored.  
Anticipated d ose levels  to be assessed in Part 1  
Dose 
Level * ≥3rd-line patients  
NUC -3373 dose (mg/m2)  
Days 1 and 15  
Arms 1a and 1b  NUC -3373 dose  (mg/m2)  
Days 1, 8, 15 and 22  
Arm 1c  
-1 1000  1250  
1 1500  1500  
NuTide:302                                                                                                                        Version 4.2, 10 Aug 2022 
Confidentia l                                                            NuCana  plc 13 2 2000  1750  
3 2500  2000  
4 3000  2250  
*Additional dose levels  could  be explored if necessary  
If cohorts at additional  doses were opened, these w ere to  utilise a  modified 3+[ADDRESS_430927] patient and treatment of subsequent patients  in a 
cohort . Once a minimum of 3 patients in each of Arms  1a, 1b and 1c had 
completed the 28 -day DLT  evaluation period  all available safety data , PK and 
PD data were  evaluated to establish the tolerability of NUC -3373  ± LV 
administered in each dose administration schedule .   
In addition to the assessment of safety, tolerability , PK and PD, a radiologic  
assessment of disease will be performed  at 8-week intervals and evaluated 
using Response Evaluation Criteria in Solid Tumours (RECIST) v1.[ADDRESS_430928] the safety or PK 
of NUC -3373; therefore, the decision was made that LV should be 
administered at 400 mg/m2 on each day of NUC -[ADDRESS_430929] s of a dose escalation  phase  using a modified 3 + 3 
design , which may be  followed by  [CONTACT_346980] p hase. The dose escalation  
phase will assess the safety and tolerability of different doses of NUC -3373 +  
LV when administered in combination with either oxal iplatin (NUFOX) or 
irinotecan (NUFIRI) in a Q1W  schedule  in ≥3rd-line patients . Oxaliplatin and 
irinotecan will be given at standard doses and schedules. In the expansion 
phase, cohorts of 2nd-/3rd-line patients may be enrolled to assess Q1W  
schedules of the NUFOX and NUFIRI regimens selected in the dose escalation  
phase.   
The dose escalation  group of patients will receive NUC -3373  + LV to assess 
the safety and tolerability  of different  doses of NUC -3373  + LV administered  
in combination with oxaliplatin  (Arm  2a) or irinotecan  (Arm 2b) .   
In Arm 2a,  ≥3rd-line patients will receive NUC -3373  + LV on Days 1, 8, 15 
and 22 and oxaliplatin on Days 1 and 15  of 28-day cycles .  
In Arm 2b,  ≥3rd-line patients will receive NUC -3373  + LV on Days 1, 8, 15 
and 22 and irinotecan on Days 1 and 15 of 28 -day cycles .  
The starting dose of NUC -3373 will be 1500 mg/m2 and the dose levels to be 
evaluated are described in the table below.  Based on a clinical study  of 
NUC -3373 ( NuTide:[ADDRESS_430930] 2015 -002250 -13, [STUDY_ID_REMOVED] ), 
alternate and/or additional dose levels may be considered and implemented 
upon recommendation  of the Data Safety Monitoring Committee ( DSM C).   
 
NuTide:[ADDRESS_430931] c                                                             Confidential  14 Anticipated dose levels to be a ssessed in Part 2 – Q1W  cohorts  
Dose Level * NUC -3373 dose (mg/m2) 
Days 1, 8, 15 and 22 
Arm 2a and Arm 2b  Oxaliplatin dose 
(mg/m2)** 
Arm 2a  Irinotecan dose 
(mg/m2)** 
Arm 2b  
-1 1250 85 180 
1 1500  85 180 
2 1750  85 180 
3 2000  85 180 
4 2250  85 180 
* Additional dose levels may be explored if necessary  
** Alternative dose levels of oxaliplatin and irinotecan may be explored based on PK analyses 
and safety observations  
 
The decision on which arm to enrol a patient to, Arm 2a or Arm 2b, will be 
made by [CONTACT_346981] t ake into account the patient’s clinical 
condition and any therapi[INVESTIGATOR_346919] .   
Patients will be enrolled into cohorts follow ing a modified 3+3 design , in 
which a fourth patient may be enrolled in each initial 3 -patient cohort as 
described above . The initial patient in each cohort will complete a 7 -day 
observ ation period before subsequent patients are enrolled . All patients in  
Arms 2a  & 2b will be monitored for DLTs  up to Day [ADDRESS_430932] 28 -day cycle.  
The recommended dose  of NUC -3373  + LV  in combination with oxaliplatin 
(Arm  2a) or irinotecan (Arm 2b)  will be determined separately , and may be 
different .  
Once the dose escalation groups have been completed, the DSMC will review 
the available safety, clinical activity  and PK/PD data to deter mine the 
recommended dose of NUC -3373  + LV when given in combination with  either 
oxaliplatin or irinotecan.  If safety concerns arise, additional cohorts assessing 
alternative doses of oxaliplatin and irinotecan may be opened  with agreement 
from the DSMC.   
Expansion cohorts may be enrolled to Part 2  to further assess the safety , 
tolerability and preliminary efficacy of the Q1W  NUFOX and NUFIRI 
regimens , using the dose of NUC -3373  selected  in the dose escalation phase . 
NUFOX and NUFIRI regimens will be administered  as described in the table 
below .   
Arm  Treatment  Number of patients  
2c  NUC -3373 + LV Q1W, oxaliplatin Q2W 
(NUFOX)  ~10 2nd-/3rd-line patients  
2d NUC -3373 + LV Q1W, irinotecan Q2W 
(NUFIRI)  ~10 2nd-/3rd-line patients  
NuTide:[ADDRESS_430933]  and will be evaluated  in 2nd-line patients . 
Following this , Q2W arms and/or cetuximab combination arms may be 
opened, depending o n emerging data. In addition, t he saf ety and efficacy of 
NUC -3373 + LV in combination with bevacizumab  may be evaluated in  
patients qualifying for maintenance therapy.   
The treatment for each arm is described in the table below.   The choice of arm 
to which an eligible patient should be enrolled will be at the Investigator’s 
discretion, taking into account the patient’s clinical condition and therapi[INVESTIGATOR_346920].    
Dose groups to be assessed in Part 3  
Arm  Treatment  Number of patients  
3a  NUFOX (NUC -3373 + LV Q1W) + 
bevacizumab  ~10 2nd-line patients  
3b NUFOX (NUC -3373 + LV Q2W) + 
bevacizumab   ~10 2nd-line patients  
3c NUFIRI (NUC -3373 + LV Q1W) + 
bevacizumab  ~10 2nd-line patients  
3d NUFIRI (NUC -3373 + LV Q2W) + 
bevacizumab  ~10 2nd-line patients  
3e NUC -3373 + LV Q1W + bevacizumab  ~10 maintenance patients  
3f NUFOX (NUC -3373 + LV Q1W or Q2W) 
+ cetuximab  ~10 2nd-line patients  
3g NUFIRI (NUC -3373 + LV Q1W or Q2W) 
+ cetuximab  ~[ADDRESS_430934] local 
practice . 
Panitumumab combination arms may also be opened  (~10 2nd-line patients) , 
depending on emerging data.  
Cohorts of rapid progressors may also be opened (~10 p atients), depending on 
emerging data.  
PK Sub -study  
A PK sub -study may be conducted during Part [ADDRESS_430935] it 
would be beneficial  to evaluate the PK relationship between NUC -3373, LV 
and irinotecan . If conducted, a n additional 8 patients would be enrolled in the 
NUFIRI Q1W cohort (Arm  2b). In Cycle 1 of the sub -study, irinotecan  and 
LV will be administered concurrently  on Day 1. On Day 8 , NUC -3373  and LV 
NuTide:[ADDRESS_430936] c                                                             Confidential  16 will be administered  sequentially . On Day 15 , 4 patients (Group A) will first 
be administered irinotecan concurrently  with LV, followed by [CONTACT_346982] -3373 . The 
remaining 4  patients (Group B) will first be administered NUC -3373, followed 
by [CONTACT_346983] . On Day 22, NUC -3373  and LV will be 
administered  sequentially . On Cycle  2 Day 1 (29 days after the start of 
treatment) , the infusion sequence will be reversed in a cross -over fashion 
whereby [CONTACT_346984] A will first be administered NUC -3373, followed 
by [CONTACT_346985]  B will first be 
administered irinotecan concurrently with LV, followed by [CONTACT_346982] -3373.  
 C1D1  C1D8  C1D15  C1D22  C2D1  
Group A  Irinotecan + 
LV LV  
NUC -3373  Irinotecan + 
LV  
NUC -3373  LV  
NUC -3373  NUC -3373 
 
Irinotecan + 
LV 
Group B  Irinotecan + 
LV LV  
NUC -3373  NUC -3373 
 
Irinotecan + 
LV LV > NUC -
3373  Irinotecan + 
LV  
NUC -[ADDRESS_430937] v1.1 criteria. Anti-tumour  activity 
will be assessed on the basis of:  
• Percentage change from baseline in tumour size  
• Objective  Response Rate (ORR ) 
• Disease Control Rate (DCR ) 
• Duration of Response (DoR ) 
• Duration of Stable Disease (DoSD ) 
• Progression -Free Survival (PFS ) 
• Overall Survival (OS) rate at 6 and 12 months  
NuTide:302                                                                                                                        Version 4.2, 10 Aug 2022 
Confidentia l                                                            NuCana  plc 17 Secondary Endpo ints 
Safety  (Phase Ib and Phase II)  
• Treatment -emergent adverse events ( TEAEs; per Common 
Terminology Criteria for Adverse Events [ CTCAE ] v5.0) 
• Clinically -significant laboratory changes (per CTCAE v5.0) 
• Changes in physical ex am, vital signs and serial electrocardiograms 
(ECGs ) 
Pharmacokinetics  (Phase Ib and Phase II)  
The PK of NUC -3373 , oxaliplatin, irinotecan and their metabolites  will be 
assessed, including:  
• Concentration at end of NUC -3373 infusion  (Cinf) 
• Maximum concentrat ion (Cmax) 
• Area under the curve (AUC)  
• Half-life (t1/2) 
• Volume of distribution (Vd) 
• Clearance  (CL)   
The analytes measured may include , but are not limited to : 
• In plasma: NUC -3373, oxaliplatin, irinotecan and their metabolites  
• In peripheral blood mononuclear cells (PBMCs): NUC -3373, 
fluorodeoxyuridine monophosphate ( FUDR -MP), FBAL, 
5-fluorouridine triphosphate (5 -FUTP ), deoxythymidine 
monophosphate (dTMP), deoxyuridine monophosphate (dUMP)  
(Part  1 only)  
Efficacy  (Phase Ib)  
Objective disease asse ssment  by [CONTACT_346986] [ADDRESS_430938] v1.1 criteria.  Anti-tumour  activity 
will be assessed on the basis of:  
• Percentage change from baseline in tumour size  
• ORR  
• DCR  
• DoR  
• DoSD  
• PFS 
• OS rate at 6 and 12 months  
Exploratory Endpoints  (Phase Ib and Phase II)  
• Pre-treatment and on -treatment measurements of PD markers in 
PBMCs  (Part 1 only)  
• Exploration of predictive biomarkers such as gene expression and /or 
genetic alternations in blood  and tumour  (e.g., genetic alterati ons in 
genes involved in PK exposure, PD effects, safety and efficacy)  
• DNA /RNA  and protein analysis  of pre- and on -treatment tumour 
samples, including but not limited to KRAS and BRAF  
• Potential s ub-study to evaluate the PK relationship between NUC -
3373 , LV and irinotecan  (Part 2 Arm 2b sub -study only)  
The PK of NUC -3373, LV and irinotecan will be assessed, including  
Cinf, Cmax, AUC , t1/2, Vd, CL 
NuTide:[ADDRESS_430939] c                                                             Confidential  18 The analytes measured in plasma  will include , but are not limited to : 
o NUC -3373, 5 -FU, and FBAL  
o LV and 5 -methyl -THF  
o Irinotecan, SN -38, SN -38 glucuronide, APC and NPC  
Study 
Populati on Patients with histologically or cytologically confirmed  CRC  that is locally 
advanced or metastatic and radiologically -measurable ; Eastern Cooperative 
Oncology Group ( ECOG ) performance status 0 -1; adequate haematologic, 
renal  and hepatic function.  
Study 
Treatment  The sections below provide suggested administration times and order for each 
of the combination agents; however, each administration in Parts 1, 2 and 3 of 
the study may be modified based on emerging safety and PK data (in line with 
local guidelines /relevant Prescribing Information ) with agreement from the 
DSMC .   
It is suggested that NUC -3373 at 1500 mg/m2 is infused over 120 minutes . The 
infusion duration for lower and higher doses of NUC -3373 should be adjusted 
relative to the 1500 mg/m2 dose ( e.g., a 25% increase in dose requires a n 
approximately  25% increase in infusion duration) . 
Phase Ib  
Part 1  (≥3rd-line and combination chemotherapy ineligible patients)  
Arm 1a  (≥3rd-line patients)  
NUC -3373 was administered by [CONTACT_346987] 1500  mg/m2 over 120 minutes  
followed by a 14-day washout period.  Thereafter, on Days 1 and 15 of 28 -day 
cycles, LV was administered by [CONTACT_22671] 400 mg/m2 over 120 minutes , 
followed by [CONTACT_346982] -3373 administration  by [CONTACT_346988] -prescribed 
dose level .   
Arm 1 b (≥3rd-line patients)  
LV was administered at 400 mg/m2 by [CONTACT_12781] 120 minutes , followed 
by [CONTACT_346982] -3373 infusion  at 1500 mg/m2 over 120 minutes . LV w as not 
administered again in Arm 1b. After a 14-day washout period , NUC -3373 was 
administered  on Days  1 and 15 of 28 -day cycles by  [CONTACT_22671] t he 
cohort -prescribed  dose level.    
Arm 1c  (≥3rd-line patients)  
On Days 1 , 8, 15 and 22 of 28 -day cycles, LV was administered by [CONTACT_123523] 400 mg/m2 over 120 minutes , followed by [CONTACT_346982] -3373 administration by [CONTACT_346989] -prescribed  dose level.  
Arm 1 d (combination chemotherapy ineligible  patients)  
On Days 1, 8, 15 and 22 of 28 -day cycles, LV will be administered by [CONTACT_269880] 400 mg/m2 over 120  minutes, followed by [CONTACT_346982] -3373 
administration by [CONTACT_22671] 2500 mg/m2 over 200 minutes . 
Part 2  Dose Escalation  (≥3rd-line patients)  
In the NUFOX and NUFIRI dose escalation cohorts , patients will receive  
NUC -3373  + LV  Q1W  combined with the standard dose and schedule of 
oxaliplatin and irinotecan.  
NuTide:302                                                                                                                        Version 4.2, 10 Aug 2022 
Confidentia l                                                            NuCana  plc 19 For patients experiencing toxicity related to NUC -3373 in the NUFOX and 
NUFIRI cohorts, initially the NUC -3373 dose modification guidelines in 
Section 9 should be followed. The doses of ox aliplatin and irinotecan may be 
adjusted (through agreement with the DSMC) based on, but not limited to, 
safety and PK data generated in patients receiving treatment with NUFOX and 
NUFIRI regimens. If oxaliplatin or irinotecan -related adverse events are 
observed, dose de -escalation should be performed as per the respective 
Prescribing Information  or standard local practice , or alternate doses may be 
explored, with approval from the DSMC. The modified dose of oxaliplatin or 
irinotecan (in combination with NUC -3373) will be assessed in approximately  
6 evaluable patients in each arm.  
The order of administration  of each of the agents  in Part 2 may be modified 
with approval from the DSMC , so that NUC -3373  + LV  is infused first 
followed by [CONTACT_346990] (Arms 2a and 2c) or irinotecan (Arms 2b and 
2d). Alternate infusion parameters may be implemented with approval from 
the DSM C.  
Arm 2a  
NUC -3373 + LV will be administered Q1W  and oxaliplatin will be 
administered Q2W  in 28 -day cycles, as outlined in the table below.  
Infusion order  Infusion 
duration  D1 D8 D15 D22 
LV (400 mg/m2)a 
120 minsa X X X X 
Oxaliplatin (85 mg/m2)a X  X  
NUC -3373   
(cohort prescribed dose level)  120 minsb X X X X 
aLV and oxaliplatin to be administered concurrently  
bSuggested duration, refer to Pharmacy Manual  
Arm 2b  
NUC -3373 + LV will be administered Q1W  and irinotecan will be 
administered Q2W  in 28 -day cycles, as outlined in the table below.  
Infusion ordera Infusion 
duration  D1 D8 D15 D22 
LV (400 mg/m2)b 
120 minsc X X X X 
Irinotecan (180 mg/m2)b   X  X  
NUC -3373   
(cohort prescribed dose level)  120 minsd X X X X 
aThe infusion order may change as a result of emerging PK or safety data (refer to the P K 
Manual for further information)  
bLV and irinotecan to be administered concurrently  
cThe infusion duration for irinotecan may be changed to 90 mins based on emerging data  
dSuggested duration, refer to Pharmacy Manual  
NuTide:[ADDRESS_430940] c                                                             Confidential  20 Part 2 Dose Expansion  (2nd-/3rd-line patients)  
Following completion of Arms 2a  and 2b , expansion cohorts may be initiated 
in 2nd-/3rd-line patient s at the selected dose levels  established in the dose 
escalation phase . The NUFOX and NUFIRI regimens  will be administered in 
separate arms of the study (Arm 2 c for NUFOX and Arm  2d for NUFIRI).  
Arm 2 c 
NUC -3373 + LV will be administered Q1W  and oxaliplatin will be 
administered Q2W  in 28 -day cycles, as outlined in the table below.  
Infusion order  Infusion 
duration  D1 D8 D15 D22 
LV (400 mg/m2)a 
120 minsa X X X X 
Oxaliplatin (85 mg/m2)a,b X  X  
NUC -3373   
(dose selected in Arm 2a)  120 minsc X X X X 
aLV and oxaliplatin to be administered concurrently  
bThe oxaliplatin dose may be reduced based on observations in Arm 2a   
cSuggested duration, refer to Pharmacy Manual  
Arm 2 d 
NUC -3373 + LV will be administered Q1W and irinotecan will be 
administered Q2W in 28 -day cycles, as outlined in the table below.  
Infusion ordera Infusion 
duration  D1 D8 D15 D22 
LV (400 mg/m2)b 
120 minsc X X X X 
Irinotecan (180 mg/m2)b X  X  
NUC -3373  
(dose selected in Arm 2 b) 120 minsd X X X X 
aThe infusion order may change as a result of emerging PK or safety data (refer to the P K 
Manual for further information)  
bLV and irinotecan to be administered concurrently  
cThe infusion duration for irinotecan may be changed to 90 mins based on emerging data  
dSuggested duration, refer to Pharmacy Manual  
 
Phase I I 
Part 3  (2nd-line patients and maintenance patients)  
In Part 3, 2nd-line patients  will receive the NUFOX and NUFIRI regimens 
selected in Part [ADDRESS_430941].  Following this , Q2W and/or cetuximab 
combination arms may be opened, depending on emerging data. In addition, 
patients q ualifying for maintenance therapy may receive NUC -3373  + LV  in 
combination with bevacizumab.  
NuTide:302                                                                                                                        Version 4.2, 10 Aug 2022 
Confidentia l                                                            NuCana  plc 21 Arm 3a  (2nd-line patients)  
NUC -3373 , LV and oxaliplatin at dose  levels  used in Arm  2a will be combined 
with bevacizumab . NUC -3373 and LV will be administered Q1W  and 
oxaliplatin  and bevacizumab  will be administered Q2W . 
Arm 3 b (2nd-line patients)  
NUC -3373 , LV and oxaliplatin at dose  levels  used in Arm 2 a will be combined 
with bevacizumab . NUC -3373 , LV, oxaliplatin  and bevacizumab  will be 
administered Q2W.   
Arm 3 c (2nd-line patients)  
NUC -3373 , LV and irinotecan  at dose  levels  used in Arm 2 b will be combined 
with bevacizumab . NUC -3373 and LV will be administered Q1W  and 
irinotecan and bevacizumab will be administered Q2W .   
Arm 3 d (2nd-line patients)  
NUC -3373 , LV and irinotecan  at dose  levels  used in Arm 2 b will be combined 
with bevacizumab . NUC -3373 , LV, irinotecan  and bevacizumab  will be 
administered Q2W.   
Arm 3 e (Maintenance  patients)  
NUC -3373 (2500 mg/m2 Q1W) + LV (400 mg/m2 Q1W) will be combined 
with bevacizumab  (5 mg/kg Q2W) . 
Arm 3 f (2nd-line patients)  
NUC -3373 , LV  and oxaliplatin  at dose  levels  used in Arm 2 a may be 
administered in subsequent cetuximab  cohorts . NUC -3373 + LV may be 
administered Q1W  or Q2W , oxaliplatin will be administered Q2W  and 
cetuximab will be administered Q1W .     
Arm 3 g (2nd-line patients)  
NUC -3373 , LV and irinotecan at dose  levels  used in Arm 2 b may be 
administered in subsequent cetuximab  cohorts . NUC -3373 + LV may be 
administered Q1W  or Q2W , irinotecan will be administered Q2W  and 
cetuximab will be administered Q1W .      
In all bevacizumab -containing arms, NUC -3373 dose adjustments may occur 
depending on emerging data.   
Panitumumab combination arms may also be opened (~10 2nd-line patients), 
depending on emerging data.  
Cohorts of rapid progressors may also be opened (~10 patients), depending on 
emerging data.  
In all  parts of the study, pat ients may continue on study until documentat ion 
of radiological disease progression or unacceptable toxicity. G uidelines for 
dose modifications and discontinuations of NUC -3373 are provided; dose and 
schedule modifications for the other agents (LV, oxaliplatin, irinotecan, 
bevacizumab , cetuximab , panitumumab ) will be in accordance with their 
respective P rescribing Information  or standard local practice , unless safety 
concerns emerge regarding dosing as determined by [CONTACT_6802] . 
NuTide:[ADDRESS_430942] c                                                             Confidential  22 PK sub -study (Arm 2b)  
Patients participating in the PK sub -study will receive NUC -3373, LV and 
irinotecan, as outlined in the table below.  Following this, patients will continue 
on the treatment schedule outlined for Arm 2b.   
Infusion 
order  Infusion 
duration  C1D1 C1D8 C1D15c C1D22 C2D1c 
(29 days 
after start of 
treatment)  
LVa 120 
minsa X X X X X 
Irinotecana   90 minsa X  X  X 
NUC -3373  120 
minsb  X X X X 
aLV and irinotecan to be administered concurrently  
bSuggested duration, refer to Pharmacy Manual  
cPatients will be  alternately assigned to two groups (Group A and Group B) for treatment 
on Cycle 1 Day 15 and Cycle 2 Day 1 (29 days after start of treatment)  and will receive the 
study treatments in an order that has been pre -specified for each group (refer to Section 7.2.1  
for details).  
Patients enrolled in the PK sub -study will be considered evaluable for PK endpoints if they 
have received planned study treatment and had PK assessments up to at least C1D15. If  
patients discontinue study treatment or require dose modifications before C1D15, they will 
be considered non -evaluable and will be replaced.   
 
Sample 
Size Part 1:   Up to 50 patients  
Part 2:   Up to 6 5 patients  
Part 3:   Up to 100 patients  
 
Total: Up to [ADDRESS_430943] h istological confirmation of CRC with evidence of locally 
advanced /unresectable  or metastatic disease  
3. Age ≥18 years  
4. Life expectancy of ≥[ADDRESS_430944] 
inhibitor (Arms 2a, 2b, 2c, 2d, 3a, 3b, 3c,  3d and 3e) must have received 
prior treatment with an EGFR inhibitor,  unless this was not standard of 
care according to relevant region -specific treatment recommendations. 
Patients with BRAF V600E mutant tumours should have received prior 
treatment with e ncorafenib in combination with an EGFR inhibitor,  unless 
this was not standard of care according to relevant region -specific 
treatment recommendations  
8. Adequate bone marrow function as defined by: [CONTACT_28763] 
≥1.5×109/L, platelet count ≥100×109/L (with no evidence of bleeding ), and 
haemoglobin ≥9 g/dL  
NuTide:302                                                                                                                        Version 4.2, 10 Aug 2022 
Confidentia l                                                            NuCana  plc 23 9. Adequate liver function, as defined by: [CONTACT_346991] ≤1.5×upper 
limit of normal (ULN), aspartate aminotransferase  and alanine 
aminotransfer ase ≤2.5×ULN (or ≤5×ULN i f liver metastases are present)  
10. Adequate renal function assessed as serum c reatinine  <1.5×ULN or 
glomerular filtration rate ≥50 m L/min. This criterion does not apply to the 
combination chemotherapy ineligible patient subgroup  (Arm 1d) ; please 
refer to specific criteria for this subgroup below  
11. Serum albumin ≥3 g/dL  
12. For the cohort in which  the patient will participate , there are n o 
contra -indications to receiving the app roved partner combination drugs  
13. Ability to comply with prot ocol requirements  
14. Female patients of child -bearin g pote ntial must have a negative  serum 
pregnancy test within [ADDRESS_430945] agree to practice true abstinence 
(defined in Section 10.3.1 ) or to use two highly effective forms of 
contraception, one of which must be a barrier method. These forms of 
contraception must be used from the time of signing consent, throughout 
the treatment period, and for [ADDRESS_430946] dose of study medication  
16. For patients receiving oxaliplatin:   Male patients must have been offered 
advice on and/or sought counselling for conservation of sperm prior to the 
first dose of study medication  
In addition to meeting the criteria above for all patients , the following criteria 
must be met for each patient population : 
≥3rd-line patients  
1. Must have received at least two  prior lines of therapy for locally advanced  
or m etastatic CRC, including one fluoropyrimidine plus oxaliplatin 
containing regimen and one fluor opyrimidine plus irinotecan containing 
regimen. Previous treatment with standard of care chemotherapy regimens 
in combination with molecular targeted therapi[INVESTIGATOR_014] ( e.g., therapi[INVESTIGATOR_346921] -oncology agents) is 
permitted . Patients who have received FOLFOXIRI -based regimens in 1st- 
and/or 2nd-line settings may also be included  
2. Patients in Part 2 of the study who are to receive NUFOX regimens should 
be suitable for re -challen ge with an oxaliplatin -based regimen  
3. Patients in Part 2 of the study who are to receive NUFIRI regimens 
should be suitable for re -challenge with an irinotecan -based regimen  
NuTide:[ADDRESS_430947] c                                                             Confidential  24 2nd-/3rd-line patients  
1. Must have received at least one, but no more than two,  prior lines of 
fluoropyrimidine -containing therapy in combination  with oxaliplatin 
and/or irinotecan for locally advanced or m etastatic CRC . Previous 
treatment with standard of care chemotherapy regimens in combination 
with molecular targeted therapi[INVESTIGATOR_014] ( e.g., therapi[INVESTIGATOR_346922] -oncology agents) is permitted . 
Patients who have received FOLFOXIRI -based regimens in 1st- and/or 
2nd-line settings may also be included . 3rd-line patients enrolled to Arms 2c 
and 2d must  have received prior bevacizumab treatment, unless ineligible 
or unless bevacizumab was not standard of care according to relevant 
region -specific treatment recommendations   
2. Patients in Part [ADDRESS_430948] received one  prior line of fluoropyrimidine -containing 
therapy  for locally advance d or metastatic CRC   
2. Ineligible to receive combination therapy for locally advanced o r 
metastatic CRC , as defined by [CONTACT_346992]:  
a. Dependency for daily activities due to comorbidities  (different to 
deterioration due to cancer)  
b. Previous history of three  or more of the following comorbidities 
(controlled or uncontrolled by [CONTACT_168647]):  
i. Congestive heart failure  
ii. Other chronic cardiovascular disease  
iii. Chronic obstructive pulmonary disease  
iv. Cerebrovascular disease  
v. Peripheral neuropathy  
vi. Chronic renal failure  
vii. Arterial hypertension  
viii. Diabetes mellitus  
ix. Systemi c vasculitis  
x. Severe arthritis  
c. At least one of the following geriatric features:  
i. Age > 75 years  
ii. Faecal or urinary incontinence  
iii. Spontaneous bone fractures  
iv. Mild or moderate dementia  
v. Frequent falls  
3. Creatinine clearance of >30 mL/min  
Rapid progressors   
1. Must have received no more than two  prior  lines of fluorop yrimidine -
containing therap y in combination  with oxaliplatin and/or irinotecan  for 
locally advanced or m etastatic CRC . Previous treatment with standard of 
NuTide:302                                                                                                                        Version 4.2, 10 Aug 2022 
Confidentia l                                                            NuCana  plc 25 care chemotherapy regimens in combination with molecular targeted 
therapi[INVESTIGATOR_014] ( e.g., therapi[INVESTIGATOR_346923] -oncology agents) is permitted. Patients who have received 
FOLFOXIRI -based regimens in 1st- and/or 2nd-line settings may also be 
included  
2. Must have had tumour progression ≤[ADDRESS_430949] received one  prior line of fluoropyrimidine -containing therapy 
in combination with oxaliplatin and/or irinotecan for locally advanced or 
metastatic CRC.  Previous treatment with standard of care chemotherapy 
regimens in combination with molecular targeted t herapi[INVESTIGATOR_014] ( e.g., therapi[INVESTIGATOR_346924] -oncology 
agents) is permitted. Previous t reatment  with triplet chemotherap y-based 
regimens  is allowed ( i.e., FOLF OXIRI ) 
Maintenance patients  
1. Must have  received at least [ADDRESS_430950] stable disease  
2. Eligible for maintenance therapy  
Exclusion 
Criteria:  
 All patients  
1. Prior history of hypersensitivity or current contra -indications to [ADDRESS_430951] formulation (Kolliphor ELP, super refined polysorbate 80, 
dimethylacetamide  [DMA])  
4. Symptomatic central nervous system  or leptomeningeal metastases  
5. Symptomatic ascites, ascites currently requiring drainage procedures  or 
ascites requiring drainage over the prior  3 months  
6. Chemotherapy , radiotherapy (other than a short cycle of palliative 
radiotherapy [e.g., for bone pain *), immunotherapy , or exposure to another 
investigational agent  within 28 days (or five times the half-life for a 
biological or molecular targeted agent  or three times the half -life for an 
immunotherapy  agent ) of first administration  of NUC -3373 : 
a. For nitrosoureas and mitomycin C within [ADDRESS_430952] 
administration of NUC -3373  
c. Corticosteroid treatment is allowed if not more than stable daily 
dosing of 10 mg prednisolone (or stero id equivalent)  
NuTide:[ADDRESS_430953] c                                                             Confidential  26 * Palliative radiotherapy during participation in the study is permitted , but 
should not include a target lesion  
7. Residual toxicities fr om prior chemotherapy or radiotherapy  which have 
not regressed to Grade ≤1 severity (CTCAE v5.0), except for alopecia .  In 
cohorts not containing oxaliplatin , residual Grade [ADDRESS_430954] , or 
low-grade prostate cancer or patients after prostatectomy not requiring 
treatment .  Patients with previous invasive cancers are eligible if treatment 
was completed more than 3 years prior to initiat ing the current study 
treatment  and there is no  evidence of recurrence  
9. Presence of an active bacterial or viral infection  (including SARS -CoV -2, 
Herpes Zoster or chicken pox ), known Human Immunodeficiency Virus 
positive or known active hepatitis B or C  
10. Presence of any uncontrolled con current  serious illness, medical condition  
or other medical history, including laboratory results, which, in the 
Investigator’s opi[INVESTIGATOR_1649], would b e likely to interfere with the patient’s ability 
to participate in the study or with the interpretation of the results , including 
any of the following:  
a. Congestive heart failure ([LOCATION_001] Heart Association Class III or 
Class IV)  
b. Myocardial infarction within [ADDRESS_430955] dose of study 
medication  
c. Unstable or poorly controlled angina pectoris  
d. Complete left bundle branch, bifascicular block or other clinically 
significant abnormal ECG finding  
e. History of or c urrent risk factor for torsad e de pointes (e.g., heart 
failure, hypokalaemia, or a family history of long QT syndrome)  
f. History of severe skin reactions  
g. History of severe ocular disorders  
h. Interstitial pneumonitis or pulmonary fibrosis  
11. Any condition ( e.g., known or suspected poor compliance, psychological 
instability, geographical location, etc.) that, in the judgment of the 
Investigator, may affect the patient’s ability to sign the informed conse nt 
and undergo study procedures  
12. Currently pregn ant, lactating  or breastfeeding  
13. QTc interval >450 milliseconds for males an d >470 milliseconds for 
females  
14. Required c oncomitant use of drugs k nown to prolong QT/QTc interval  
15. Required c oncomitant use of  strong CYP3A4 inducers or strong CYP3A4 
inhibitors, or use of strong  CYP3A4 inducers within [ADDRESS_430956] receipt of study drug (refer to Section 10.3. 2) 
16. For patients receiving irinotecan:  Use of strong UGT1A1 inhibitors within 
[ADDRESS_430957] receipt of study drug (refer to Section 10. 3.3) 
17. Has received a live vaccination within four weeks of first planned dose of 
study medication  
NuTide:302                                                                                                                        Version 4.2, 10 Aug 2022 
Confidentia l                                                            NuCana  plc 27 18. Known DPD or TYMP mutations associated with toxicity to 
fluoropyrimidines  
19. Use of w arfarin and other types of long acting anti -coagulants (such as 
phenproc oumon and anti ‑Xa inhibitors with a half ‑life of >12 hours) is 
prohibited within [ADDRESS_430958] dose of study treatment. Patients 
requiring anti -coagulant treatment should switch to low molecular weight 
heparin or anti ‑Xa inhibitors with a half ‑life of ≤12 hours  
Patients receiving bevacizumab  
1. Patients with a history of h aemoptysis ( 1/2 teaspoon or more of red blood)  
2. Wound  healing complications or surgery within 28 days of starting 
bevacizumab  (wound healing must have been fully completed before 
starting bevacizumab ) 
3. Severe chronic wou nds, ulcers or bone fracture  
4. Arterial thromboembolic events or haemorrhage within 6 months prior to 
study entry (except for tumour bleeding surgically treated by [CONTACT_346993])  
5. Bleeding diatheses or coagulopathy  
6. Receiving full -dose anti -coagulation treatment . Patients  who have been on 
stable doses for at least [ADDRESS_430959] 12 months or high risk of uncontrolled arrhythmia  
9. Severe proteinuria (nephrotic syndrome)  
10. Acute or subacute ileus, chronic infl ammatory bowel disease or chronic 
diarrhoea  
11. Any contraindication present in the bevacizumab Prescribing Information  
Patients receiving cetuximab  or panitumumab  
1. Clini cally significant coronary heart disease or myocardial infarction 
within the last 12 months  or high risk of uncontrolled arrhythmia  
2. Acute or subacute ileus, chronic inflammatory bowel disease or chronic 
diarrhoea  
3. Hypomagnesaemia or hypokalaemia not controlled by [CONTACT_346994]  
4. Any contraindication present in the cetuximab  or panitumumab  
Prescribing Information  
Patients participating in the PK sub -study (Arm 2b)  
1. Patients with the UGT1A1 *28/*28 genotype (homozygous poor UGT1A1 
metabolisers)  
Study 
Duration 
Per 
Patient  Patients may continue to receive treatment  in the absence of radiological 
disease progression or un acceptable  toxicity  that is not ameliorated by [CONTACT_346995] -medical supportive or prophylactic care , or withdrawal of 
consent . All patients will be followed up until withdrawal of consent, lost to 
follow -up, death, or the overall end of study  has been reached (defined in 
Section 3.6) , whichever occurs first . 
NuTide:[ADDRESS_430960] c                                                             Confidential  28 OVERALL STUDY DESIGN  
 
 
Abbreviations: Iri=irinotecan; LV=leucovorin; NUFIRI=NUC -3373 + LV + irinotecan; NUFOX=NUC -3373 + LV + oxaliplatin; Ox=oxaliplatin; Q1W=weekly; 
Q2W=fortni ghtly.

NuTide:302                                                                                                                        Version 4.2, 10 Aug 2022 
Confidentia l                                                            NuCana  plc  29 SUMMARY SCHEDULE OF EVENTS: ARM  1a AND ARM 1b 
Study  
Assessments1 Screening/ 
Baseline  Cycle 
0* Cycle  
1** Additional  
Cycles**  End of 
Treatment  Follow -
up 
Visits16 
 D1 D1 D2 D3 D8 D15 
(±1) D16 D1 
(±3) D15 
(±1) [ADDRESS_430961] 
dose  
(+7 days)  Q8 wks  
(±7 
days)  
Informed consent 
(including 
pregnancy 
counselling)  X            
Inclusion/e xclusion 
criteria  X            
Demographic d ata X            
Previous medical 
history  X            
Concomitant 
medication  X X X    X  X X X  
Physical 
examination  
(including 
neurological)  X X X    X  X X X  
Urinalysis  X X X      X  X  
ECOG performance 
status  X X X      X  X  
Vital signs   
(including weight)2 X X X    X  X X X  
ECG3 X X3 X3    X3  X3 X3 X  
Pregnancy test4 X X X      X  X  
FBC and chemistry5 X X X    X  X X X  
Coagulation profile  X X X        X  
Tumour markers6 X X X      X  X  
Radiologic tumour 
assessment  
(CT / MRI)7 X        Assessed 
every 8 
weeks from 
the start of 
Cycle 1   X8 
Randomise to Arm  
1a or 1b   X           
NUC -3373 
administration  
(all patients)   X X    X  X X   
Leucovorin 
administration9  X X    X  X X   
AEs/SAEs10  X X X X  X X X X X X10 
PK blood sample11  X X X X  X X     
PD blood sample12  X X    X      
PGx blood sample13 X        X13    
Archived sample14 X            
Tumour biopsy15 X     X       
* Cycle [ADDRESS_430962] to the patient 
completing the cycle and subsequently commencing Cycle 1  
NuTide:[ADDRESS_430963] c                                                             Confidential  30 ** Cycle 1 and all additional cycles ther eafter are assumed to be 28 days in duration (excluding 
any al lowances for visit window) subject to the patient completing the cycle in full  
1 Assessments scheduled on days of dosing should be done prior to administration of all 
Investigational Medicinal Products ( IMPs), unless otherwise specified. Lab 
assessments may be performed up to 72  hours prior to IMP administration.  
2 Vital signs include respi[INVESTIGATOR_1487], pulse, temperature and blood pressure.  Height 
should be recorded at baseline only. Weight should be recorded at baseline, D ay 1 of 
every cycle and at end of study visit.  If a patient’s weight increases or decreases by 
≥10% during the study, the dose of ‘NUC -3373  for infusion’  should be recalculated . 
[ADDRESS_430964] 12-lead ECG measurements will be performed  prior to administration of all 
IMPs, at the indicated visits.   
Note: Additional  ECG measurements must be taken  at 30-[ADDRESS_430965] 
administration of all IMPs at the C0D1,  C1D1 , C1D15, C3D1,  and C3D15 visits.  
All 12-lead ECG measurements should be performed in tr iplicate (keepi[INVESTIGATOR_346925] ) and reviewed by [CONTACT_346996] .    
4 Serum pregnancy assessment to be performed within 7 days of C0D1.  Required only in 
women of childbearing potential.   
5 Clinical chemistry (including hepatic panel) and haematology will be conducted every 
2 weeks throughout the study. In the event of neutropaenia (absolute neutrophil count 
[ANC] less than 0.5x109/L), throm bocytopaenia (platelet count less than 50x109/L), or 
≥Grade 2 clinical chemistry toxicity, these assessments will be conducted more 
frequently as clinically indicated until toxicity resolves to ≤Grade 1.  
[ADDRESS_430966] a pre -dose blood sample for evaluation of carcinoembryonic antigen ( CEA ).  
7 Computed tomography ( CT)/magnetic resonance imaging ( MRI ) disease assessment s 
will be performed at Screening (within [ADDRESS_430967] dose of IMP) and every 
8 weeks (±7 days) from Cycle 1 Day 1. Additional tests may be requested at the 
Investigator’s discretion. The same modality should be used throughout . 
8 Patients withdrawing from study treatment with no radiological evidence of disease 
progression wil l remain in the study and receive scans every 8 weeks (±7 days) from 
C1D1 until disease progression, initiation of a new treatment for CRC  or death in order 
to determine duration of overall response and progression -free survival  (PFS) .  
9 Leucovorin is administered with all doses beginning at C1D1 in Arm 1a and once at 
C0D1 in Arm 1b. 
10 After informed consent has been obtained, but prior to init iation of study drug, only 
adverse events  (AEs)  and serious adverse events  (SAEs)  caused by a protocol -mandated 
intervention will be reported.  Thereafter, all AEs occurring up to and including [ADDRESS_430968] be reported in detail on the 
AE case report form ( CRF ). 
Note : SAE reporting is required until [ADDRESS_430969] dose of study medication.  
11 Blood  samples for PK measurements, based on a 2 -hour and a 4 -hour infusion duration 
of NUC -3373, will be drawn on C0D1, C1D1  (Samples 1 -12) and C1D15  (Samples 1 -
11) as follows:   
NuTide:302                                                                                                                        Version 4.2, 10 Aug 2022 
Confidentia l                                                            NuCana  plc 31 Sample 
Number  Sample Collection Time   
(NUC -3373 2 -hour infusion)  Sample Collection Time   
(NUC -3373 4 -hour infusion)  Sample  Collection 
Window  
PRIOR TO NUC -3373 INFUSION  
1 Pre-dose Up to 30 minutes prior  
to starting infusion  
DURING NUC -3373 INFUSION  
2 T0 + 30 minutes  T0 + 60 minutes  
+/- 5 minutes  3 T0 + 60 minutes  T0 + 120 minutes  
4 T0 + 120 minutes  T0 + 240 minutes  
AFTER NUC -3373 INFUSION  
5 T1 + 15 minutes  
+/- 5 minutes  6 T1 + 30 minutes  
7 T1 + 60 minutes  
8 T1 + 90 minutes  
9 T1 + 120 minutes  +/- 15 minutes  
10 T1 + 240 minutes  + 4 hours  / - 15 minutes  
11 T1 + 24 hours  
+ 4 hours  
12* T1 + 48 hours  
• T0 = Start of NUC -3373 infusion  
• T1 = End of NUC -3373 infusion  
• Samples 2, 3, and 4 are triggered by [CONTACT_346997] a 
2-hour or a 4 -hour infusion duration. Collection times will be modified in 
alignment with infusion duration changes  
• Sample s 5-12 are timed from the end of the infusion  
* Sample 12 is optional  for C1D1. Sample 12 will not be taken for C1D15.  
12 Blood samples for PD measurements will be drawn Pre -dose (sample to be drawn 
within  [ADDRESS_430970] dose) and at 30  minutes (±5 mins) following the end 
of the NUC -3373 infusion , (i.e., T1+30 mins, where T1 = end of NUC -3373 infusion).   
Sample  
Number  Sample  
Time   Sample  Collection  
Window  
PRIOR TO NUC -3373 INFUSION  
1 Pre-dose Up to 30 minutes prior  
to starting infusion  
AFTER  NUC -3373 INFUSION  
2 T1 + 30 minutes  +/- 5 minutes  
13 Blood samples  (optional)  for mRNA analyses ( e.g., PAX gene)  will be drawn at 
baseline  or pre-dose on C0D1  and again at C3D1 .   
14 Original diagnostic block will be recalled (where available).  
NuTide:[ADDRESS_430971] c                                                             Confidential  32 15 Fresh biopsy  (optional)  will be performed at Screening ( maximum [ADDRESS_430972] dose ) and on treatment on C1 D8 or C1D15 at 3 -6 hours after study treatment , in 
consenting patients . 
16 During the COVID -19 pandemic, collection of follow -up data can be performed via a 
telephone call with the patient where possible ( e.g., for data regarding concomitant 
medications, AEs, and quality of life [ QoL]). The data collected and the follow -up 
schedule remain a s per the schedule of events. Patients in follow -up who have not 
experienced radiological disease progression should continue to attend the clinic for 
planned radiologic scans; however, other follow -up data can be collected via telephone 
to limit patient v isits.  
  
NuTide:302                                                                                                                        Version 4.2, 10 Aug 2022 
Confidentia l                                                            NuCana  plc 33 SUMMARY SCHEDULE OF EVENTS: ARM  1c and ARM 1d  
Study  
Assessments1 Screening/ 
Baseline  Cycle  
1* Additional  
Cycles * End of 
Treatment  Follow -up 
Visits18 
Days -28  
to 1 D1 D2 D3 D8 
(±1) D15 
(±1) D16 D22 
(±1) D1  
(±3) D8, 15, 
22 (±1) [ADDRESS_430973] dose  
(+7 days)  Q8 wks  
(±7 days)  
Informed consent 
(including pregnancy 
counselling)  X            
Inclusion/e xclusion 
criteria  X            
Demographic d ata X            
Previous medical history  X            
Concomitant medication  X X   X X  X X X X  
Physical examination  
(including neurological)  X X   X X  X X X X  
Urinalysis  X X       X  X  
ECOG performance status  X X       X  X  
Vital signs   
(including weight)2 X X   X X  X X X X  
Height2  X            
ECG3 X X3   X3 X3  X3 X3 X3 X  
Pregnancy test4 X X       X  X  
FBC and chemistry5 X X   X X  X X X X  
RAS/BRAF status testing  X6            
Coagulation profile  X X       X  X  
Tumour markers7 X X       X  X  
Radiologic tumour 
assessment (CT / MRI)8 X        Assessed every 8 
weeks from the start 
of Cycle 1   X9 
NUC -3373 administration  
(all patients)   X   X X  X X X   
Leucovorin 
administration10  X   X X  X X X   
AEs/SAEs11  X X X X X X X X X X X11 
PK blood sample12  X X X  X X      
PK urine sample13  X X X  X X      
PGx blood sample14 X14        X14    
Archived sample15 X            
Tumour biopsy16 X    X X       
Survival17 Assessed every 3 months from the start of Cycle 1 
 
* Cycle 1 and all additional cycles ther eafter are assumed to be 28 days in duration (excluding 
any allowances for visit window) subject to the patient completing the cycle in full   
NuTide:[ADDRESS_430974] c                                                             Confidential  34 1. Assessments scheduled on days of dosing should be done prior to administration of all 
IMPs, unless otherwise specified. Lab assessments may be performed up to 72  hours 
prior to IMP administration .  
2. Vital signs include respi[INVESTIGATOR_1487], pulse, temperature and blood pressure. Height 
should be recorded at baseline only.  Weight should be recorded at baseline, D ay 1 of 
every cycle and at end of study visit.   If a patient’s weight increases or decreases by 
≥10% during the study, the dose of ‘NUC -3373  for infusion’  should be recalculated . 
3. Standard 12-lead ECG measurements will be performed  prior to administration of all 
IMPs , at the indicated visits.   
Note: Additional  ECG measurements must be taken  at 30-[ADDRESS_430975] 
administration of all IMPs at the C1D1 , C1D15, C3D1,  and C3D15 visits.  
All 12-lead ECG measurements should be performed in triplicate (keepi[INVESTIGATOR_346925] ) and reviewed by [CONTACT_346996] . 
4. Serum pregnancy assessment to be performed within 7 days of C1D1.  Perform only in 
women of childbearing potential.  
5. Clinical chemistry (including hepatic panel) and haematology will be conducted every 
week throughout the study. In the event of neutropaenia ( ANC  less than 0.5x109/L), 
thrombocytopaenia (platelet count less than 50x109/L), or ≥Grade 2 clinical chemistry 
toxicity, these assessments will be conducted more frequently as clinically indicated 
until toxicity resolves to ≤Grade 1.  
6. If RAS /BRAF  mutation status is unknown, perform  genetic testing.  
7. Collect a pre -dose blood sample for evaluation of CEA.  
8. CT/MRI disease assessment s will be performed at Screening (within [ADDRESS_430976] dose of IMP) and every 8 weeks (±7 days) from Cycle 1 Day 1. Additional 
tests may be reque sted at the Investigator’s discretion. The same modality should be 
used throughout . 
9. Patients withdrawing from study treatment with no radiological evidence of disease 
progression will remain in the study and receive scans every 8 weeks (±7 days) from 
C1D1 until disease progression , initiation of a new treatment for CRC  or death in order 
to determine duration of overall response and PFS.  
10. Leucovorin is administered with all doses beginning at C1D1.  
11. After informed consent has been obtained, but prior to initiation of study drug, only 
AEs and serious adverse events caused by a protocol -mandated intervention will be 
reported.  Thereafter, all AEs occurring up to and including [ADDRESS_430977] be reported in detail on the AE CRF . 
Note : SAE reporting is required until [ADDRESS_430978] dose of study medication.  
12. Blood samples for PK measurements, based on a 2 -hour and a 4 -hour infusion duration  
of NUC -3373 , will be drawn on C1D1  (Samples 1 -12) and C1D15  (Samples 1 -11) as 
follows:  
NuTide:302                                                                                                                        Version 4.2, 10 Aug 2022 
Confidentia l                                                            NuCana  plc 35 Sample 
Number  Sample Collection Time   
(NUC -3373 2 -hour infusion)  Sample Collection Time   
(NUC -3373 4 -hour infusion)  Sample  Collection 
Window  
PRIOR TO NUC -3373 INFUSION  
1 Pre-dose Up to 30 minutes prior  
to starting infusion  
DURING NUC -3373 INFUSION  
2 T0 + 30 minutes  T0 + 60 minutes  
+/- 5 minutes  3 T0 + 60 minutes  T0 + 120 minutes  
4 T0 + 120 minutes  T0 + 240 minutes  
AFTER NUC -3373 INFUSION  
5 T1 + 15 minutes  
+/- 5 minutes  6 T1 + 30 minutes  
7 T1 + 60 minutes  
8 T1 + 90 minutes  
9 T1 + 120 minutes  +/- 15 minutes  
10 T1 + 240 minutes  + 4 hours  / - 15 minutes  
11 T1 + 24 hours  + 4 hours  12* T1 + 48 hours  
• Sample 1, pre-dose should be collected prior to infusion of a ny IMPs  
• T0 = Start of NUC -3373 infusion  
• T1 = End of NUC -3373 infusion  
• Samples 2, 3, and 4 are triggered by [CONTACT_346997] a 
2-hour or a 4 -hour infusion duration. Collection times will be modified in 
alignment with infusion duration changes  
• Sample s 5-12 are timed from the end of the infusion  
* Sample 12 is optional  for C1D1. Sample 12 will not be taken for C1D15.  
13. Urine samples for PK analyses will be collected in Arm 1d only. Samples will be 
collected 0 -8 hours and 8 -24 hours from the start of NUC -3373 infusion. For patients 
who provide optional consent, urine collection will continue for 48 hours on C1D1 
only.  
14. Blood samples (optional) for mRNA analyses ( e.g., PAX gene)  will be drawn at 
baseline  or pre-dose on C1D1  and again at C3D1 . 
15. Original diagnostic block will be recalled (where available).  
16. Fresh biopsy  (optional)  will be performed at Screening ( maximum 14-days before the 
first dose ) and on treatment on C1D8 or C1D15 at [ADDRESS_430979] to follow -up, death, 
or the overall end of study  has been reached (defined in Section 3.6) , whichever occurs 
first. Survival follow -up may be performed via telephone call.  
NuTide:[ADDRESS_430980] c                                                             Confidential  36 18. During the COVID -19 pandemic, collecti on of follow -up data can be performed via a 
telephone call with the patient where possible ( e.g., for data regarding concomitant 
medications, AEs, and QoL). The data collected and the follow -up schedule remain as 
per the schedule of events. Patients in follow -up who have not experienced radiological 
disease progression should continue to attend the clinic for planned radiologic scans; 
however, oth er follow -up data can be collected via telephone to limit patient visits.  
NuTide:302                                                                                                                        Version 4.2, 10 Aug 2022 
Confidentia l                                                            NuCana  plc 37 SUMMARY SCHEDULE OF EVENTS: PART 2 (ALL ARMS)  
Study  
Assessments1 Screening  Cycle  
1* Additional 
Cycles * End of 
Treatment  Follow -
up 
Visits19 
Days -28  
to 1 D1 D2 D3 D8 
(±1) D15 
(±1) D16 D22 
(±1) D1 
(±3) D8,1
5, 22 
(±1) 30-days 
post last 
dose  
(+7 days)  Q8 wks  
(±7 days)  
Informed consent 
(including pregnancy 
counselling)  X            
Inclusion/e xclusion 
criteria  X            
Demographic d ata X            
Previous medical 
history  X            
Concomitant 
medication  X X   X X  X X X X  
Physical examination  
(including 
neurological)  X X   X X  X X X X  
Urinalysis  X X       X  X  
ECOG performance 
status  X X       X  X  
Vital signs  
(including weight)2 X X   X X  X X X X  
Height2 X            
ECG3 X X3   X3 X3  X3 X3 X3 X  
Pregnancy test4 X X       X  X  
FBC and chemistry5 X X   X X  X X X X  
RAS/BRAF status 
testing  X6            
Coagulation profile  X X       X  X  
Tumour markers7 X X       X  X  
Radiologic tumour 
assessment  
(CT / MRI)8 X        Assessed 
every 8 weeks 
from the start 
of Cycle 1   X9 
NUC -3373  (+LV) 
administration   X   X X  X X X   
Combination agent 
administration based 
on arm 10  X    X [IP_ADDRESS].1.1.1   X X11   
AEs/SAEs12  X X X X X X X X X X X12 
PK blood sample(s)13   X X X  X X      
PGx blood sample14 X14        X14    
Archived sample15 X            
Tumour biopsy16 X    X X       
Survival17 Assessed every 3 months from the start of Cycle 1 
* Cycle 1 and all additional cycles ther eafter are assumed to be 28 days in duration (excluding 
any allowances for visit window) subject to the patient completing the cycle in full  
NuTide:[ADDRESS_430981] c                                                             Confidential  38 1. Assessments scheduled on days of dosing should be done prior to administration of all 
IMPs, unless otherwise specified. Lab assessments may be performed up to 72  hours 
prior to IMP administration .  
2. Vital signs include respi[INVESTIGATOR_1487], pulse, temperature and blood pressure. Height 
should be recorded at baseline only.  Weight should be recorded at baselin e, Day 1 of 
every cycle and at end of study visit.   If a patient’s weight increases or decreases by 
≥10% during the study, the dose of ‘NUC -3373  for infusion’  should be recalculated . 
3. Standard 12-lead ECG measurements will be performed  prior to administrati on of all 
IMPs , at the indicated visits.   
Note: Additional  ECG measurements must be taken  at 30-[ADDRESS_430982] 
administration of all IMPs at the C1D1 , C1D15, C3D1,  and C3D15 visits.  
All 12-lead ECG measurements should be performed in triplicate (keepi[INVESTIGATOR_346925] ) and reviewed by [CONTACT_346996] . 
4. Serum pregnancy assessment to be performed within 7 days of C1D1 . Perform only in 
women of childbearing potential.  
5. Clinical chemistry (including hepatic panel) and haematology will be conducted every 
week throughout the study. In the event of neutropaenia ( ANC  less than 0.5x109/L), 
thrombocytopaenia (plat elet count less than 50 109/L), or ≥Grade 2 clinical chemistry 
toxicity, these assessments will be conducted more frequently as clinically indicated 
until toxicity resolves to ≤Grade 1.   
6. If RAS /BRAF  mutation status is unknown, perform genetic testing.  
7. Collect a pre -dose blood sample for evaluation of CEA.  
8. CT/MRI disease assessment s will be performed at Screening (within [ADDRESS_430983] dose of IMP) and every 8 weeks (±7 days) from Cycle 1 Day 1. Additional 
tests may be requested at the Investigator’s discretion. The same modality should be 
used throughout .  
9. Patients withdrawing from study treatment with no radiological evidence of disease 
progression will remain in the study and receive sca ns every 8 weeks (±7 days) from 
C1D1 until disease progression , initiation of a new treatment for CRC , or death in order 
to determine duration of overall response and PFS.  
10. IV administration of combination agents as follows:  
Arm s Cycle 1 Day 1 and beyond  
Arm 2a & Arm 2 c Days 1, 8, 15, 22: NUC -3373  + LV  
Days 1 & 15: oxaliplatin  
Arm 2b & Arm 2 d Days 1, 8, 15, 22: NUC -3373  + LV  
Days 1 & 15: irinotecan  
11. Combination agent administration on Day 15 of additional cycles only ( Q2W  schedule) . 
NuTide:[ADDRESS_430984] be reported in detail on the AE CRF . 
Note : SAE reporting is required until [ADDRESS_430985] dose of study medication.  
13. Blood samples for PK measurements, based on  a 2-hour and a 4 -hour infusion duration  
of NUC -3373 , will be draw n on C1D1  (Samples 1 -12) and C1D15  (Samples 1 -11) as 
follows:  
Sample 
Number  Sample Collection Time   
(NUC -3373 2 -hour infusion)  Sample Collection Time   
(NUC -3373 4 -hour infusion)  Sample  Collection 
Window  
PRIOR TO NUC -3373 INFUSION  
1 Pre-dose Up to 30 minutes prior  
to starting infusion  
DURING NUC -3373 INFUSION  
2 T0 + 30 minutes  T0 + 60 minutes  
+/- 5 minutes  3 T0 + 60 minutes  T0 + 120 minutes  
4 T0 + 120 minutes  T0 + 240 minutes  
AFTER NUC -3373 INFUSION  
5 T1 + 15 minutes  
+/- 5 minutes  6 T1 + 30 minutes  
7 T1 + 60 minutes  
8 T1 + 90 minutes  
9 T1 + 120 minutes  +/- 15 minutes  
10 T1 + 240 minutes  + 4 hours  / - 15 minutes  
11 T1 + 24 hours  + 4 hours  12* T1 + 48 hours  
• Sample 1, pre -dose should be collected prior to infusion of a ny IMPs  
• T0 = Start of NUC -3373 infusion  
• T1 = End of NUC -3373 infusion  
• Samples 2, 3, and 4 are triggered by [CONTACT_346997] a 
2-hour or a 4 -hour infusion duration. Collection times will be modified in 
alignment with infusion duration changes  
• Sample s 5-12 are timed from the end of the infusion  
* Sample 12 is optional  for C1D1. Sample 12 will not be taken for C1D15.  
14. Blood samples  (optional)  for mRNA analyses ( e.g., PAX gene)  will be drawn at 
baseline  or pre-dose on C1D1  and again at C3D1 . 
15. Original diagnostic block will be recalled (where available).  
16. Fresh biopsy  (optional)  will be performed at Screening ( maximum [ADDRESS_430986] dose ) and on treatment on C1D8 or C1D15 at 3 -6 hours after study treatment , in 
consenting patients . If this is not possible, it may be obtained at any time after C 1D15 
with agreement from the Medical Monitor.  
NuTide:[ADDRESS_430987] to follow -up, death, 
or the overall end of study  has been reached (defined in Section 3.6) , whichever occurs 
first. Survival follow -up may be performed v ia telephone call.  
18. During the COVID -19 pandemic, collection of follow -up data can be performed via a 
telephone call with the patient where possible ( e.g., for data regarding concomitant 
medications, AEs, and QoL). The data collected and the follow -up sche dule remain as 
per the schedule of events. Patients in follow -up who have not experienced radiological 
disease progression should continue to attend the clinic for planned radiologic scans; 
however, other follow -up data can be collected via telephone to li mit patient visits.  
NuTide:302                                                                                                                        Version 4.2, 10 Aug 2022 
Confidentia l                                                            NuCana  plc 41 SUMMARY SCHEDULE OF EVENTS: PART 3  
Study  
Assessments1 Screening  Cycle 1*  Additional Cycles*  End of 
Treatment  Follow -up 
Visits18 
Days  
-28 to 1  D1 D2 D3 D8 
(±1)**  D15 
(±1) D16 D22 
(±1)**  D1 (±3)  D8,15, 22 
(±1)**  30-days post 
last dose (+7 
days)  Q8 wks  
(±7 days)  
Informed consent 
(including pregnancy 
counselling)  X            
Inclusion/  
exclusion criteria  X            
Demographic d ata X            
Previous medical 
history  X            
Concomitant 
medication  X X   X X  X X X X  
Physical examination  
(including 
neurological)  X X   X X  X X X X  
Urinalysis  X X       X  X  
ECOG performance 
status  X X       X  X  
Vital signs   
(including weight)2 X X   X X  X X X X  
Height2 X            
ECG3 X X3   X3 X3  X3 X3 X3 X  
Pregnancy test4 X X       X  X  
FBC and chemistry5 X X   X X  X X X X  
RAS /BRAF  status 
testing  X6            
Coagulation profile  X X       X  X  
Tumour markers7 X X       X  X  
Radiologic tumour 
assessment (CT/MRI)8 X        Assessed every 8 weeks 
from the start of Cycle 1   X9 
NUC -3373 (+LV) 
administration   X   X** X  X** X X**   
Combination agent 
administration10   X   X*** X  X*** X X***   
AEs/SAEs11  X X X X X X X X X X X11 
PK blood sample(s)12   X X X  X X      
PK urine sample (Arm 
3e)13  X X X  X X      
PGx blood sample14 X14        X14    
Archived sample15 X            
Tumour biopsy16 X    X X       
Survival17 Assessed every 3 months from the start of Cycle 1 
 
* Cycle 1 and all additional cycles ther eafter are assumed to be 28 days in duration (excluding 
any allowances for visit window) subject to the patient completing the cycle in full  
** Day 8 and Day 22 will only be completed in the  Q1W  NUC -3373  + LV cohorts (Arms 3a, 
3c, 3e, 3 f and 3 g) 
*** Day 8 and Day 22 will only be completed in arms containing cetuximab (Arms 3 f and 3g), 
depending on the chosen schedule  
 
NuTide:[ADDRESS_430988] c                                                             Confidential  42 1. Assessments scheduled on days of dosing should be done prior to administration of all 
IMPs, unless otherwise specified. Lab assessments may be perfor med up to 72  hours 
prior to IMP administration .  
2. Vital signs include respi[INVESTIGATOR_1487], pulse, temperature and blood pressure. Height 
should be recorded at baseline only.  Weight should be recorded at baseline, Day 1 of 
every cycle and at end of study visit.   If a patient’s weight increases or decreases by 
≥10% during the study, the dose of ‘NUC -3373  for infusion’  should be recalculated . 
3. Standard 12-lead ECG measurements will be performed  prior to administration of all 
IMPs , at the indicated visits.   
Note: Additional  ECG measurements must be taken  at 30-[ADDRESS_430989] 
administration of all IMPs at the C1D1 , C1D15, C2D1, C2D15, C3D1,  and C3D15 
visits.  
All 12-lead ECG measurements should be performed in triplicate (keepi[INVESTIGATOR_346925] ) and reviewed by [CONTACT_346998]  
4. Serum pregnancy assessment to be performed within 7 days of C1D1 . Perform only in 
women of childbearing potential.  
5. Clinical chemistry (including hepatic panel) and haematology will be conducted every 
week for patients on Q1W schedules and every 2 weeks for patients on Q2W schedules 
throughout the study. In the event of neutropaenia ( ANC  less than 0.5x109/L), 
thrombocyt opaenia (platelet count less than 50x109/L), or ≥Grade 2 clinical chemistry 
toxicity, these assessments will be conducted more frequently as clinically indicated 
until toxicity resolves to ≤Grade 1.  
6. If RAS /BRAF  mutation status is unknown, perform genetic t esting.  
7. Collect a pre -dose blood sample for evaluation of CEA.  
8. CT/MRI disease assessment s will be performed at Screening (within [ADDRESS_430990] dose of IMP) and every 8 weeks (±7 days) from Cycle 1 Day 1. Additional 
tests may be requested at th e Investigator’s discretion. The same modality should be 
used throughout .  
9. Patients withdrawing from study treatment with no radiological evidence of disease 
progression will remain in the study and receive scans every 8 weeks (±7 days) from 
C1D1 until disease progression, initiation of a new treatment for CRC , or death in order 
to determine duration of overall response and PFS.  
10. IV administration of combination agents as follows:  
Arm  Cycle 1 Day 1 and beyond  
Arm 3a NUFOX + bevacizumab  
Days 1, 8, 15, 22: NUC -3373  + LV  
Days 1 & 15: oxaliplatin  
Arm 3b NUFOX + bevacizumab  
Days 1  & 15: NUC -3373  + LV + oxaliplatin  
NuTide:[ADDRESS_430991] be reported in detail on the AE CRF .  
Note : SAE reporting is required until [ADDRESS_430992] dose of study medication.  
12. Blood samples for PK  measurements , based on a 2 -hour and a 4 -hour infusion duration,  
will be drawn on C 1D1 (Samples 1 -12) and C 1D15 (Samples  1-11) as follows  as 
follows:  
Sample 
Number  Sample Collection Time   
(NUC -3373 2 -hour infusion)  Sample Collection Time   
(NUC -3373 4 -hour infusion)  Sample  Collection 
Window  
PRIOR TO NUC -3373 INFUSION  
1 Pre-dose Up to 30 minutes prior  
to starting infusion  
DURING NUC -3373 INFUSION  
2 T0 + 30 minutes  T0 + 60 minutes  
+/- 5 minutes  3 T0 + 60 minutes  T0 + 120 minutes  
4 T0 + 120 minutes  T0 + 240 minutes  
AFTER NUC -3373 INFUSION  
5 T1 + 15 minutes  
+/- 5 minutes  6 T1 + 30 minutes  
7 T1 + 60 minutes  
8 T1 + 90 minutes  
9 T1 + 120 minutes  +/- 15 minutes  
10 T1 + 240 minutes  + 4 hours  / - 15 minutes  
11 T1 + 24 hours  + 4 hours  12* T1 + 48 hours  
• Sample 1, pre-dose should be collected prior to infusion of any IMPs  Arm 3 c NUF IRI + bevacizumab  
Days 1, 8, 15, 22: NUC -3373  + LV 
Days 1 & 15: irinotecan  
Arm 3d NUFIRI + bevacizumab  
Days 1  & 15: NUC -3373  + LV + irinotecan  
Arm 3e  NUC -3373  + LV + bevacizumab  
Days 1, 8, 15, 22: NUC -3373  + LV  
Arm 3f NUF OX + cetuximab  
Q1W or Q2W  
Arm 3g  NUFIRI + cetuximab  
Q1W or Q2W  
Bevacizumab and cetuximab should be administered in accordance with standard local practice.   
NuTide:[ADDRESS_430993] c                                                             Confidential  44 • T0 = Start of NUC -3373 infusion  
• T1 = End of NUC -3373 infusion  
• Samples 2, 3, and 4 are triggered by [CONTACT_346997] a 
2-hour or a 4 -hour infusion duration. Collection times  will be modified in 
alignment with infusion duration changes  
• Sample 6 -12 are timed from the end of the infusion  
* Sample 12 is optional  for C 1D1. Sample 12 will not be taken for C 1D15.  
13. Urine samples for PK analyses will be collected in Arm 3e only. Samples will be 
collected 0 -8 hours and 8 -24 hours from the start of NUC -3373 infusion. For patients 
who provide optional consent, urine collection will continue for 48 hours on C1D1 
only.  
14. Blood samples (optional) for mRNA analyses ( e.g., PAX gene)  will be drawn at 
baseline  or pre-dose on C1D1  and again at C3D1. 
15. Original diagnostic block will be recalled (where available).  
16. Fresh biopsy  (optional)  will be performed at Screening ( maximum [ADDRESS_430994] dose ) and on treatment on C1D8 or C1D15 at [ADDRESS_430995] to follow -up, death, 
or the overall end of study  has been reached (defined in Section 3.6) , whichever occurs 
first. Survival follow -up may be performed via telephone call.  
18. During the COVID -19 pandemic, collection of follow -up data can be performed via a 
telephone call with the patient where possible ( e.g., for data regarding concomitant 
medications, AEs, and QoL). The data collected and the follow -up schedule remain as 
per the schedule of events. Patient s in follow -up who have not experienced radiological 
disease progression should continue to attend the clinic for planned radiologic scans; 
however, other follow -up data can be collected via telephone to limit patient visits.  
 
 
NuTide:302                                                                                                                        Version 4.2, 10 Aug 2022 
Confidentia l                                                            NuCana  plc 45 SUMMARY SCHEDULE OF EVENTS: PK SUB -STUDY (PART 2 
ARM  2B; CYCLE 1 AND CYCLE 2 DAY S 1 AND 2 ) 
Study  
Assessments1 Screening  Cycle 1  Cycle 2 
Days -28  
to 1 D1 D2 D8 D9 D15 D16 D22 D23 D1 D2 
Informed consent 
(including 
pregnancy 
counselling)  X           
Inclusion/e xclusion 
criteria  X           
Demographic d ata X           
Previous medical 
history  X           
Concomitant 
medication  X X  X  X  X  X  
Physical 
examination  
(including 
neurological)  X X  X  X  X  X  
Urinalysis  X X        X  
ECOG performance 
status  X X        X  
Vital signs  
(including weight)2 X X  X  X  X  X  
Height2 X           
Safety ECG3 X X3  X3  X3  X3  X3  
Holter ECG4    X4 X4   X4 X4   
Pregnancy test5 X X        X  
FBC and chemistry6 X X  X  X  X  X  
RAS/BRAF status 
testing  X7           
Coagulation profile  X X        X  
Tumour markers8 X X        X  
Radiologic tumour 
assessment  
(CT / MRI)9 X           
Genotypi[INVESTIGATOR_324729]10 X           
NUC -3373 
administration11    X  X  X  X  
LV 
administration11  X  X  X  X  X  
Irinotecan 
administration11  X    X [IP_ADDRESS].1.1.2    X  
AEs/SAEs12  X X X X X X X X X X 
PK blood sample13   X X X X X X X X X X 
PGx blood sample14 X           
Archived sample15 X           
Tumour biopsy16 X   X  X      
 
NuTide:[ADDRESS_430996] c                                                             Confidential  46 The rows in bold font are the only rows that are different from the main Part 2 Summary 
Schedule of Events, and only apply to Cycle 1  and Day 1 /2 of Cycle 2 . Following this, 
patients in the PK sub -study will continue with the main schedule for Part 2 (Arm 2b).  
 
1. Assessments scheduled on days of dosing should be done prior to administration of all 
IMPs, unless otherwise specified. Lab assessments may be performed up to 72  hours 
prior to IMP administration.  
2. Vital signs include respi[INVESTIGATOR_1487], pulse, temperature a nd blood pressure. Height 
should be recorded at baseline only.  Weight should be recorded at baseline, Day 1 of 
every cycle and at end of study visit.   If a patient’s weight increases or decreases by 
≥10% during the study, the dose of ‘NUC -3373  for infusion ’ should be recalculated . 
3. Standard 12-lead ECG measurements will be performed  prior to administration of all 
IMPs , at the indicated visits.   Note: Additional  ECG measurements must be taken  at 
30-[ADDRESS_430997] administration of all IMPs at the C1D1 , C1D15, C3D1,  and C3D15 
visits.  
All 12-lead ECG measurements should be performed in triplicate (keepi[INVESTIGATOR_346925] ) and reviewed by [CONTACT_346996] . 
4. Holter  ECG mea surements will be performed  on C1D8 and C1D22, with continuous 
readings taken over 24  hours , starting  from 30 minutes prior to the start of infusion  (see 
footnote 13). Patients must be supi[INVESTIGATOR_2525]  [ADDRESS_430998] 5 minutes prior to, and during, the other timepoints where PK draws are 
taken (as outlined in footnote 1 3). 
All Holter ECG data should be transmitted for blinded central review.  
5. Serum pregnancy assessment to be performed within 7 days of C1D1 . Perform only in 
women of childbearing potential.  
6. Clinical chemistry (including hepatic panel) and haematology will be conducted every 
week throughout the study. In the event of neutropaenia ( ANC  less than 0.5x109/L), 
thrombocytopaenia (platelet count less th an 50 x109/L), or ≥Grade 2 clinical chemistry 
toxicity, these assessments will be conducted more frequently as clinically indicated 
until toxicity resolves to ≤Grade 1.   
7. If RAS /BRAF  mutation status is unknown, perform genetic testing.  
8. Collect a pre -dose blood sample for evaluation of CEA.  
9. CT/MRI disease assessment s will be performed at Screening (within [ADDRESS_430999] dose of IMP) and every 8 weeks (±7 days) from Cycle 1 Day 1. Additional 
tests may be requested at the Investigator’s discretion. The same modality should be 
used throughout .  
10. Genotypi[INVESTIGATOR_346926] a [ADDRESS_431000] a known UGT1A1 status from prior testing.  
NuTide:302                                                                                                                        Version 4.2, 10 Aug 2022 
Confidentia l                                                            NuCana  plc 47 11. LV is administered on Days 1, 8, 15 & 22  of Cycle 1  and Day 1 of Cycle 2  (29 days 
after start of treatment) ; irinotecan is administered on Days 1 & 15  of Cycle 1 an d Day 
1 of Cycle 2 (29 days after start of treatment) ; NUC -3373 is administered on Days 8, 
15 & 22  of Cycle 1 and Day 1 of Cycle 2 (29 days after start of treatment) . Patients will 
be alternately assigned  to two groups (Group A and Group  B) for treatment o n Cycle 1 
Day 15 and Cycle 2 Day 1 and will receive the study treatments in an order that has 
been pre -specified for each group (refer to Section 7.2.1  for details).  Following this, 
patients in the PK sub -study will continue to receive study treatment as outlined for 
Arm 2b.  Patients enrolled in the PK sub -study  will be considered evaluable for PK 
endpoints if they have received planned study treatment  and had PK assessments  up to 
at least  C1D15. If patients discontinue study treatment or require  dose modifications 
before C1D15, they will be considered  non-evaluable and will be replaced .  
12. After informed consent has been obtained, but prior to initiation o f study drug, only 
AEs and serious adverse events caused by a protocol -mandated intervention will be 
reported.  Thereafter, all AEs occurring up to and including [ADDRESS_431001] be reported in detail on the AE CRF . 
Note : SAE reporting is required until [ADDRESS_431002] dose of study medication.  
13. PK sub -study blood samples for analysis of irinotecan , NUC -3373  and their metabolites 
will be drawn for patients assigned to Group A and Group B as follows  (sample 
collection times may be adjusted based on emerging data) : 
Group A  
      Timepoints (min post -first infusion)  
    Pre-
dose* 60 mins  
(+/- 5 mins) 120 mins  
(+/- 5 mins) 150 mins  
(+/- 5 mins) 180 mins  
(+/- 5 mins) 250 mins  
(+/- 5 mins) 280 mins  
(+/- 5 mins) 300 mins  
(+/- 5 mins) 360 mins  
(+/- 15 mins) 480 mins  
(+/- 15 mins) 24 hours  
(+/- 2 hours) 
C1D1 Infusion   Irinotecan + LV                 PK Draw X X X   X X   X X X X 
C1D8 Infusion   LV NUC -3373           PK Draw X       X X X X X X X 
C1D15 Infusion   Irinotecan + LV NUC -3373           PK Draw X X X   X X X X X X X 
C1D22 Infusion   LV NUC -3373           PK Draw X       X X X X X X X 
C2D1 Infusion   NUC -3373 Irinotecan + LV           PK Draw X X X X X X   X X X X 
*Pre -dose = up to 30 minutes prior to the administration of irinotecan + LV (C1D1, C1D15) or NUC -3373 (C1D8, C1D22, C2D1)               
Group B  
      Timepoints (min post -first infusion)  
    Pre-
dose* 60 mins  
(+/- 5 mins) 120 mins  
(+/- 5 mins) 150 mins  
(+/- 5 mins) 180 mins  
(+/- 5 mins) 250 mins  
(+/- 5 mins) 280 mins  
(+/- 5 mins) 300 mins  
(+/- 5 mins) 360 mins  
(+/- 15 mins) 480 mins  
(+/- 15 mins) 24 hours  
(+/- 2 hours) 
C1D1 Infusion   Irinotecan + LV                 PK Draw X X X   X X   X X X X 
C1D8 Infusion   LV NUC -3373           PK Draw X       X X X X X X X 
C1D15 Infusion   NUC -3373 Irinotecan + LV           PK Draw X X X X X X   X X X X 
C1D22 Infusion   LV NUC -3373           PK Draw X       X X X X X X X 
C2D1 Infusion   Irinotecan + LV NUC -3373           PK Draw X X X   X X X X X X X 
*Pre -dose = up to 30 minutes prior to the administration of irinotecan + LV (C1D1, C2D1) or NUC -3373 (C1D8, C1D15, C1D22) 
The exact time each PK sample is taken must be recorded . 
NuTide:[ADDRESS_431003] 5 minutes prior to, and during, the other timepoints whe n PK draws are 
taken  (see footnote  4). 
14. Blood samples (optional) for mRNA analyses ( e.g., PAX gene)  will be drawn at 
baseline  or pre-dose on C1D1  and again at C3D1 . 
15. Original diagnostic block will be recalled (where available).  
16. Fresh biopsy  (optional)  will be performed at Screening (maximum [ADDRESS_431004] dose ) and on treatment on C1D8 or C1D15 at 3 -6 hours after study trea tment , in 
consenting patients.  If this is not possible, it may be obtained at any time after C 1D15 
with agreement from the Medical Monitor.  
NuTide:[ADDRESS_431005] Adverse drug reaction
AE Adverse event
ALT Alanine aminotransferase
ANC Absolute neutrophil count
APC Irinotecan metabolite ( 7-ethyl -10-[4-N-(5-aminopentanoic acid) -1-
pi[INVESTIGATOR_99200]] -carbonyloxycamptothecin )
aPTT  Activated partial thromboplastin time
AST  Aspartate aminotransferase
AUC  Area under the curve
AUC 0-24 Area under the plasma concentration -time curve from time zero to 24 hours
BRAF  Proto -oncogene protein B -raf gene
BSA  Body surface area
CAPI[INVESTIGATOR_167224] + irinotecan
CAPOX  Capecitabine + oxaliplatin
CEA  Carcinoembryonic antigen
CFR  Code of Federal Regulations
Cinf Concentration at the end of infusion
CL Apparent clearance
Cmax Maximum plasma concentration; peak plasma concentration
COVID -[ADDRESS_431006] Computed tomography
CTCAE  Common Terminology Criteria for Adverse Events
CYP3A4  Cytochrome P450 3A4
DCR  Disease control rate
DLT  Dose -limiting toxicity
DMA  Dimethylacetamide
DNA  Deoxyribonucleic acid
DoR  Duration of response
DoSD  Duration of stable disease
DPD  Dihydropyrimidine dehydrogenase
DSMC  Data Safety M onitoring Committee
DSUR  Development safety update report
dTMP  Deoxythymidine monophosphate
dUMP  Deoxyuridine monophosphate
EC 50 Half-maximal effective concentration
ECG  Electrocardiogram
ECOG  Eastern Cooperative Oncology Group
eCRF  Electronic Case Report Form
EFR Evaluable for response
NuTide:[ADDRESS_431007]  European Clinical Trials Database  
FAS Full analysis set  
FBAL  α-fluoro -β-alanine  
FDA  (US) Food and Drug Administration  
FOLFIRI  5-FU + LV + irinotecan  
FOLFOX  5-FU + LV + oxaliplatin  
FOLFOXIRI  5-FU + LV + oxaliplatin + irinotecan  
FUDR  Floxuridine ; (5-fluorodeoxyuridine ) 
FUDR -MP Fluorodeoxyuridine -monophosphate  
G-CSF Granulocyte colony stimulating factor  
IB Investigator’s Brochure  
ICF Informed consent form  
ICH-GCP  International Council for  Harmonisation - Good Clinical Practice  
IMP Investigational medicinal product  
IND Investigational New Drug  
INR International normalised ratio  
IRB/EC  Institutional review board/ ethics committee  
IV Intravenous (ly) 
KRAS  Gene that codes for the KRAS protein  
L Litre  
LDH  Lactate dehydrogenase  
LV Leucovorin  
m2 Meter2 
MedDRA  Medical Dictionary for Regulatory Activities  
Mg Milligram  
µM Micromolar  
Ml Millilitre  
mM Millimolar  
MRI  Magnetic resonance imaging  
MTD  Maximum tolerated dose  
NE Not evaluable  
NPC  Irinotecan metabolite ( 7-ethyl -10-(4-amino -1-pi[INVESTIGATOR_99200]) -
carbonyloxycamptothecin ) 
NUFIRI  NUC -3373 + LV + irinotecan  
NUFOX  NUC -3373 + LV + oxaliplatin  
OPRT  Orotate Phosphoribosyl Transferase  
ORR  Objective Response Rate  
OS Overall survival  
PBMC  Peripheral blood mononuclear cell  
PD Progressive Disease or Pharmacodynamics  
PFS Progression -Free Survival  
PGx Pharmacogenomics  
PK Pharmacokinetics  
PR Partial Response  
PT Prothrombin time  
Q1W  Weekly  
NuTide:302                                                                                                                        Version 4.2, 10 Aug 2022 
 
Confidentia l                                                            NuCana  plc 51 Q2W  Fortnightly  
QoL Quality of life  
QT/QTc  QT interval / Corrected QT interval  
RECIST  Response Evaluation Criteria In Solid Tumours (version 1.1)  
RBC  Red blood cell  
RNA  Ribonucleic acid  
RP2D  Recommended Phase II dose  
RSI Reference Safety Information  
SAE  Serious adverse event  
SAP Statistical analysis plan  
SD Stable Disease  
SmPC  Summary of Product Characteristics  
SN-38 Irinotecan metabolite ( 7-ethyl -10-hydroxycamptothecin ) 
SOC  System Organ Class  
S[LOCATION_003]R  Suspected Unexpected Serious Adverse Reaction  
t1/[ADDRESS_431008]  Upper limit of normal  
Vd Volume of distribution  
VEGF  Vascular endothelial growth factor  
VEGFR  Vascular endothelial growth factor receptor  
WBC  White blood cell  
WHO DD  World Health Organisation Drug Dictionary  
 
NuTide:[ADDRESS_431009] c                                                             Confidential  52 1. INTRODUCTION  AND STUDY RATIONALE  
1.1. Treatment Option s for Recurrent Colorectal Cancer  
Colorectal cancer (CRC) is the third most common cancer  in males and the second most 
common in females , accounting for 10% of all cancers. The incidence worldwide is 
approximately 1. 8 million new cases per year with a 5 -year survival rate of 10% for patients 
diagnosed with metastatic disease  (De Falco et al , 2020 ). In the [LOCATION_002], there are 
approximately 1.[ADDRESS_431010] systemic therapi[INVESTIGATOR_346927] 5-fluorouracil ( 5-FU), either 
as monotherapy or in combination with another chemotherapeutic, typi[INVESTIGATOR_346928].  Both alone and in c ombination, [ADDRESS_431011].  
1.2. 5-FU in Colorectal Cancer  
1.2.1 Adjuvant T reatment  
5-FU has been the mainstay of adjuvant treatment for high -risk Stage II or Stage III colon 
cancer for several decades.  Adjuvant chemotherapy with a 5 -FU-based regimen has been 
shown to improve overall survival  (OS)  by 7% (5% for those with Stage II and 10% wi th 
Stage  III cancer ; Ragnhammar et al , 2001 ).  In the adjuvant setting, 5 -FU is given with 
leucovorin ( LV) or combined with LV and oxaliplatin (FOLFOX).   The oral 5 -FU prodrug 
capecitabine (Xeloda) can be used instead of 5 -FU, either as monotherapy or in c ombination 
with oxaliplatin (CAPOX ). 
1.2.2 Treatment for Metastatic Disease  
5-FU is an essential component of chemotherapy for CRC  in the metastatic setting, as part of 
FOLFOX (5 -FU, LV and oxaliplatin), FOLFIRI (5 -FU, LV and irinotecan) , FOLFOXIRI  
(5-FU, LV, oxaliplatin and irinotecan),  CAPOX ( capecitabine and oxaliplatin)  or CAPI[INVESTIGATOR_166770] 
(capecitabine and irinotecan) .  The use of 5 -FU in these combinations, and the addition of 
targeted therapi[INVESTIGATOR_014], such as a vascular endothelial growth factor ( VEGF) inhibitor , vascul ar 
endothelial growth factor receptor (VEGFR) inhibitor  or an epi[INVESTIGATOR_3506] 
(EGFR ) inhibitor , has seen the median survival from CRC  increase to 24 months (compared  to 
12 months with 5 -FU alone)  (Ikoma et al, 2017 ).   
The standard of care  for 1st-line metastatic patients is either  a FOLFOX -based  or 
FOLFIRI -based  regimen, usually in combination with the VEGF inhibitor bevacizumab . 
Following progression, most patients receive 2nd-line FOLFIRI -based  or FOLFOX -based  
regimens, with or without bevacizumab . A Phase III study investigating the sequence of 
FOLFOX and FOLFIRI regimens as 1st- and 2nd-line therapy for patients with advanced CRC 
demonstrated no significant difference in median OS between the FOLFIRI followed  by 
[CONTACT_16679]6 (20.4 months) and FOLFOX6 followed by [CONTACT_346999] (21.5 months) regimens (Lee 
& Sun, 2016 ).  
NuTide:302                                                                                                                        Version 4.2, 10 Aug 2022 
 
Confidentia l                                                            NuCana  plc 53 In the 2nd-line, anti -VEGF therapy with bevacizumab  was shown to improve outcomes when 
combined with FOLFOX compared to FOLFOX alone, with significant diff erences in median 
OS (12.9 months vs 10.8 months), median progression -free survival ( PFS) (7.3 months vs 
4.7 months), and objective response rate ( ORR ) (22.7% vs 8.6%) (Giantonio et al , 2007 ). 
Furthermore, it has been shown that continuation of bevacizumab  in combination with 
chemotherapy in 2nd-line treatment resulted in improved OS when compared to 2nd-line 
chemotherapy alone (median OS: 11.2 months vs 9.8 months) (Bennouna et al, 2013 ). 
1.3. Limitations of 5-FU Treatment  
First introduced in 1957, [ADDRESS_431012] been 
approved that generate th e same active anti -cancer metabolite as 5 -FU: 
fluorodeoxyuridine/floxuridine, marketed as FUDR®, and capecitabine, marketed as Xeloda®.  
Like [ADDRESS_431013] be converted to  an active anti -cancer 
metabolite,  fluorodeoxyur idine -monophosphate ( FUDR -MP) inside the cancer cell in order to 
exert their primary cytotoxic activity.  Capecitabine is a derivative of [ADDRESS_431014] -MP binds to and inhibit s thymidylate synthase ( TS), a critical enzyme in de novo  
nucleotide synthesis and cell survival ( Longley et al,  2003 ).  TS is required to convert uridine, 
specifically deoxyuridine  monophosphate , or dUMP , to thymidine, specifically 
deoxythymidine  monophosphate , or dTMP , one of the four nucleotides that comprise DNA.  
The inhibition of TS results in an imbalance in the ratio of the nucleotides dUMP and dTMP, 
disrupting DNA synthesis and repair, which ultima tely leads to cancer cell death. Due to 
multiple limitations, [ADDRESS_431015] been 
associated with a poor prognosis to treatment  (Longley et al,  2003; Longley & Johnston , 2005 ). 
1.3.1 Susceptibility  to Breakdown  
More than 85% of administered 5 -FU is degra ded by [CONTACT_347000] (DPD) in the liver, therefore most of the drug is catabolised before it has an 
opportunity to enter cancer cell s, become activated and exert any therapeutic effect ( Diasio & 
Harris, 1989 ).  DPD is also present in other tissues, such as the gastrointestinal tract ( Pi[INVESTIGATOR_346929],  2003 ), and in tumour cells, resulting in additional 5 -FU catabolism.  
In an analysis of more than 60 human cancer cell lines, a highly significant inverse correlation 
between DPD  expression and activity and response to 5 -FU was demonstrated ( Beck et al,  
1994; Scherf et al,  2000 ).  The overexpression of DPD in a number of different cancer cells 
has been shown to confer resistance to 5 -FU (Takebe et al,  2001 ).  Furthermore, high lev els of 
DPD were associated with a poorer response to 5 -FU in tumour xenograft studies ( Ishikawa et 
al, 1999 ).  
In patients, DPD activity has been found to be elevated in hepatocellular carcinomas that are 
inherently resistant to fluoropyrimidine -based ther apy ( Jiang et al,  1997 ) and DPD levels were 
found to predict resistance to 5 -FU in patients with CRC  (Diasio et al,  1999; Etienne et al, 
1995 ).  High transcription of DPD mRNA in colorectal tumours has been shown to correlate 
with resistance to 5 -FU, poten tially caused by [CONTACT_347001] -mediated catabolism of 5 -FU in these 
NuTide:[ADDRESS_431016] c                                                             Confidential  54 tumours  (Salonga et al,  2000 ).  Moreover, a significantly shorter OS (4.9 vs 13.1  months) has 
been observed among patients with CRC  receiving 5 -FU treatment whose DPD levels were 
high compared to patients with low DPD expression ( Salonga  et al,  2000 ). The catabolism of 
5-FU by [CONTACT_347002], leading to increased breakdown of 
5-FU at certain times throughout the day with consequent reductions in [ADDRESS_431017] attempted to overcome these challenges by [CONTACT_347003] 
5-FU infusion rate on a circadian schedule, necessitating an increased infusion rate in the early 
morning ( Pi[INVESTIGATOR_346930],  2003 ).  
In addition to t he reduced efficacy, 5 -FU catabolism by [CONTACT_347004], such as α-fluoro -β-alanine (FBAL ), which has been  associated with off -target 
toxicity including hand foot syndrome, which is also known as chemotherapy -induced acra l 
erythema or palmar plantar erythrodysesthesia . This well -established cutaneous toxicity  occurs 
in 25-75% of patients treated with 5 -FU (Meta Analysis Group in Cancer, 1998; Hansen et al,  
1996; Chiara et al, 1997; Chau et al,  2005 ; Kwakman et al, 2020 ) and  is characterised by 
[CONTACT_93489], dysesthesia, pain, cracking, and desquamation on the palms of the hands and the 
soles of the feet ( Nikolaou et al,  2016 ).  Hand foot syndrome can be debilitating and 
significantly affects quality of life, often necessitatin g 5-FU dose modifications or treatment 
discontinuation.  Additional  off-target toxicities associated with 5 -FU by -products  
(predominantly FBAL and its breakdown products fluoroacetate and F -citrate)  include 
cardiotoxicity and neurotoxicity, both of which are known to be dose limiting ( Yamashita et 
al, 2004; Jensen & Sorensen, 2006; Deboever et al, 2013 ).  Moreover, there is evidence 
indicating that these 5 -FU catabolites interfere with the anti -cance r efficacy of 5 -FU (Spector 
et al , 1995 ).  Therefore, circumventing DPD -mediated degradation is anticipated to 
significantly improve the safety and efficacy of fluoropyrimidines.  
Although high levels of DPD have a clear impact on efficacy and safety , 5-FU and related 
agents are also associated with risk of severe or fatal toxicities in patients who are 
DPD-deficie nt.  Partial D PD deficiency is carried in an estimated 2 -5% of the Caucasian and 
Asian populations, and in 8% of African -Americans.  These patient s are unable to effectively 
breakdown [ADDRESS_431018], leading to prolonged exposure to toxic 
levels of 5 -FU metabolites with resultant adverse events (AEs), including mucositis, 
granulocytopaenia, neuropathy, and even death ( Baek et al, 2006 ).  Techniques are available 
for the detection of this autosomal dominant condition ( Mattison et al,  2004; Innocenti, 2014; 
Henricks et al, 2018 ) and testing is becoming more widely used in clinical practice.  
5-FU is also phosphorylated to 5 -fluorouridine triphosphate (5 -FUTP), which is known to be 
partially responsible for 5 -FU-associated off -target toxicity through incorporation into RNA in 
healt hy cells  (Brutcher et al, 2018 ).  Indeed, 5 -FUTP is thought to be the primary mediator 
underlying diarrhoea, a key dose -limiting toxicity (DLT), in patients treated with 5 -FU (Adjei, 
1999 ). Fluoropyrimidines are also susceptible to enzymatic hydrolysis by [CONTACT_347005] (TP), which is commonly overexpressed in tumours (Longley et al,  2003; 
Bronckaers et al , 2009 ) or introduced by [CONTACT_347006] ( Huang  et al , 2001 ) and 
interferes with chemo -sensitivity ( Jetté et al, 2008 ). 
Overall, the by -products FBAL and 5 -FUTP produced during metabolism of 5 -FU are 
associated with significant off -target toxicities that limit the clinical utility of 5 -FU. 
NuTide:[ADDRESS_431019] -MP, which binds to and inhibits TS. The inhibition of TS results 
in an imbalance in the ratio of the nucleotides dUMP and dTMP, disrupt ing DNA synthesis 
and repair, which ultimately leads to cancer cell death ( Longley et al, 2003 ). 
The levels of two key enzymes in the [ADDRESS_431020] been shown to correlate 
with treatment  efficacy . Orotate phosphoribosyltransferase (OPRT) con verts [ADDRESS_431021] -MP. Low levels of 
OPRT in tumour cells is associated with resistance to 5 -FU ( Tsutani et al, 2008 ). In patients 
with CRC  receiving 5 -FU based chemotherapy, low levels of OP RT is associated with 
significantly worse OS rates ( Komori et al,  2013 ).  In addition, TP converts [ADDRESS_431022] -MP by [CONTACT_19098] (TK). It has been shown 
that TK deficiency in human cancer cells diminishes the activity of 5 -FU (Vande Voorde et al,  
2011 ).  It has been observed that expression of TP correlates with response to 5 -FU therapy 
(Panczyk, 2014 ).  Higher TP levels theoretically should correlate to greater sensitivity to [ADDRESS_431023] shown mixed results 
regarding response to 5 -FU-based chemotherapy and level of TP expression.  Low TP  
expression in one study correlated with improved OS in patients with metastatic CRC  treated 
with adjuvant 5 -FU (Soong et al, 2008 ; Salonga  et al, 2000 ).  A more recent study in patients 
with m CRC  demonstrated longer time to progression with high TP expres sion ( Lindskog et al, 
2014 ).  Further studies are needed to establish a definitive link between TP expression and 
5-FU sensitivity.  
1.3.3 Dosing Administration Challenges  
5-FU is associated with significant dosing administration challenges  due to poor 
pharmacoki netic (PK) properties.  The plasma  half-life (t1/2) of 5-FU is very short at 8 to 
14 minutes ; consequently, prolonged  infusion times  over [ADDRESS_431024] also 
attempting to minimise maximum concentration ( Cmax) levels of toxic by -products.   This 
dosing regimen and the substantial off -target toxiciti es are  burdensome for providers, 
inconveniences patients , and contributes additional costs to the healthcare system.  
1.4. NUC -[ADDRESS_431025] 
also reduc ing the dosing administration burden s associated with 5 -FU (McGuigan et al,  2011; 
Vande Voorde et al , 2011 ). NUC -[ADDRESS_431026] s and associated off -target toxicities, such as hand 
foot syndrome.    
In ad dition, NUC -3373 generates much lower levels of  FUTP  compared to 5 -FU, and the 
incidence of Grade 3 or higher toxicities  associated with off -target incorporation of this 
molecule into the RNA of normal cells  has been low in clinical studies to date .   
NuTide:[ADDRESS_431027] -MP.  This results in enhanced interaction with, and inhibition of, the target 
enzyme TS, driving an imbalance in the dUMP:dTMP ratio with subsequent disruption of DNA 
synthesis and repair and, ultimately, cancer cell death.  
Refer to the NUC -[ADDRESS_431028] 
non clinical and  clinical data.  
1.4.1 Non Clinical Data 
NUC -3373 has consistently demonstrated greater activity  than 5 -FU across a range of 
non-clinical studies.  
• In vitro  cytotoxic activity of NUC -3373 and 5 -FU was examined across a range of human 
tumour cell lines, including the colorectal cell lines HT29, SW620 and Colo205.   The 
half-maximal effective concentration ( EC50) data from the majority of cell lines tested 
demon strated that NUC -3373 has up to 330 -times greater activity than 5 -FU. 
• The ability of NUC -3373, FUDR and [ADDRESS_431029] -MP compared with 
5-FU. 
• Over half of CRC  cases a re infected by [CONTACT_347007]  (Huang et al , 2001 ).  
Mycoplasma -encoded TP reduces the activity of several chemotherapeutic agents ( Liekens 
et al, 2009 ), including 5 -FU.  In cancer cell lines, mycoplasma  infection decreases 5 -FU 
activity by [CONTACT_8622] 100 -times ( Jetté et el, 2008 ).  Non clinical studies have shown that 
NUC -[ADDRESS_431030] its cytotoxic activity 429 -fold, whereas NUC -3373 activity 
was unaffected (Vande Voorde et al, 2011 ). 
• An in vitro  study investigating the effect of DPD activity on the intracellular concentrations 
of NUC -3373 was conducted in cell lysate from pooled CRC  cell lines (SW620, HCT116 
and HT29 ). NUC -3373 was not susceptib le to DPD -mediated degradation unlike 5 -FU, 
which was rapi[INVESTIGATOR_346931] . 
• The cytotoxicity of NUC -[ADDRESS_431031] were compared in CEM wild type and 
TK-deficient CEM human leukaemia cells ( McGuigan et al, 2011 ).  NUC -[ADDRESS_431032] loses activity was decreased by [CONTACT_726] 136 -fold. 
NuTide:[ADDRESS_431033] of NUC -3373 and 5 -FU on the growth of HT29 
human colorectal tumour cell line , NUC -3373 showed significant reduction in tumour volume 
compared to 5 -FU.   NUC -3373 showed a statistically significant increase in t umour doubling 
time when compared with the control group , whereas 5 -FU did not.  
A formal good laboratory practice repeat dose study has been conducted to assess the toxicity 
and toxicokinetic profile of NUC -3373 in the Beagle dog. NUC -3373 was administered 
intravenously  (IV) to dogs at 1, 4 and 8  mg/kg/day once daily for 5  days/ week f or 4 consecutive 
weeks.  Doses greater than 4  mg/kg/day induced weight loss as the most significant side effect 
as well as histopathological changes in testes, e pi[INVESTIGATOR_346932]. These findings  
showed full reversibility after a 2-week treatment -free period, except for testes and 
epi[INVESTIGATOR_346933].  
Based on the results of this study, the highest non -severely toxic dose was considered to be 
8 mg/kg/day.  These results compare favoura bly with the reported toxicity of 5 -FU in Beagle 
dogs following single bolus IV administration ( Sayre et al, 2012 ) 
More details on the toxicology, pharmacology and toxicok inetics can be found in the 
NUC -3373 Investigator’s Brochure  (IB). 
1.5. Clinical Data 
NuTide:[ADDRESS_431034] -in-human dose escalation study in patients with advanced solid tumours 
(EudraCT 2015 -002250 -13, [STUDY_ID_REMOVED] ) which  enrol led patie nts across three investigative 
sites in the [LOCATION_006]. The study had a two-part dose escalation and expansion design which  evaluate d 
safety, PK, pharmacodynamic ( PD) and anti -tumour activity, in addition to establishing the  
maximum tolerated dose (MTD),  recommended  Phase II dose (RP2D) and schedule of 
single -agent IV NUC -3373 .   
Enrolment has completed and the final results are being collated and analysed . In Part 1, 
NUC -3373 was administered on a weekly ( Q1W ) schedule on Days 1, 8, 15 and 22 of a 28 -day 
cycle.  In Part 2, NUC -3373 was administered as a fortnightly ( Q2W ) infusion on Days 1 and 
15 of a 28 -day cycle.   
A total of 59 patients  received NUC -3373 in th e study .  The dosing schedule is summarised in 
Table 1. 
All patients received NUC -3373 by [CONTACT_347008] 30 minutes to 
4 hours. Considering that NUC -3373 is 5 -times the equimolar weight of 5 -FU, the starting dose 
of 125  mg/m2 NUC -3373 equates to approximately 25 mg/m2 5-FU; thus, micro -doses of 
NUC -3373 were given in the early stages of the study.  
This heavily pre -treated patient population (median of 3 prior lines of chemotherapy ; range 
0-11 lines ) had a variety of pri mary tumour types, with CRC  representing approximately half 
of the cases.  
Promising signs of activity have been observed, with  at least [ADDRESS_431035] 4 months and  3 of these patients  achiev ing prolonged stable disease  (SD)  
lasting more than nine months.  A 70 -year-old male patient with CRC  had received 6 prior lines 
of therapy, including 5 prior lines of 5 -FU-based therapy ( progressed  within [ADDRESS_431036]-
line treatment with CapOx, progressed  within 8 months o n 4th-line treatment with FOLFIRI, 
progressed  within 3 months on 5th-line treatment with trifluridine -tipi[INVESTIGATOR_14965] ). This patient 
received 1500  mg/m2 NUC -3373 Q1W and achieved SD for 9  months before choosing to 
suspend treatment to go on vacation.  
NuTide:[ADDRESS_431037]-line of therapy (gemcitabine  in combination with cisplatin)  achieved SD for 
11 months during treatment with 1125 mg/m2 NUC -[ADDRESS_431038] previous treatment (paclitaxel in combination with 
carboplatin). This patient received  NUC -3373 at  1500 mg/m2 every 2 weeks and achieve d SD 
for 10  months.  
Table 1 NuTide:301 dose escalation, treatment schedule, and enrolment  
Group  Dosing Schedule  Number of Patients  
Cohort 1  NUC -3373 IV infusion 125 mg/m2 
On days 1, 8, 15, 22 of a 28 -day cycle  3 
Cohort 2  NUC -3373 IV infusion 250 mg/m2 
On days 1, 8, 15, 22 of a 28 -day cycle  6 
Cohort 3  NUC -3373 IV infusion 500 mg/m2 
On days 1, 8, 15, 22 of a 28 -day cycle  8 
Cohort 4  NUC -3373 IV infusion 750 mg/m2 
On days 1, 8, 15, 22 of a 28 -day cycle  4 
Cohort 5 a NUC -3373 IV infusion 1125  mg/m2 
On days 1, 8, 15, 22 of a 28 -day cycle  3 
Cohort 6 a NUC -3373 IV infusion 1500 mg/m2 
On days 1, 8, 15, 22 of a 28 -day cycle  3 
Cohort 5b  NUC -3373 IV infusion 1500  mg/m2 
On days 1  and 15 of a 28 -day cycle  4 
Cohort 6b  NUC -3373 IV infusion 1875  mg/m2 
On days 1  and 15 of a 28 -day cycle  6 
Cohort 7a  NUC -3373 IV infusion 1875  mg/m2 
On days 1, 8, 15, 22 of a 28 -day cycle  6 
Cohort 7b  NUC -3373 IV infusion 2500  mg/m2 
On days 1  and 15 of a 28 -day cycle  6 
Cohort 8a  NUC -3373 IV infusion 2500  mg/m2  
On Days 1, 8, 15, 22 of a 28 -day cycle  6 
Cohort 9a  NUC -3373 IV infusion 3250  mg/m2  
On Days 1, 8, 15, 22 of a 28 -day cycle  4 
TOTAL  59 
NUC -3373 was well tolerated at doses up to and including 2500  mg/m2. The most common 
treatment -emergent adverse events ( TEAEs ) considered related to NUC -3373 were fatigue 
(46%), nausea ( 36%), diarrhoea ( 31%), infusion reactions (most commonly described as a 
feeling of flushing; 29%), transaminases increased (19%), vomiting (15%),  and anaemia 
(15%) . The majority of events were Grade 1/2, with Grade 3 treatment -related events reported 
in only 7 patients (4  patients with transamin ases increased  and 1 patient each with fatigue, 
shingles and hypotension). None of the reported events appeared to be dose -related.   
NuTide:302                                                                                                                        Version 4.2, 10 Aug 2022 
 
Confidentia l                                                            NuCana  plc 59 Twenty -nine serious adverse events ( SAEs ) were  reported in [ADDRESS_431039] of these SAEs 
resolved a nd only two were  considered by [CONTACT_347009].  Six of the SAEs 
were judged by [CONTACT_347010], probably or possibly related to NUC -3373 
(chest pain, transaminases increased , infusion  reaction, shingles , PRES  and pyrexi a).  
Four  patients experienced  DLT s; 1 out of 8 patients in the 500 mg/m2 Q1W cohort, 1 out of 6 
patients in the 1875  mg/m2 Q1W  cohort  and 2  out of 4 patients in the 3250  mg/m2 Q1W  cohort . 
In the 500 mg/m2 and 1875  mg/m2 Q1W  cohort , DLT s of Grade 3 transamin ases increased  
were reported . In the 3250  mg/m2 Q1W  cohort , DLTs of Grade 2 headache and Grade 3 
transient hypotension ( decreased blood pressure for <5 minutes) were reported. Based on this, 
the MTD for single -agent NUC -3373 was determ ined to be 2500  mg/m2 Q1W . 
1.6. Pharmacokinetics  
Plasma and intracellular (PBMC) PK analyses have been conducted on 45 patients recruited to 
the NuTide:301 ( range: 125 to 3250  mg/m2) and NuTide:302 (1500 mg/m2) studies .  The PK 
profile of NUC -[ADDRESS_431040] and FBAL, over a dose 
range of 500 -2500 mg/m2. A do se-proportional increase in the NUC -3373 AUC was observed 
over the dose range. Over the range studied, NUC -3373 had a mean elimination half -life of 
5-10 hours (vs 8 -14 minutes for 5 -FU). The volume of distribution and the clearance of 
NUC -3373 at the 1500 mg/m2 dose (n=20) was 198 L and 28.5 L/h, respectively.  
The mean C max and AUC values for NUC -3373 at the MTD (2500 mg/m2) were found to be 
41.7 µg/mL and 222.2 µg•h/mL.  C max and AUC values for FUDR and FBAL were 0.3 µg/mL 
and 1.3 µg•h/mL and 3.4 µg/mL an d 34.1 µg•h/mL, respectively. No accumulation was 
observed for NUC -3373 or its circulating metabolites (FUDR and FBAL) between Day [ADDRESS_431041] -MP was observed over a dose range of 125 -2500 mg/m2 in PBMCs. The C max and T max 
of intracellular FUDR -MP was influenced by [CONTACT_347011]. In the 1500 mg/m2 cohort, 
the mean intracellular C max and AUC 0‐[ADDRESS_431042]‐MP were 1 1.7 pmol/ million  cells and 
95.6 pmol/ million  cells/h, respectively. In the 2500 mg/m2 cohort, the mean intracellular C max 
and AUC 0‐[ADDRESS_431043]‐MP were 23.0 pmol/ million  cells and 135.5 pmol/ million  cells/h, 
respectively.  The half-life of intracellular FUDR -MP was calculated to be [ADDRESS_431044]‐MP and dUMP levels. 
The toxic metabolites FBAL and FUTP were undetectable intracellularly at the dose levels 
tested. I. 
1.7. Study Rationale  
NUC-3373 is a pre -activated  (monophosphorylated)  and protected form of the active anti -
cancer agent FUDR -MP. The addition of the phosphoramidate group to the FUDR -MP protects 
NUC -[ADDRESS_431045] inactivation by [CONTACT_347012], resulting in greater stabili ty, and 
reduces  the release of p otentially toxic metabolites.  
NUC -3373 is lipophilic and can enter cancer cells without the need for nucleobase transporters. 
It is synthesised as the monophosphate and, as such, has already by -passed the activation steps 
NuTide:[ADDRESS_431046] -MP and markedly inhibit 
tumour cell growth in non  clinical studies.  In particular, the degree of tumour regression with 
NUC -3373 is g reater than with 5 -FU in human CRC  xenograft models.  Toxicology results 
compare favourably with the reported toxicity of 5 -FU in Beagle dogs following single bolus 
IV administration ( Sayre et al, 2012 ).  The first-in-human  Phase  I clinical study , NuTide :301, 
has confirmed the potential for NUC -[ADDRESS_431047] -MP. NUC -3373 has been well -tolerated in 59 patients at doses up to and including 
2500 mg/m2 and has shown encouraging sign s of anti -cancer a ctivity .   
Together these data demonstrate the potential for NUC -[ADDRESS_431048] -MP, as well as stabilis ing the 
complex it makes with TS. Because it improves the clinical efficacy of 5 -FU, LV has  become 
an integral part of infusional 5 -FU based regimens .  
Additionally , 5-FU is commonly used in combination with oxaliplatin  (comprising the 
FOLFOX regimen)  and irinotecan  (comprising the FOLFIRI regimen); these regimens are 
often combined with agent s that target the VEGF  (e.g., bevacizumab ) and EGFR  (e.g., 
cetuximab)  pathways .  In order to maxim ise clinical benefit for patients, it is important to study 
NUC -[ADDRESS_431049] limited 
treatment options. Combination chemotherapy ineligible patients are generally frail with a 
poorer performance status and, therefore, require more tolerable therapi[INVESTIGATOR_014]. Given the 
favourable risk/benefit profile observed with NUC -3373, these patients could be good 
candidates for treatment with NUC -3373  + LV . Rapid progressors  are unlikely to receive 
benefit from treatment with further lines of [ADDRESS_431050]-line and 2nd-line treatment of patients with advanced  or 
metastatic CRC is FOLFOX, FOLFIRI or FOLFOX IRI in combination with VEGF inhibitors 
or EGFR inhibitors.  During the patient’s treatment journey, components of the 1st-line regimen 
(e.g., oxaliplatin or irinotecan) will be either paused and re -instated , or switched to introduc e a 
new combination agent , for the 2nd-line regimen . Some patients may receive maintenance 
therapy with a fluoropyrimidine ± bevacizumab . Data in the 2nd-line setting show that 
following irinotecan -based 1st-line treatment  (e.g., FOLFIRI) , FOLFOX is genera lly the best 
NuTide:[ADDRESS_431051] appropriate options  for 2nd-line treatment . Interim data from Part 1 of NuTide:302 show 
that NUC -3373 has promising anti -tumour activity, including tumour shrinkage and  
encouraging rates of prolonged disease stabili sation beyond 3 months (11/ 38 patients) in 
heavily pre -treated patients (3 -11 prior l ines of treatment for metastatic disease) in whom 
disease stabili sation is difficult to  achieve. Furthermore, NUC -3373 has a favourable  
tolerability profile compared to either 5 -FU or capecitabine ( Table 2) and offers an attractive 
administration schedule with a  short (2 -4 hours) Q1W or Q2W  infusion, instead of the 
prolonged infusion (46 hours) required for  5-FU. These data suggest that NUC -[ADDRESS_431052] o f care FOLFOX and FOLFIRI 
regimens in the 2nd-line setting . Addition of targeted agents  to these combinations  offers a n 
additional potential advantage for tumour control in this setting, justifying the evaluation of 
NUFOX and NUFIRI regimens in combination with bevacizumab  or cetuximab in 
NuTide :302. 
Table 2 NUC -3373 safety profile  (Part 1 of NuTide :302)  
 
 
Depending on response to combination therapi[INVESTIGATOR_130243] 1st-line metastatic setting in CRC, 
maintenance therapi[INVESTIGATOR_346934] a break from intensive combination treatments  while  
maintaining tumour control. The goal of maintenance therapy  is to ma ximise quality of life 
(QoL) by [CONTACT_347013] a new intensive combination regimen. Based on the favourable safety and tolerability profile 
observed to date, and the more convenient administration schedule, NUC -3373 may offer a 
good maintenance therapy option for patients. Bevacizumab  as single agent or in combination 
with a fluoropyrimid ine has shown good efficacy in this setting (single agent activity of disease 
stabili sation between 5 -10 months , depending on the study; Ma et al , 2019 ); thus , the 
combination of  NUC -3373 and bevacizumab  could provide  an additional option for delay ing 
the initiation of  2nd-line therapy.  
 

NuTide:[ADDRESS_431053] c                                                             Confidential  62 2.  STUDY OBJECTIVES  AND ENDPOINTS  
This study consists of two phases (Phase Ib and Phase II) and includes three study parts (Parts  1, 
2 and 3) with several treatment arms within each part. Phase Ib includes Part 1 (Arms 1a -1d) 
and Part 2 (Arms 2a -2d) and Phase II includes Part 3 (Arms 3a -3g). 
2.1. Primary Objective s 
Phase Ib  
The primary objective is  to identify a recommended dose and schedule for NUC -3373 when 
combined with other agents commonly used in treatment of advanced CRC, including:  
• LV  
• oxaliplatin  
• oxaliplatin and VEGF pathway inhibitors  (bevacizumab)  
• oxaliplatin and EGFR inhibitors  (cetuximab or panitumumab)   
• irinotecan  
• irinotecan and VEGF pathway inhibitors (bevacizumab)  
• irinotecan and EGFR inhibitors  (cetu ximab or panitumumab)  
Phase II  
To explore the anti -cancer activity of NUC -3373 when combined with other agents commonly 
used in the treatment of advanced CRC using Response Evaluation in Solid Tumours (RECIST) 
v1.1 criteria.  
2.2. Secondary Objectives  
The second ary objectives are:  
• To assess the safety and tolerability of each NUC -3373 -containing regimen  
(Phase  Ib and Phase II)  
• To assess the PK of NUC -3373 , oxalipla tin, irinotecan  and their metabolites in each 
NUC -3373 -containig regimen (Phase  Ib and Phase II)  
• To make a preliminary assessment of the anti-tumour  activity  of NUC -3373 alone 
and in each NUC -3373 -containig regimen  (Phase Ib  only) 
• To conduct a within -patient and between -patient analysis of the effect of LV when 
added to NUC -3373 on intracellular PD pa rameters and haematological parameters  
and use this information to determine if the addition of LV to NUC -3373 -containing 
regimens is required for clinical activity  (Part 1 Arm 1a and Arm 1b only)  
2.3. Exploratory Objective s 
• To explore predictive biomarkers of biological activity and possible relationships 
between PK and PD effects  (Phase  Ib and Phase II)  
• Depending on emerging data, t o potentially conduct a within -patient analysis of the 
effect of combining NUC -3373 with irinotecan on the plasma PK parameters of 
both NUC -3373 and irinotecan  (Part 2 Arm 2b sub -study only ) 
NuTide:[ADDRESS_431054] v1.1 criteria. Anti-tumour  activity will be assessed on the basis of:  
• Percentage change from baseline in tumour size  
• Objective  Response Rate (ORR ) 
• Disease Control Rate (DCR ) 
• Duration of Response (DoR ) 
• Duration of Stable Disease (DoSD ) 
• Progression -Free Survival (PFS ) 
• Overall Survival (OS) rate at 6 and 12 months  
2.5. Secondary Endpoint s 
2.5.1 Safety  (Phase Ib and Phase II)  
• TEAEs  (per Common Terminology Criteria for Adverse Events [ CTCAE ] v5.0) 
• Clinically -significant laboratory changes (per CTCAE v5.0) 
• Changes in physical exam, vital signs and serial  electrocardiograms ( ECGs ) 
2.5.2 Pharmacokinetics  (Phase Ib and Phase II)  
The PK of NUC -3373 , oxaliplatin, irinotecan and their metabolites  will be assessed, including:  
• Concentration at end of NUC -3373 infusion (C inf) 
• Maximum concentration (C max) 
• AUC  
• t1/2 
• Volume of distribution (V d) 
• Clearance (CL)  
The analytes measured will include , but are not limited to : 
• In plas ma:  NUC -3373, oxaliplatin, irinotecan and their metabolites  
• In peripheral blood mononuclear cells ( PBMCs ):  NUC -3373, FUDR -MP, FBAL, 
5-FUTP , dTMP , dUMP  (Part 1 only)  
NuTide:[ADDRESS_431055] c                                                             Confidential  64 2.5.3 Efficacy Endpoints  (Phase Ib)  
Objective disease asse ssment  by [CONTACT_347014] 8 weeks and 
analysed using Response Evaluation Criteria in Solid Tumours  (RECIST ) v1.1 criteria 
(Appendix 1 ).  Anti-tumour  activity will be assessed on the basis of : 
• Percentage change from baseline in tumo ur size 
• ORR  
• DCR  
• DoR  
• DoSD  
• PFS 
• OS rate at 6 and 12 months  
2.6. Exploratory Endpoint s (Phase Ib and Phase II)  
• Pre-treatment  and on-treatment  measurements of PD markers in PMBCs  (Part 1 
only)  
• Exploration of predictive biomarkers such as gene expression and/or genetic 
alternations in blood  and tumour  (e.g., genetic alterations in genes involved in PK 
exposure, PD effects, safety and efficacy)  
• DNA /RNA and protein analysis of pre - and on -treatment tumour samples, including  
but not limited to  KRAS and BRAF  
• Potential  sub-study to evaluate the PK relationship  between NUC -3373, LV and 
irinotecan  (Part 2 Arm 2b sub -study only ) 
The PK of NUC -3373, LV and irinotecan will be assessed, including  Cinf, Cmax, 
AUC, t 1/2, Vd, CL 
The analytes measured in plasma  will include , but are not limited to : 
o NUC -3373, 5 -FU, and FBAL  
o LV and 5 -methyl -THF  
o Irinotecan, SN -38, SN -38 glucuronide, APC and NPC  
NuTide:302                                                                                                                        Version 4.2, 10 Aug 2022 
 
Confidentia l                                                            NuCana  plc 65 3. INVESTIGATIONAL PLAN  
3.1. Overall Study Design  
This is a three -part, Phase Ib /II study of NUC -3373 administered by [CONTACT_16228]  (Q1W or 
Q2W) , either as monotherapy or as part of various combinations with LV, oxaliplatin,  
irinotecan,  VEGF inhibitors and EGFR inhibitors . (Figure 1). Phase Ib includes Part  1 
(Arms  1a-1d) and Part 2 (Arms 2a -2d) and Phase  II includes Part 3 (Arms 3a -3g). The opening 
and timing of study arms will depend on emerging data.  
For VEGF inhibitors, the preferred treatment option is Avastin; however, biosimilars may be 
used after discussion with the Sponsor. For EGFR inhibitors, the preferred treatment options 
are Erbitux ( cetuximab ) or Vectibix ( panitumumab ); however, if biosimil ars become available, 
their use may be discussed with the Sponsor.      
Patients may continue treatment until radiological disease progression or unacceptable toxicity 
despi[INVESTIGATOR_346935] , or withdrawal of 
consent. All patients will be followed up until withdrawal of consent,  lost to follow -up, death, 
or the overall end of study  has been reached (defined in Secti on 3.6), whichever occurs first . 
 
Abbreviations: Iri=irinotecan; LV=leucovorin; NUFIRI=NUC -3373 + LV + irinotecan; NUFOX=NUC -3373 + LV + oxaliplatin; Ox=oxaliplatin; Q1W=weekly; 
Q2W=fortnightly  
Figure 1 NuTide:302  study schema  

NuTide:[ADDRESS_431056] c                                                             Confidential  66 Part 1 determined that NUC -3373 should be administered with LV (Arms 1a, 1b and 1c) and 
will further assess the safety and tolerability of NUC -3373 + LV on a Q1W schedule  (Arm 1d) .  
Part 2 will assess the safety and tolerability of different doses of Q1W NUC -3373 +  LV when 
administered in combination with either oxaliplatin (NUFOX) or irinotecan (NUFIRI) .  
Part 3 will assess the safety and efficacy of Q1W NUFOX and NUFIRI regimens administered 
in combination with bevacizumab  (Q2W arms may also  be opened). NUFOX and NUFIRI 
regimens may also be administered in combination with  cetuximab  or panitumumab, 
depending on emerging data . In addition, Q1W NUC -3373 + LV in combination with 
bevacizumab may be assessed in patients qualifying for maintenance therapy.  
A Q2W schedule may be explored at any time, depending on emergent safety, efficacy and PK 
data.  
It is anticipated that approximately [ADDRESS_431057] patients who withdraw prior to completing Cycle 0 (where relevant) and 
the initial  28-day safety evaluation period in Cycle 1.  Additionally, if the Data Safety 
Monitoring Committee (D SMC)  determine that an increased number of patients are required 
to evaluate alternate doses within a  study part , enrolment in a cohort may be expanded.  If 
positive efficacy signals are observed in any of the patient populations included in Parts 1, 2 or 
3 of the study, expansion cohorts may be opened to further assess efficacy in approximately 
20 patients per cohort .  
The patient  populations outlined in Table 3 will be included in the stud y. 
Table 3 Patient populations  
Patient Population  Criteri a Study 
Phase/ Part 
≥3rd-line patients  Received ≥[ADDRESS_431058] 
include a fluoropyrimidine plus irinotecan.  Phase Ib  
Part 1  
Part 2 (dose 
escalation)  
Combination 
chemotherapy ineligible 
patients  Considered unable to receive combination 
chemotherapy for locally advanced or metastatic 
disease and may have received 1 prior line of 
fluoropyrimidine -containing therapy.  Phase Ib  
Part 1 
2nd-/3rd-line patients  Received at least 1, but no more than 2, prior lines 
of fluoropyrimidine -containing therapy combined 
with oxaliplatin and/or irinotecan for locally 
advanced or metastatic disease.  3rd-line patients 
enrolled to Arms 2c and 2d should have received 
prior bevacizumab treatment, unless ineligible or 
unless bevacizumab was not standard of care 
according to relevant region -specific treatment 
recommendations.  Phase Ib  
Part 2 
(expansion)  
Rapid progressors  
(on prior fluoropyrimidine 
therapy)  Received ≤2 prior lines of fluoropyrimidine -
containing therapy combined with oxaliplatin and/or 
irinotecan for locally advanced or  metastatic disease 
and progressed ≤[ADDRESS_431059] 
fluoropyrimidine -containing regimen . To be 
determined. 
Cohorts of rapid 
progressors may 
be opened 
NuTide:302                                                                                                                        Version 4.2, 10 Aug 2022 
 
Confidentia l                                                            NuCana  plc 67 depend ing on 
emerging data  
2nd-line patients  Received 1 prior line of fluoropyrimidine -
containing therapy combined with oxaliplatin and/or 
irinotecan for locally advanced or metastatic 
disease.  Phase II  
Part 3 
Maintenance patients  Received ≥[ADDRESS_431060] stable disease and are eligible for 
maintenance therapy.  Phase II  
Part 3 
Previous treatment with triplet chemotherapy -based regimens is permitted  (i.e., FOLFOXIRI ), as long as any 
toxicities from the previous regimen still allow repeated treatment with oxaliplatin or irinotecan . 
 
3.1.1 Part 1  
Part 1  determined that NUC -3373 should be administered with LV (Arms 1a, 1b and 1c) and 
will further assess the safety and tolerability of NUC -3373  + LV (Arm 1d)  in patients with 
advanced or metastatic CRC  (Figure 2).  Initially, ≥3rd-line patients were  randomised via block 
randomisation to two parallel arms, each receiv ing NUC -3373 Q2W  either with  LV (Arm 1a)  
or without LV  (Arm  1b). Upon completion of the Q2W  dose administration arms , a third arm 
of ≥3rd-line patients was enrolled to a Q1W  administration schedule of NUC -3373 plus LV  
(Arm 1c) . Arms 1a, 1b, and 1c are now complete. Following this, approximately 
10 combination chemothera py ineligible patients will be enrolled to a Q1W  administration 
schedule of NUC -3373 plus LV (Arm 1d).  
 
Figure 2 NuTide:302  Part 1 study schema  
In Arm 1a, an initial arm of up to 6 evaluable patients  were to  receive a single dose of 
NUC -3373 at 1500  mg/m2.  This visit w as considered Cycle 0, Day 1 (C0D1) for the purposes 
of the study visits.  The initial dose was followed by a 2 -week washout period, during which 
safety and PK /PD were  monitored. The next dose of NUC -3373 was given in combination with 
LV at 400 mg/m2.  This visit was considered Cycle 1, Day  1 (C1D1) for the purposes of the 
study visits. All subsequent doses of NUC -3373 were  given Q2W  in combination with LV  in 
28-day cycles . A total of 10 patients were finally enrolled in Arm 1a  to obtain 6 evaluable 
patients . 
In Arm 1b, an initial arm of up to 6 evaluable  patients  were to  receive a single  dose of 
NUC -3373 at 1500 mg/m2 in combination with LV at 400 mg/m2.  This visit was considered 
C0D1 for the purposes of the study visits. The initial combination dose was followed by a 
2-week washout period during which safety and PK /PD were  monitored. The next dose of 
NUC -3373 was given without any LV.  This visit was considered C1D1 for th e purposes of the 
study visits.  All subsequent doses of NUC -3373 were  given Q2W without LV  in 28 -day cycles . 
A total of 11 patients were finally enrolled in Arm 1 b to obtain 6 evaluable patients.  

NuTide:[ADDRESS_431061] c                                                             Confidential  68 In Arm 1c, two initial cohort s of up to 12 evaluable patients  each were to  receive NUC -3373 
Q1W at either 1500  mg/m2 or 2500 mg/m2 in combination with LV Q1W at 400  mg/m2.  
NUC -3373 and LV were  administered on Days 1, 8, 15 and 22 of 28 -day cycles . A total of 
17 patients were finally enrolled in Ar m 1c to obtain 6 evaluable patients per cohort.  
The dose of NUC -3373 selected from Arm 1c for further exploration  was 2500  mg/m2 in 
combination with LV at 400 mg/m2.  
In Arm 1d, a cohort of approximately 10 combination chemotherapy ineligible patients will 
receive NUC -3373  at 2500 mg/m2 in combination with LV  at 400  mg/m2.  NUC -3373 and LV 
will be administered on Days 1, 8, 15 and 22 of 28 -day cycles . 
All patients in Part 1  (Arms 1a, 1b and 1c)  were  monitored for DLTs  up to Day 28 of  Cycle  1.   
If the dose of NUC -3373 was not tolerable  or was sub-optimal , alternate dose levels (as 
described in Table 6) may have been explored. If cohorts at additional  doses were  opened, these 
were to  utilise a modified 3+[ADDRESS_431062] patient and  treatment of subsequent patients  in a cohort .  
Once a minimum of 3 patients in each of Arms 1a, 1b and 1c had completed the 28 -day DLT  
evaluation period  all available safety, PK and PD data were  evaluated to establish the 
tolerability of NUC -3373  ± LV administered in each dose administration schedule.   
Patients who completed the DLT period may have been switched from a Q1W to a Q2W 
schedule if they experience d drug-related toxicity (other than fatigue) that would otherwise 
have led to treatment discontinuation. In addition, patients who completed the DLT period may 
have move d from a Q2W to a Q1W schedule. The decision to switch schedules was to  be 
discussed wit h and approved by [CONTACT_347015].   
In addition to the assessment of safety, tolerability , PK and PD, a radiologic assessment of 
disease will be performed at [ADDRESS_431063] the safety or PK of NUC -3373; 
therefore, the decision was made that LV should be administered at 400 mg/m2 on each day of 
NUC -3373 administration in all parts  of the study.  
Part 2 of the study consists of a dose escalation phase  using a modified 3 + 3 design , which 
may be  followed by  [CONTACT_171342]  (Figure 3). The dose escalation phase will assess the 
safety and tolerability of different doses of NUC -3373 +  LV when administered in combination 
with either oxaliplatin (NUFOX) or irinotecan (NUFIRI) in a Q1W  schedule  in ≥3rd-line 
patients . Oxaliplatin and irinotecan will be given at standard doses and schedules. In the 
expansion phase, cohorts of 2nd-/3rd-line patients  may be enrolled to assess Q1W schedules of 
the NUFOX and NUFIRI regimens selected in the dose escalation  phase .  
 
Figure 3 NuTide:302  Part 2 study schema  

NuTide:302                                                                                                                        Version 4.2, 10 Aug 2022 
 
Confidentia l                                                            NuCana  plc 69 The dose escalation group of patients will receive NUC -3373  + LV to assess the safety and 
tolerability of different  doses of NUC -3373  + LV administered  in combination with oxaliplatin  
(Arm 2a) or irinotecan (Arm 2b).   
In Arm 2a,  ≥3rd-line patients will receive NUC -3373  + LV on Days 1, 8, 15 and 22 and 
oxaliplatin on Days 1 and 15 of 28 -day cycles .  
In Arm 2b,  ≥3rd-line patients will receive NUC -3373  + LV on Days 1, 8, 15 and 22 and 
irinotecan on Days 1 and 15 of 28 -day cycles .  
The starting dose of NUC -3373 will be 1500 mg/m2 and the dose levels to be evaluated are 
described in Table 7 and Table 8. Based on a clinical study of NUC -3373 ( NuTide:[ADDRESS_431064] 2015 -002250 -13, [STUDY_ID_REMOVED] ), alternate and/or additional dose levels may be 
considered and implemented upon recommendation of the DSMC.   
The decision on which arm to enrol a patient to, Arm 2a or Arm 2b, will be made by [CONTACT_347016] t ake into account the patient’s clinical condition and any therapi[INVESTIGATOR_346936].   
Patients will be enrolled into cohorts following a modified 3+3 design , in which a fourth patient 
may be enrolled in each initial 3 -patient cohort as described above . The initial patient in each 
cohort will complete a 7 -day observation period before subsequ ent patients are enrolled . All 
patients Arms 2a & 2b will be monitored for DLTs  up to day [ADDRESS_431065] 28 -day cycle.  
The recommended dose  of NUC -3373  + LV  in combination with oxaliplatin (Arm 2a) or 
irinotecan (Arm 2b)  will be determined separately , and may be different .  
Patients who have completed the DLT period may be switched from a Q1W to a Q2W schedule 
if they experien ce drug -related toxicity (other than fatigue) that would otherwise lead to 
treatment discontinuation. In addition, patients who have completed the DLT period may move 
from a Q2W to a Q1W schedule. The decision to switch schedules must be discussed with and  
approved by [CONTACT_347015].   
Once the dose escalation groups have been completed, the DSMC will review the available 
safety, clinical activity and PK data to determine the recommended dose of NUC -3373  + LV 
when given in combin ation with oxaliplatin or irinotecan.  If safety concerns arise, additional 
cohorts assessing alternative doses of oxaliplatin and irinotecan may be opened  with agreement 
from the DSMC.   
The MTD for NUFIRI has been established in Arm 2b and was determined to be 1500 mg/m2 
NUC -3373 + 400 mg/m2 LV + 180 mg/m2 irinotecan.   
Expansion cohorts may be enrolled to Part 2 to further assess the safety , tolerability and 
preliminary efficacy of the Q1W NUFOX and NUFIRI regimens, using the dose of NUC -3373  
selected in the dose escalation phase . NUFOX and NUFIRI regimens will be administered  as 
described in Table 4.  
Table 4 Part 2 expansion phase treatment arms  
Arm  Treatment  Number of patients  
2c  NUC -3373 + LV Q1W, oxaliplatin Q2W (NUFOX)  ~10 2nd-/3rd-line patients  
2d NUC -3373 + LV Q1W, irinotecan Q2W (NUFIRI)  ~10 2nd-/3rd-line patients  
NuTide:[ADDRESS_431066] c                                                             Confidential  70 3.1.3 Part 3  
Following determination of the recommended NUFOX and NUFIRI regimens in the Part 2 
dose escalation phase, Part 3 will open . The Part 2 expansion phase may open  in parallel . 
In Part 3, 2nd-line patients will receive the NUFOX and NUFIRI regimens selected in Part 2 in  
combination with bevacizumab  (Figure 4). Q1W b evacizumab -containing arms  will be opened 
first. Following this, Q2W arms and/or cetuximab combination arms  may be opened, 
depending on emerging data . In addition,  patients qualifying f or maintenance therapy may 
receive NUC -3373  + LV  in combination with bevacizumab .  
 
Figure 4 NuTide:302  Part 3 study schema  
The treatment for each arm is described in Table 5. The choice of arm to which an eligible 
patient should be enrolled will be at the Investigator’s discretion, taking into account the 
patient’s clinical condition and therapi[INVESTIGATOR_346937].   
Table 5 Part 3 treatment arms  
Arm  Treatment  Number of patients  
3a  NUFOX (NUC -3373 + LV Q1W) + bevacizumab  ~10 2nd-line patients  
3b NUFOX (NUC -3373 + LV Q2W) + bevacizumab   ~10 2nd-line patients  
3c NUFIRI (NUC -3373 + LV Q1W) + bevacizumab  ~10 2nd-line patients  
3d NUFIRI (NUC -3373 + LV Q2W) + bevacizumab  ~10 2nd-line patients  
3e NUC -3373 + LV Q1W + bevacizumab  ~10 maintenance patients  
3f NUFOX (NUC -3373 + LV Q1W or Q2W) + 
cetuximab  ~10 2nd-line patients  
3g NUFIRI (NUC -3373 + LV Q1W or Q2W) + 
cetuximab  ~[ADDRESS_431067] local practice . 
Panitumumab combination arms may also be opened  (~10 2nd-line patients) , depending on 
emerging data.  
Cohorts of rapid progressors may also be opened (~10 patients), depending on emerging data.  

NuTide:[ADDRESS_431068] it would be beneficial 
to evaluate the PK relationship between NUC -3373, LV and irinotecan. If conducted, a n 
additional 8 patients would  be enrolled in the NUFIRI Q1W cohort (Arm  2b). Inclusion into 
this sub -study will also involve individual patient genotypi[INVESTIGATOR_346938] -related toxicities. Genotypi[INVESTIGATOR_346939]. The genomic DNA will be analysed using pharmacogenomic protocols 
specific for individual genotypes for drug metabolising enzymes and drug transporters, e.g., 
TATA box polymorphism of the UGT1A1 p romoter region and NR1I2 -rs10934498 
polymorphism, prior to admission to this sub -study . Genotypi[INVESTIGATOR_346940] a known UGT1A1 status from prior testing.  
In Cycle 1 of the sub -study, irinotecan and LV will be administered concurren tly on Day 1. On 
Day 8, NUC -3373 and LV will be administered  sequentially . On Day 15, 4 patients (Group A) 
will first be administered irinotecan concurrently  with LV , followed by  [CONTACT_346982] -3373. The 
remaining 4  patients (Group B) will first be administered NUC -3373, followed by [CONTACT_347017] . On Day 22,  NUC -[ADDRESS_431069] be administered irinotecan concurrently  with LV, followed 
by [CONTACT_346982] -3373. Patients will be alternately  assigned to Group A or Group B. The dose s of 
NUC -3373  and irinotecan  used in the sub -study will be the recommended dose s determined in 
Arm 2b.  
 C1D1  C1D8  C1D15  C1D22  C2D1  
Group A  Irinotecan + LV  LV  NUC -
3373  Irinotecan + LV 
 NUC -3373  LV  NUC -
3373  NUC -3373  
Irinotecan + LV  
Group B  Irinotecan + LV LV  NUC -
3373  NUC -3373  
Irinotecan + LV  LV > NUC -
3373  Irinotecan + LV 
 NUC -[ADDRESS_431070] C1D15. If patients 
discontinue study treatment or require dose modifications before C1D15, they will be 
considered non -evaluable and will be replaced.  Following this, patients will continue on the 
treatment  schedule outlined for Arm 2b .  
3.2. Rationale for the NUC -3373  Dose S elected  
The safety of NUC -3373 as a single agent at doses ranging from 125 to 3250  mg/m2 
adminis tered on Days 1, 8, 15 and 22 of a 28 -day schedule has been studied in the  NuTide:301 
study as described in Section 1.5 . This study also include d a Q2W schedule and doses of 1500 
to 2500  mg/m2 administered on Days [ADDRESS_431071] been evaluated. 
Enrolment to this  study has completed and the final results are being collated and analysed . 
Four  patients experienced DLTs . In the 500 mg/m2 Q1W  and 1875  mg/m2 Q1W cohort s, DLT s 
NuTide:[ADDRESS_431072] c                                                             Confidential  72 of Grade 3 transamin ases increased  were reported. In the 3250 mg/m2 Q1W  cohort, two DLTs  
were reported, one DLT  of Grade 2 headache and one DLT of Grade 3 transient hypotension 
(drop in blood pressure for <5 minutes). Based on th ese findings , the MTD for single -agent 
NUC -3373 was determined to be 2500  mg/m2 Q1W . The DSMC for the NuTide :301 st udy has 
determined that NUC -3373 as evaluated to date is safe and well -tolerated in patients with 
advanced solid malignancies.  Based on safety data from the NuT ide:301 study and because 
the 1500  mg/m2 dose has been shown to be safe when administered on Da ys 1 and 15 ( Q2W ) 
and when administered more frequently on Days  1, 8, 15 and 22 (Q1W ), this dose was selected 
for all arms of Part 1.  
For Part 2 , NUC -3373  + LV will be given in combination with  oxaliplatin and irinotecan at 
doses standardly used in the FOLFOX and FOL FIRI regimens .  The initial dose of NUC -3373 
to be administered on a Q1W basis with oxaliplatin or irinotecan in Ar m 2a and Arm 2b was 
determined on the basis of safety data collecte d in Part 1 (see Section  3.4) and additional  data 
collected in NuTide:301 .   
For Part 3, the NUC -3373 dose + LV with oxaliplatin selected as the NUFOX regimen and the 
NUC -3373 dose + LV with irinotecan selected as the NUFIRI regimen in Part 2 w ill be 
administered in combination with bevacizumab  or cetuximab . For patients in the maintenance 
cohort, the NUC -3373 dose +  LV selected in Part 1 (2500 mg/m2) will be administered in 
combination with bevacizumab . 
3.3. Study Treatment  
This is a three -part, multi -cohort combination chemotherapy study.  Study treatment s given in 
each arm are described below. Patients may continue to receive NUC -3373 and the 
combination agent(s) until documentation of radiological disease progression using RECIST 
v1.1 or unacceptable toxicity.  Treatment cycles are 28  days in duration.  
Protocol -specific guidelines for NUC -3373  dosage and administration are provided in det ail in 
Section 8. 3. Guidelines for protocol -specific dose modifications and discontinu ations of 
NUC -3373 are provided in  Section 9 . For patients experiencing toxicity related to NUC -3373 
in NUFOX and NUFIRI cohorts, initially the NUC -3373 dose modification  guidelines in 
Section 9 should be followed.  Schedule modifications for the other agents (LV, oxaliplatin, 
irinotecan, VEGF pathway inhibitors, EGFR  inhibitors) will be in accordance with their 
Respective P rescribing Information  or standard local practice , unless safety concerns emerge 
regarding dosing as determined by [CONTACT_6802] .   
The sections below provide suggested administration times and order for each of the 
combination agents; however, each administration in Parts 1, 2 and 3 of the study  may be 
modified based on emerging safety and PK data (in line with local guidelines /relevant 
Prescribing Information ) with agreement from the DSMC .  
It is suggested that NUC -3373 at 1500 mg/m2 is infused over 120 minutes . The infusion 
duration for lower and higher doses of NUC -3373 should be adjusted relative to the 
1500  mg/m2 dose ( e.g., a 25% increase in dose requires a n approximately  25% increase in 
infusion duration) . 
NuTide:302                                                                                                                        Version 4.2, 10 Aug 2022 
 
Confidentia l                                                            NuCana  plc 73 3.3.1 Part 1  (≥3rd-line and combination chemotherapy ineligibl e patients)  
[IP_ADDRESS]  Arm  1a (≥3rd-line patients)  
NUC -3373 was administered by [CONTACT_22671] 1500 mg/m2 over 120 minutes followed by a 
14-day washout period. Thereafter, on Days 1 and 15 of 28 -day cycles, LV was administered 
by [CONTACT_22671] 400 mg/m2 over 120 minutes, followed by [CONTACT_346982] -3373 administration by [CONTACT_346989] -prescribed  dose level.  
[IP_ADDRESS]  Arm 1b  (≥3rd-line patients)  
On Day 1, LV was administered by [CONTACT_22671] 400 mg/m2 over 120 minutes, followed by 
[CONTACT_346982] -3373 infusion at 1500 mg/m2 over 120 minutes.  LV was not administered again in 
Arm 1b.  A fter a 14 -day washout period, NUC -3373 was administered on Days 1 and 15 of 
28-day cycles by [CONTACT_346988] -prescribed  dose level.   
[IP_ADDRESS]  Arm 1c  (≥3rd-line patients)  
On Days 1, 8, 15 and 22 of 28 -day cycles, LV was administered by [CONTACT_22671] 400 mg/m2 
over 120 minutes, followed by [CONTACT_346982] -3373 administration by [CONTACT_347018] -prescribed  dose level.   
[IP_ADDRESS]  Arm 1 d (combination chemotherapy ineligible patients)  
On Days 1, 8, 15 and 22 of 28 -day cycles, LV will be administered by [CONTACT_22671] 400 mg/m2 
over 120  minutes, followed by [CONTACT_346982] -3373 administration by [CONTACT_22671] 2500 mg/m2 over 
200 minutes . 
[IP_ADDRESS]  NUC -3373 Dosing  for Part 1  
It was anticipated that 1500 mg/m2 would be the starting dose for all arms in Part [ADDRESS_431073]  been evaluated 
if recommended by [CONTACT_6802].   
If cohorts at additional dose levels  were opened, these w ere to  utilise a modified 3+[ADDRESS_431074] patient and treatment of 
subsequent patients  in a cohort .  
Table 6 Anticipated dose levels of NUC -3373 to be evaluated in Part 1  
 ≥3rd-line patients  
Dose 
Level * NUC -3373 dose (mg/m2)  
Days 1 and 15  
Arms 1a and 1b  NUC -3373 dose (mg/m2)  
Days 1, 8, 15 and 22 
Arm 1c  
 -1 1000 1250 
1 1500  1500  
2 2000  1750  
3 2500 2000  
4 3000  2250  
* Additional dose levels could  be explored if necessary  
 
NuTide:[ADDRESS_431075] c                                                             Confidential  74 3.3.2 Part 2   
The order of administration of each of the agents in Part 2 may be modified with approval from 
the DSMC, so that NUC -3373 + LV is infused first followed by [CONTACT_346990] (Arms 2a 
and 2c) or irinotecan (Arms 2b and 2d). Alternate infusion parameters may be implemented 
with approval from the DSMC . 
[IP_ADDRESS]  Dose Escalation ( ≥3rd-line patients)  
In the NUFOX and NUFIRI dose escalation cohorts, patients will receive NUC -3373 + LV 
Q1W combined with the standard dose and schedule of oxaliplatin and irinotecan.  
Arm 2a  
NUC -3373 + LV will be administered Q1W  and oxaliplatin will be administered Q2W  in 
28-day cycles, as outlined in Table 7. 
Table 7 Study treatment in Arm 2a  
Infusion order  Infusion duration  D1 D8 D15 D22 
LV (400 mg/m2)a 
120 minsa X X X X 
Oxaliplatin (85 mg/m2)a X  X  
NUC -3373  (cohort prescribed dose level)  120 minsb X X X X 
aLV and oxaliplatin to be administered concurrently  
bSuggested duration, refer to Pharmacy Manual  
 It is anticipated that 1500 mg/m2 will be the starting dose in the first dose administration cohort 
for Arm 2a and is noted as ‘Dose Level 1 ’ in Table 8.  The starting dose will not be higher than 
the MTD established in Part 1c. Based on a clinical study  of NUC -3373 ( NuTide:[ADDRESS_431076] 
2015 -002250 -13, [STUDY_ID_REMOVED] ), alternate and/or additional  dose levels may be considered 
and implemented upon recommendation of the DSMC.   
Table 8 Anticipated dose levels of agents to be evaluat ed in Arm 2a  
Dose Level * NUC -3373  (mg/m2) 
Days 1, 8, 15 and 22 Leucovorin  (mg/m2) 
Days 1, 8, 15 and 22 Oxaliplatin  (mg/m2)** 
Days 1 and 15  
-1 1250 400 85 
1 1500  400 85 
2 1750  400 85 
3 2000  400 85 
4 2250  400 85 
* Additional dose levels may be explored if necessary  
** Alternative dose levels of oxaliplatin may be explored based on PK analyses and safety observations  
Arm 2b  
NUC -3373 + LV will be administered Q1W  and irinotecan will be administered Q2W  in 
28-day cycles, as outlined in Table 9. 
NuTide:302                                                                                                                        Version 4.2, 10 Aug 2022 
 
Confidentia l                                                            NuCana  plc 75 Table 9 Study treatment in Arm 2b  
Infusion ordera Infusion duration  D1 D8 D15 D22 
LV (400 mg/m2)b 
120 minsc X X X X 
Irinotecan (180 mg/m2)b   X  X  
NUC -3373  (cohort prescribed dose level)  120 minsd X X X X 
aThe infusion order may change as a result of emerging PK or safety data (refer to the PK Manual for further 
information)  
bLV and irinotecan to be administered concurrently  
cThe infusion duration for irinotecan may be changed to 90 mins based on emerging data  
dSuggested duration, refer to Pharmacy Manual  
It is anticipated that 1500 mg/m2 will be the starting dose in the first dose administration cohort 
for Arm  2b and is noted as Dose Level 1 in Table 10.  The starting dose w ill not be higher than 
the MTD es tablished in Part 1c. Based on a clinical study  of NUC -3373 ( NuTide:[ADDRESS_431077] 
2015 -002250 -13, [STUDY_ID_REMOVED] ), alternate and/or additional dose levels may be considered 
and implemented upon recommendation of the DSMC.   
Table 10 Anticipated dose levels of NUC -3373 to be evaluated in Arm 2 b 
Dose Level * NUC -3373  (mg/m2) 
Days 1, 8, 15 and 22 Leucovorin (mg/m2) 
Days 1, 8, 15 and 22 Irinotecan (mg/m2)** 
Days 1 and 15  
-1 1250 400 180 
1 1500  400 180 
2 1750  400 180 
3 2000  400 180 
4 2250  400 180 
* Additional dose levels may be explored if necessary  
** Alternative dose levels of irinotecan may be explored based on PK analyses and safety observations  
The MTD for NUFIRI has been established in Arm 2b and was determined to be 1500 mg/m2 
NUC -3373 + 400 mg/m2 LV + 180 mg/m2 irinotecan.   
[IP_ADDRESS]  Dose Expansion (2nd-/3rd-line patients)  
Following completion of Arms 2a and 2b, expansion cohorts may be initiated at the selected 
dose levels established in the dose escalation phase. The NUFOX and NUFIRI regimens will 
be administered in separate arms of the study (Arm 2c for NUFOX and Arm 2d f or NUFIRI).  
Arm 2c  
NUC -3373 + LV will be administered Q1W and oxaliplatin will be administered Q2W  in 
28-day cycles, as outlined in Table 11. 
Table 11 Study treatment in Arm 2c  
Infusion order  Infusion duration  D1 D8 D15 D22 
LV (400 mg/m2)a 
120 minsa X X X X 
Oxaliplatin (85 mg/m2)a,b X  X  
NUC -3373  (dose selected in Arm 2a)  120 minsc X X X X 
NuTide:[ADDRESS_431078] c                                                             Confidential  76 aLV and oxaliplatin to be administered concurrently  
bThe oxaliplatin dose may be reduced based on observations in Arm 2a  
cSuggested duration, refer to Pharmacy Manual  
 Arm 2d   
NUC -3373 + LV will be administered Q1W and irinotecan will be administered Q2W  in 
28-day cycles, as outlined in Table 12. 
Table 12 Study treatment in Arm 2d  
Infusion ordera Infusion duration  D1 D8 D15 D22 
LV (400 mg/m2)b 
120 minsc X X X X 
Irinotecan (180 mg/m2)b X  X  
NUC -3373  (1500 mg/m2) 120 minsd X X X X 
aThe infusion order may change as a result of emerging PK or safety data (refer to the P K/PD  Manual for 
further information)  
bLV and irinotecan to be administered concurrently  
cThe infusion duration for irinotecan may be changed to 90 mins based on emerging da ta 
dSuggested duration, refer to pharmacy manual  
For patients experiencing toxicity related to NUC -3373 in the NUFOX and NUFIRI cohorts, 
initially the NUC -3373 dose modification guidelines in Section 9 should be f ollowed. The 
doses of oxaliplatin and irinotecan may be adjusted (through agreement with the DSMC) based 
on, but not limited to, safety and PK data generated in patients receiving treatment with 
NUFOX and NUFIRI regimens. If oxaliplatin or irinotecan -related AEs are observed, dose 
de-escalation should be performed as per the respective Prescribing Information  or standard 
local practice . The modified dose of oxaliplatin or irinotecan (in combination with NUC -3373) 
will be assessed in approximately  6 evaluabl e patients in each arm.  
3.3.3 Part 3  (2nd-line patients and maintenance patients)  
 In Part 3, 2nd-line patients will receive the NUFOX and NUFIRI regimens selected in Part [ADDRESS_431079]. 
Following this,  Q2W arms and/or cetuximab combination arms may be opened, depending on 
emerg ing data.  In addition, patients qualifying for maintenance therapy may receive NUC -3373 
in combination with bevacizumab.  
Refer to Section 8.3.3  for detailed guidance on administration of each study drug.  
[IP_ADDRESS]  Arm 3a  (2nd-line patients)  
NUC -3373 , LV and oxaliplatin at dose  levels  used in Arm 2 a will be combined with 
bevacizumab . NUC -3373 and LV will be administered Q1W  and oxaliplatin  and bevacizumab  
will be administered Q2W .    
[IP_ADDRESS]  Arm 3b  (2nd-line patients)  
NUC -3373 , LV and oxaliplatin at dose  levels  used in Arm 2 a will be combined with 
bevacizumab . NUC -3373 , LV, oxaliplatin  and bevacizumab  will be administered Q2W.     
NuTide:302                                                                                                                        Version 4.2, 10 Aug 2022 
 
Confidentia l                                                            NuCana  plc 77 [IP_ADDRESS]  Arm 3c  (2nd-line patients)  
NUC -3373 , LV and irinotecan at dose  levels  used in Arm 2 b will be combined with 
bevacizumab . NUC -3373 and LV will be administered Q1W  and irinotecan  and bevacizumab  
will be administered Q2W .    
[IP_ADDRESS]  Arm 3d  (2nd-line patients)  
NUC -3373 , LV and irinotecan  at dose  levels  used in Arm 2 b will be combined with 
bevacizumab . NUC -3373 , LV, irinotecan  and bevacizumab  will be administered Q2W.   
[IP_ADDRESS]  Arm 3e (Maintenance patients ) 
NUC -3373 (2500 mg/m2 Q1W) + LV (400 mg/m2 Q1W) will be combined with bevacizumab  
and bevacizumab  (5 mg/kg Q2W).  
Arm 3f (2nd-line patients)  
NUC -3373, LV and oxaliplatin at dose  levels  used in Arm 2 a may be administered in 
subsequent  cetuximab  cohorts . NUC -3373 + LV may be administered Q1W or Q2W , 
oxaliplatin will be administered Q2W and cetuximab will be administered Q1W  
[IP_ADDRESS]  Arm 3g (2nd-line patients ) 
NUC -3373 , LV  and irinotecan  at dose  levels  used in Arm 2 b may be administered in 
subsequent  cetuximab  cohorts . NUC -3373 + LV  may be administered Q1W  or Q2W , 
irinotecan will be administered Q2W and cetuximab will be administered Q1W .  
In all bevacizumab -containing arms, NUC -3373 dose adjustments may occur depending on 
emerging data.  
Panitumumab combination arms may also be opened  (~10 2nd-line patients) , depending on 
emerging data.  
Cohorts of rapid progressors may also be opened (~10 patients), depending on emerging data.  
3.3.4 PK sub -study  
Patients participating in the PK sub -study will receive NUC -3373, LV and irinotecan, as 
outlined in Table 13. 
Table 13 Study treatment in PK sub -study  
Infusion order  Infusion duration  C1D1 C1D8 C1D15c C1D22 C2D1c 
(29 days 
after start 
of 
treatment)  
LVa 120 minsa X X X X X 
Irinotecana,   90 minsa X  X  X 
NUC -3373  120 minsb  X X X X 
aLV and irinotecan to be administered concurrently  
bSuggested duration, refer to Pharmacy Manual  
cPatients will be alternately assigned  to two groups (Group A and Group B) for treatment on Cycle 1 Day 15 
and Cycle 2 Day 1 (29 days after the start of treatment)  and will receive the study treatments in an order that 
has been pre -specified for each group (refer to Section 7.2.1  for details)  
Patients enrolled in the PK sub -study will be considered evaluable for PK endpoints if they have received 
planned study treatment and had PK assessments up to at least C1D15. If patients discontinue study treatment 
or require dose modifications before C1D1 5, they will be considered non -evaluable and will be replaced.   
NuTide:[ADDRESS_431080] c                                                             Confidential  78 Following this, patients will continue on the treatment schedule outlined for Arm 2b.  
3.4. Dose Escalation Guidelines  
In those arms in which dose escalation is considered (Arm 1a, Arm 1b, Arm 1c, Arm 2a, and 
Arm 2b), d ose escalation  decisions will be made according to the dose escalation  guidance 
rules in Table [ADDRESS_431081] received 
NUC -3373 and any assigned combination agent(s)  in accordance with the arm to which the 
patient is assigned, have completed the 28-day safety evaluation requirements , and must have 
- Either received 75% or more of the specified dose  of each agent  during the DLT 
evaluation period  
or 
- experienced a DLT in the assessment period  
Dose escalation  decisions  will occur based on review of  available  safety  information obtained 
during the 28 -day DLT period, including AEs (regardless of causality), laboratory safety data, 
vital signs and ECG data .  Emerging safety data for patients who continue treatment beyond 
Cycle 1 will also be reviewed.   
Table 14 Dose escalation guidance  rules 
Number of Patients with 
DLT at a Given Dose Level  Escalation Decision Rule  
0 out of 3  patient s (0 out of 4 
in modified 3+3)  Dose is tolerable  
≥1 out of 3  patients  Expand cohort, if needed, to include 6 patients.  
• If only 1 out of 6 has DLT, dose is tolerable  
• If ≥ [ADDRESS_431082] DLT s, dose is not tolerable  and lower 
dose cohort should be explored  
≥[ADDRESS_431083] 6 patients are required for the dose to be declared as the MTD; therefore,  additional 
patients may need to be enrolled . 
Patients who withdraw from study treatment prior to the end of  Cycle 1, due to a DLT, will not 
be replaced. Patients who withdraw for other reasons may be replaced.  
3.4.[ADDRESS_431084] 28-day treatment cycle that 
are not due to CRC  or to a known concurrent medical condition  and are judged as clinically 
significant and related to study treatment . 
• Grade 4 neutrop aenia ( absol ute neutrophil count [ ANC ] <0.5x109/L) that persists 
for more than 7 days  
NuTide:302                                                                                                                        Version 4.2, 10 Aug 2022 
 
Confidentia l                                                            NuCana  plc 79 • Febrile neutrop aenia ( ANC <1000/mm3 with a single temperature of  >38.3 °C 
[101°F] or a sustained temperature of ≥38°C [100.4 °F] for >1 hour) 
• Grade 3 thrombocytop aenia (platelets <50.0x109/L) with bleeding complications 
requiring platelet transfusions or that persists for more than 7  days  
• Grade 4 thrombocytop aenia 
• Grade 4 anaemia unexplained by [CONTACT_27846]  
• Grade 5 haematological toxicity  
• Grade 4 diarrhoea or vomiting  that persists despi[INVESTIGATOR_3062]  
• Grade 3 or greater aspartate aminotransferase ( AST )/alanine aminotransferase 
(ALT ) elevation (exceptions may be made for transient [<7 days ] Grade [ADDRESS_431085]/ALT in the presence of known liver metastases and without 
evidence of other hepatic injury, if agreed by [CONTACT_347019])  
•  Grade [ADDRESS_431086]/ALT elevation and Grade 2 or greater bilirubin elevation 
(excep tions may be made for transient [<7 days ] elevations of AST/ALT and 
bilirubin in the presence of known liver metastases without evidence of other 
hepatic injury, if agreed upon by [CONTACT_347019])  
• Any prolonged toxicity that does not re solve to ≤ Grade 1 or baseline within 21  days 
of dose interruption  
• Any other non-haematological toxicity Grade ≥3 except for:  
- Alopecia  
- Grade  3 nausea, vomiting, or diarrhoea events that resolve  within 72 hours  with 
anti-emetic or anti-diarrhoeal therapy  
3.5 Duration of Patient Participation  
Patients may continue to receive NUC -3373  in accordance with the dosing regimen (schedule 
and specific combination) to which they were assigned until the occurrence of radiological 
disease progressi on by [CONTACT_393] v1.[ADDRESS_431087] and on the Treatment Discontinuation page of the case report form ( CRF). 
Should a patient discontinue treatment without radiological evidence of disease progression, 
the p atient should continue to undergo tumo ur assessment every [ADDRESS_431088] to follow -up, death, or the 
overall end of study  has been reached (defined in Section 3.6), whichever occurs first . 
3.[ADDRESS_431089] e lapsed since the final patient 
was enrolled (whichever occurs first, unless the study is terminated early on the 
recommendation of the DSMC or decision of the Sponsor), and it is determined that no further 
arms should be opened based on emerging data.   
NuTide:[ADDRESS_431090] meet the following criteria during the Screening 
period:  
All patients  
1. Provision of written informed consent  
2. Have histological confirmation of CRC with evidence of locally advanced/unresectable 
or metastatic disease  
3. Age ≥18 years  
4. Life expectancy of ≥12 weeks   
5. Eastern Cooperative Oncology Group ( ECOG ) Performance status [ADDRESS_431091] inhibitor (Arms 2a, 2b, 2c, 
2d, 3a, 3b, 3c, 3d and 3e) must have received prior treatment with an EGFR 
inhibito r, unless this was not standard of care according to relevant region -specific 
treatment recommendations. Patients with BRAF V600E mutant tumours should have 
received prior treatment with encorafenib in combination with an EGFR 
inhibitor,  unless this was no t standard of care according to relevant region -specific 
treatment recommendations  
8. Adequate bone marrow function as defined by: [CONTACT_58846]  ≥1.5×109/L, platelet count 
≥100×109/L (with no evidence of bleeding ), and haemoglobin ≥9 g/dL  
9. Adequate liver function, as defined by: [CONTACT_346991] ≤1.5×upper limit of normal 
(ULN), AST  and ALT  ≤2.5×ULN (or ≤5×ULN if liver metastases are present ) 
10. Adequate renal function assessed as serum c reatinine  <1.5×ULN or glomerular 
filtration rate  ≥50 mL/min. This criterion does not apply to the combination 
chemotherapy ineligible patient subgroup  (Arm 1d) ; please refer to specific criteria for 
this subgroup below  
11. Serum albumin ≥3 g/dL  
12. For the cohort in which  the patient will participate, there are no contra -indications to 
receiving the approved partner combination drugs  
13. Ability to comply with protocol requirements  
14. Female patients of child -bearing potential must have a negative serum pregnancy test 
within [ADDRESS_431092] agree to practice true 
abstinence (defined in Section 10.3.1 ) or to use two hi ghly effective forms of 
contraception, one of which must be a barrier method. These forms of contraception 
must be used from the time of signing consent, throughout the treatment period, and for 
[ADDRESS_431093] dose of any study medication. Ora l or injectable 
contraceptive agents cannot be the sole method of contraception  
NuTide:[ADDRESS_431094] dose of study medication  
16. For patients receiving oxaliplatin:   Male patients must have been offered advice on 
and/or sought counselling for conserva tion of sperm prior to the first dose of study 
medication  
In addition to meeting the criteria above for all patients , the following criteria must be met for 
each patient population : 
≥3rd-line patients  
1. Must have received at least two prior lines of therapy for locally advanced or m etastatic 
CRC, including one fluoropyrimidine plus oxaliplatin containing regimen and one 
fluor opyrimidine plus irinotecan containing regimen. Previous treatment with standard 
of care chemotherapy regimens in combination wi th molecular targeted therapi[INVESTIGATOR_014] ( e.g., 
therapi[INVESTIGATOR_346941] -oncology agents) 
is permitted . Patients who have received FOLFOXIRI -based regimens in 1st- and/or 
2nd-line settings may also be included  
2. Patients in Part  2 of the study who are to receive NUFOX regimens should be suitable 
for re -challenge with an oxaliplatin -based regimen   
3. Patients in Part 2 of the study who are to receive NUFIRI regimens should be suitable 
for re -challenge with an irinotecan -based regimen  
2nd-/3rd-line patients  
1. Must have received at least one, but no more of two, prior lines of fluoropyrimidine -
containing therapy  in combination  with oxaliplatin and/or irinotecan  for locally 
advanced or m etastatic CRC. Previous treatment with standard of ca re chemotherapy 
regimens in combination with molecular targeted therapi[INVESTIGATOR_014] ( e.g., therapi[INVESTIGATOR_346942] -oncology agents) is permitted . 
Patients who have received FOLFOXIRI -based regimens in 1st- and/or 2nd-line settings 
may also be include d. 3rd-line patients enrolled to Arms 2c and 2d must have received 
prior bevacizumab treatment, unless ineligible or unless bevacizumab was not standard 
of care according to relevant region -specific treatment recommendations  
2. Patients in Part [ADDRESS_431095] received one  prior line of fluoropyrimidine -containing therapy  for 
locally advanced or m etastatic CRC   
2. Ineligible to receive combination therapy for locally advanced o r metastatic CRC, as 
defined by [CONTACT_347020]:  
a. Dependency for daily activities due to comorbidities (different to deterioration due 
to cancer)  
b. Previous history of t hree or more of the following comorbidities (controlled or 
uncontrolled by [CONTACT_168647]):  
NuTide:[ADDRESS_431096] one of the following geriatric features:  
i. Age > 75 years  
ii. Faecal or urinary incontinence  
iii. Spontaneous bone fractures  
iv. Mild or moderate dementia  
v. Frequent falls 
3. Creatinine clearance of >30 mL/min  
Rapid progressors   
1. Must have received no more than two prior lines of fluoropyrimidine -containing 
therap y in combination  with oxaliplatin and/or irinotecan for locally advanced or 
metastatic CRC . Previous treatment with standard of care chemotherapy regimens in 
combination with molecular targeted therapi[INVESTIGATOR_014] ( e.g., therapi[INVESTIGATOR_346922] -oncology agents) is permitted. Patients who 
have received FOLFOXIRI - based regimen s in 1st - and/or 2nd -line settings may also 
be included  
2. Must have had tumour progression ≤[ADDRESS_431097] received one prior line of fluoropyrimidine -containing therapy in 
combination with oxaliplatin and/or irinotecan for locally advanced or m etastatic CRC. 
Previous treatment with standard of care chemotherapy regimens in combination with 
molecular targeted therapi[INVESTIGATOR_014] ( e.g., therapi[INVESTIGATOR_346943] -oncology agents ) is permitted. Previous treatment with triplet 
chemotherapy -based regimens is allowed ( i.e., FOLF OXIRI ) 
Maintenance patients  
1. Must have  received at least [ADDRESS_431098] stable disease  
2. Eligible for maintenance therapy  
NuTide:302                                                                                                                        Version 4.2, 10 Aug 2022 
 
Confidentia l                                                            NuCana  plc 83 4.2 Exclusion Criteria  
Potential patients who meet any of the following criteria at Screening will be excluded from 
the study:  
All patients  
1. Prior history of hypersensitivity or current contra -indications to [ADDRESS_431099] 
formulation  (Kolliphor ELP, super refined polysorbate 80, dimethylacetamide  [DMA])  
4. Symptomatic central nervous system or leptomeningeal metastases  
5. Symptomatic ascites, ascites currently requiring drainage procedures  or ascites 
requiring drainage over the prior 3 months  
6. Chemotherapy , radiotherapy (other than a short cycle of palliative radiotherapy  [e.g., 
for bone pain]* ), immunotherapy or exposure to another investigational agent  within 
28 days (or five times the half -life for a biological or molecular targeted agent  or three 
times the half -life for an immunotherapy agent ) of first administration  of NUC -3373 : 
• For nitrosoureas and mitomycin C , within [ADDRESS_431100] administration of 
NUC -3373  
• For hormone or biological therapy , within [ADDRESS_431101] administration of 
NUC -3373  
• Corticosteroid treatment is allowed if not more than stable daily dosing of 10 mg 
predn isolone (or steroid  equivalent)  
* Palliative radiotherapy during participation in the study is permitted , but should not 
include a target lesion  
7. Residual toxicities from prior chemotherapy or radiotherapy which have not regressed 
to Grade ≤1 severity ( CTCAE v5.0), except for alopecia. In cohorts not containing  
oxaliplat in, residual Grade [ADDRESS_431102] , or low -grade prostate cancer or patients after 
prostatectomy not requiring treatment .  Patients with previous invasive cancers are 
eligible if treatment was completed more  than 3 years prior to initiating the current 
study treatment and there is  no evidence of recurrence  
9. Presence of an active bacterial or viral infection (including SARS -CoV -2, Herpes 
Zoster or chicken pox ), known Human Immunodeficiency Virus positive or known 
active hepatitis B or C  
10. Presence of any uncontrolled concurrent serious illness, medical condition or other 
medical history, including laboratory results, which, in the Investigator’s opi[INVESTIGATOR_1649], 
would be likely to interfere with the patient ’s ability to participate in the study or with 
the interpretation of the results, including any of the following:  
NuTide:[ADDRESS_431103] c                                                             Confidential  84 a. Congestive heart failure ([LOCATION_001] Heart Association Class III or Class IV)  
b. Myocardial infarction within [ADDRESS_431104] dose of study m edication  
c. Unstable or poorly controlled angina pectoris  
d. Complete left bundle branch, bifascicular block or other clinically significant 
abnormal ECG finding  
e. History  of or current risk factor for torsade s de pointes (e.g., heart failure, 
hypokalaemia, or a family history of long QT syndrome)    
f. History of severe skin reactions  
g. History of severe ocular disorders  
h. Interstitial pneumonitis or pulmonary fibrosis  
11. Any condition ( e.g., known or suspected poor compliance, psychologic al instability, 
geographical location, etc.) that, in the judgment of the Investigator, may affect the 
patient’s ability to sign the informed consent and undergo study procedures  
12. Currently pregnant, lactating or breastfeeding  
13. QTc interval >450 milliseconds  for males and >470 milliseconds for females  
14. Required concomitant use of drugs known to prolong QT/QTc interval  
15. Required c oncomitant use of  strong CYP3A4 inducers or strong CYP3A4 inhibitors, 
or use of strong CYP3A4 inducers within [ADDRESS_431105] receipt of study drug (refer to 
Section 10.3.2 ) 
16. For patients recei ving irinotecan:  Use of strong UGT1A1 inhibitors within [ADDRESS_431106] receipt of study drug (refer to Section 10. 3.3)  
17. Has received a live vaccination within four weeks of first planned dose of study 
medication  
18. Known DPD or TYMP mutations associated with  toxicity to fluoropyrimidines  
19. Use of warfarin and other types of long acting anti -coagulants (such as phenprocoumon 
and anti ‑Xa inhibitors with a half ‑life of >12 hours) is prohibited within [ADDRESS_431107] dose of study treatment. Patients requiring  anti-coagulant treatment should switch 
to low molecular weight heparin or anti ‑Xa inhibitors with a half ‑life of ≤12 hours  
Patients receiving bevacizumab  
1. Patients with a history of haemoptysis (1/2 teaspoon or more of red blood)  
2. Wound healing complications or surgery within 28 days of starting bevacizumab  
(wound healing must have been fully completed before starting bevacizumab ) 
3. Severe chronic wou nds, ulcers or bone fracture  
4. Arterial thromboembolic events or haemorrhage within 6 months prior to study entry 
(except for tumour bleeding surgically treated by [CONTACT_347021])  
5. Bleeding diatheses or coagulopathy  
6. Receiving full -dose anti -coagulation treatment . Patients who have been on stable doses 
for at least [ADDRESS_431108] 
12 months or high risk of uncontrolled arrhythmia  
NuTide:302                                                                                                                        Version 4.2, 10 Aug 2022 
 
Confidentia l                                                            NuCana  plc 85 9. Severe proteinuria (nephrotic syndrome)  
10. Acute or subacute ileus, chronic inflammatory bowel disease or chronic di arrhoea  
11. Any contraindication present in the bevacizumab Prescribing Information  
Patients receiving cetuximab  or panitumumab  
1. Clini cally significant coronary heart disease or myocardi al infarction within the last 
12 months or high risk of uncontrolled arrhythmia  
2.  Acute or subacute ileus, chronic inflammatory bowel disease or chronic diarrhea  
3. Hypomagnesaemia or hypokalaemia not controlled by [CONTACT_346994]  
4. Any contraindication present in the cetuximab or panitumumab Prescribing Information  
Patients participating in the PK sub -study (Arm 2b)  
1. Patients with the UGT1A1 *28/*28 genotype (homozygous poor UGT1A1 
metabolisers)  
4.[ADDRESS_431109] the Medical Monitor  who will consult the 
Sponsor before responding to the enquiry.  
NuTide:[ADDRESS_431110] be recorded in the patient’s medical record for 
extraction into the CRF.  Refer to the Summary Schedule of Events  for further details . 
5.1 Informed Consent  
Potential patients will be given the current approved version of the study information sheet and 
informed consent form (ICF). They will also receive clear verbal information ab out the study 
detailing no less than: the nature of the study; the implications and constraints of the protocol; 
the known side effects and any risks involved in taking part. It will be explained that they will 
be free to withdraw from the study at any tim e, for any reason, without prejudice to future care, 
and with no obligation to give a reason for withdrawal. They will have at least [ADDRESS_431111] be authoris ed by [CONTACT_347022]. The Investigator is 
responsible for ensuring that the study consent procedures comply with International Council 
for Harmonisation Good Clinical Practice ( ICH-GCP ) and any other additional local regulatory 
requirements. Informed consent discussions and out comes must be well documented in the 
medical record. The Investigator must be satisfied that the patient has made an informed 
decision before taking consent. The patient and the Investigator  or author ised designee  who 
obtains consent must personally sign a nd date the current approved version of the ICF in each 
other’s presence.  
A copy of the study information and signed ICF will be given to the patient. The original signed 
form will be retained at the study site, with copi[INVESTIGATOR_346944].  Written informed consent for participation in the study must be obtained 
prior to  performing  any study -specific screening tests or evaluations.  
5.1.[ADDRESS_431112] be kept of all patients considered for the 
study ( i.e., all those that are included for screening and any that are subseque ntly excluded). 
The reason for exclusion must be recorded on this form.  A copy of the Screening Log must be 
retained on site and provided to the Clinical Research Organisation ( CRO ) upon request, but 
without patient identifiers.  
NuTide:302                                                                                                                        Version 4.2, 10 Aug 2022 
 
Confidentia l                                                            NuCana  plc 87 5.3 Screening Assessments  
Screening assessments of consented patients will comprise the following:  
• Provision of written informed consent  
• Eligibility confirmation, including histological diagnosis of m CRC , with evidence 
of disease recurrence  
• Recording of demographic data  
• Assessment of medical and surgical history, including prior therapy for CRC  
• Recording of concomitant medication  
• Routine physical examination  (including neurological exam) , including vital signs. 
Vital signs include measurement of pulse rate, respi[INVESTIGATOR_98157], blood pressure and 
temperature, after the patient has been seated or in the supi[INVESTIGATOR_19636] 5 minutes  
• Height and weight  
• Baseline assessment of symptoms  
• ECOG performance s tatus  
• 12-lead ECG   
o The 12-lead ECGs should be performed in triplicate (keepin g the leads in place 
and patient supi[INVESTIGATOR_346945]) and reviewed by [CONTACT_46874] a 
qualified designee for safety and quality  
o The QTc interval should be calculated for each ECG using the Fridericia  
formula and averaged. Management of QT/QTc prol ongation should be 
performed in accordance with institutional standard of care at the discretion of 
the treating physician  
o Digital and certified paper copi[INVESTIGATOR_346946] a future analysis  
• Blood samples drawn for: 
o Haematology: white blood c ell (WBC) count, differential WBC count,  red 
blood cell count (RBC) , haemoglobin, h aematocrit and platelets  
o Coagulation parameters : prothrombin time/international normalised ratio 
(PT/INR ) and activated partial thromboplastin time ( aPTT ) 
o Chemistry: sodium, potassium, magnesium, urea, creatinine, glucose, 
phosphate, total protein, albumin, adjusted calcium, total bilirubin, bicarbonate, 
chloride, u ric acid, alkaline phosphatase, AST, ALT and lactate dehydrogenase 
(LDH ) 
o Pregnancy testing : For women of childbearing potential serum pregnancy  must 
be performed within [ADDRESS_431113] dose  
o RAS /BRAF  mutation status testing, if unknown  
o Tumo ur markers  (carcinoembryonic antigen [ CEA ]) 
NuTide:[ADDRESS_431114] c                                                             Confidential  88 o PK sub -study only:  genotypi[INVESTIGATOR_346947] . Genotypi[INVESTIGATOR_346948] a known 
UGT1A1 status from prior testi ng.   
• Urinalysis: pH, specific gravity, ketones, leukocytes, protein, glucose, bilirubin, 
urobilirubin and occult blood. Dipstick testing is acceptable  
• Tumo ur imaging (computed tomography [ CT] or magnetic resonance imaging 
[MRI ] of thorax , abdomen  and pelvis)  – performed within [ADDRESS_431115]  v1.1  
• Advise the patient to take measures to avoid or minimise exposure to UV light for 
the duration of study participation and for a period of [ADDRESS_431116] 
dose of study medication  
• For patien ts receiving oxaliplatin:   Male patients must have been advised on and/or 
sought counselling for conservation of sperm prior to the first dose of study 
medication  
• Patient registration  
• Obtain  an archival  tumo ur tissue  block , if available  
• For consenting patients with an accessible tumo ur that is not a target lesion for the 
purposes of the study, obtain a  fresh tumour specimen . Patients should  not be put at 
undue risk for collection of tumo ur samples. For sampling procedures, storage 
conditions,  and shipment instructions, see the Laboratory Manual  
• Blood samples  (optional)  for mRNA analyses ( e.g., PAX gene)  – Refer to 
Section  7.4 for more details  
5.4 Re-Screening Patients who Fail Screening  
If a patient does not meet the inclusion/exclusion criteria upon first assessment, the patient can 
be re -screened within [ADDRESS_431117] be 
repeated and confirmed as meeti ng the inclusion criteria for the study in advance of C0D1 
(Arms  1a and 1b) or C1D1 of all other parts of the study .  During the re -screening process, any 
Screening assessment that will be greater than 28 days from the date taken to C0D1 (Arms 1a 
and 1b) o r C1D1 of all other parts of the study must also be repeated.  
5.[ADDRESS_431118] the assessments detailed in Section 
5.5.9  during Cycle 1 and on Days 1 and 2 of Cycle 2. Following this, patients in the sub -study 
will continue with the normal assessments described for patients in Arm 2b ( Sections 5.5.2  to 
5.5.8 ).  
NuTide:302                                                                                                                        Version 4.2, 10 Aug 2022 
 
Confidentia l                                                            NuCana  plc 89 5.5.1 Cycle 0  (Arm  1a and Arm  1b) 
All procedures to be completed prior to dosing except treatment  and collection of on -treatment 
and post -treatment blood samples.   
• Recording of new or changes to concomitant medication  
• Routine physical examination  (including neurological examination) , including vital 
signs. Vital signs include measurement of pulse rate, respi[INVESTIGATOR_697], blood pressure 
and temperature, after the patient has been seated or in the supi[INVESTIGATOR_19636] 
5 minutes  
• Weight  
• ECOG performance s tatus  
• 12-lead ECGs should be performed prior to infusion of all IMPs   
o At Cycle  [ADDRESS_431119]-infusion  of NUC -3373   
o The ECGs should be performed in triplicate (keepi[INVESTIGATOR_346949]) and reviewed by [CONTACT_46874] a qualified 
designee for safety and quality  
o The QTc interval should be calculated fo r each ECG using the Fridericia  
formula and averaged. Management of QT/QTc prolongation should be 
performed in accordance with institutional standard of care at the discretion of 
the treating physician  
o Digital and certified paper copi[INVESTIGATOR_346946] a future analysis  
• Blood samples drawn for:  
o Haematology: WBC count, differential WBC count, RBC, haemoglobin, 
haematocrit and platelets  
o Coagulation parameters : PT/INR and  aPTT  
o Chemistry: sodium, potassium, magnesium, urea, creatinine, glucose, 
bicarbonate, chloride, uric acid, phosphate, total protein, albumin, adjusted 
calcium, total bilirubin, alkaline phosphatase, AST, ALT and LDH  
o Tumo ur markers ( CEA ) 
• Urinalys is: pH, specific gravity, ketones, leukocytes, protein, glucose, bilirubin, 
urobilirubin and occult blood. Dipstick testing is acceptable  
• Urine pregnancy test for women of child -bearing potential. If any urine test result 
is positive, patient dosing will b e postponed until the result is confirmed by a serum 
pregnancy test. Any patient with a positive serum test will not be allowed to receive 
any study treatment  
• IV administration of NUC -3373 ± LV: 
o Arm 1a: NUC -3373  only 
o Arm1b: LV + NUC -3373  
• AE recording and causality assessment  
NuTide:[ADDRESS_431120] c                                                             Confidential  90 • Blood  samples for PK  measurements  - Refer to Section 7.2  for more details  
• Part 1 only : Blood samples for PD  measurements  - Refer to Section 7.3  for more 
details  
• Blood samples  (optional)  for mRNA analyses ( e.g., PAX gene)  if not taken at 
Baseline/Screening  – Refer to Section 7. 4 for more details  
5.5.2 Each c ycle, Day 1  
All procedures to be c ompleted prior to dosing  except study drug  administration and applicable 
PK samples.  
• Recording of new or changes to concomitant medication.  
• Routine physical examination  (including neurological examination) , including vital 
signs.  Vital signs include measurement of pulse rate, respi[INVESTIGATOR_697], blo od pressure  
and temperature , after the patient has been seated or in the supi[INVESTIGATOR_19636] 
5 minutes  
• Weight  
• ECOG performance s tatus  
• 12-lead ECGs should be performed prior to infusion of all IMPs  
o At Cycle 1 Day 1 , Cycle 2 Day 1 (Part 3 only) and Cycle [ADDRESS_431121] -infusion  of NUC -3373   
o The ECGs should be performed in triplicate (keepi[INVESTIGATOR_346949]) and reviewed by [CONTACT_46874] a qualified 
designee for safety and quality  
o The QTc interval should be calculated for each ECG using the Fridericia  
formula and averaged. Management of QT/QTc prolongation should be 
performed in accordance with institutional standard of care at the discretion of 
the tr eating physician  
o Digital and certified paper copi[INVESTIGATOR_346946] a future analysis  
• Blood samples drawn for: 
o Haematology: WBC  count, differential WBC count, RBC, haemoglobin, 
haematocrit and platelets  
o Coagulation parameters : PT/INR and  aPTT * 
* Do not repeat for patients enrolled into Arms  1a and 1b  
o Chemistry: sodium, potassium, magnesium, urea, creatinine, glucose, 
bicarbonate, chloride, uric acid, phosphate, total protein, albumin, adjusted 
calcium, total bilirubin, alkaline phosphatase, AST, ALT and LDH  
o Tumour markers (CEA)  
• Urinalysis: pH, specific gravity, ketones, leukocytes, protein, glucose, bilirubin,  
urobilirubin and occult blood. Dipstick testing is acceptable  
NuTide:302                                                                                                                        Version 4.2, 10 Aug 2022 
 
Confidentia l                                                            NuCana  plc 91 • Urine pregnancy test for women of child -bearing potential. If any urine test result 
is positive, patient dosing will be postponed until the result is confirmed by a serum 
pregnancy test. Any patient with a positive serum test will not be allowed to receive 
any study treatment  
• IV administration of study drug:  
o Arm 1a: NUC -3373 + LV 
o Arm 1b: NUC -3373 alone  
o Arm 1c: NUC -3373 + LV  
o Arm 1d: NUC -3373 + LV  
 
o Arm 2a: NUC -3373 + LV + oxaliplatin  
o Arm 2b: NUC -3373 + LV + irinotecan  
o Arm 2c: NUC -3373 + LV + oxaliplatin  
o Arm 2d: NUC -3373 + LV + irinotecan  
 
o Arm 3a: NUC -3373 + LV + oxaliplatin  + bevacizumab  
o Arm 3b: NUC -3373 + LV + oxaliplatin  + bevacizumab  
o Arm 3c: NUC -3373 + LV + irinotecan  + bevacizumab  
o Arm 3d: NUC -3373 + LV + irinotecan  + bevacizumab  
o Arm 3e: NUC -3373 + LV + bevacizumab  
o Arm 3f: NUC -3373 + LV + oxaliplatin + cetuximab  
o Arm 3g: NUC -3373 + LV + irinotecan  + cetuximab  
• AE recording and causality assessment . 
5.5.3 Cycle 1  ONLY  – Days 1, 2 & 3, and Day s 15 & 16  
• Blood samples for PK  measurements  - Refer to Section 7.2  for more details  
• Arms 1d and 3e only:  Urine  samples for PK  measurements  - Refer to Section 7.2  
for more details  
o 0-8 and 8 -24* hour or 48 -hour urine collection starting from the beginning of 
NUC -3373 infusion (to be collected in 3 -6 patients in each arm). For patients 
who provide optional consent, urine collection will continue for 48 hours on 
C1D1 only.  
*Patient to be provided with sample collection kit so they can continue to collect 
urine samples at home. The samples will then be brought back when the patient 
attends for the Day 2  or Day 16  (24 hours) or Day 3 (48 hours) blood samples. For 
logistical reasons ( e.g., if the patient lives far away) it may be necessary for the 
patient to stay overnight.  
• Part 1 only:  Blood samples for PD  measurements  (Days 1 and 15 only)  - Refer to 
Section 7.3  for more details  
NuTide:[ADDRESS_431122] c                                                             Confidential  92 • Blood samples (optional) for mRNA analyses ( e.g., PAX gene)  if not taken at 
Baseline/Screening  – at Day 1 only  in Cycle 1  (Cycle 0 Day 1 in Arms 1a and 1b)  
- Refer to Section 7. 4 for more details  
5.5.4 Cycle 1 ONLY – Day 8 (or Day 15)  
• For consenting patients with an accessible tumour  that is not a target lesion for the 
purposes of the study, obtain a n optional  fresh tumour specimen  3-6 hours after 
study drug treatment . Patients should not be put at undue risk for collection of 
tumour sample s. For sampling procedures, storage conditions, and shipment 
instructions, see the Laboratory Manual  
5.5.5 Cycle 3  – Days 1 & 15 (C3D1  & C3D15 ; all cohorts)  
• Blood samples (optional) for mRNA analyses ( e.g., PAX gene)  – at Day 1 only  in 
Cycle 3  - Refer to Section 7. 4 for more details  
5.5.6 Each c ycle, Day 8 (Q1W  dosing cohorts only)  
All procedures to be completed prior to dosing : 
• Recording of new or changes to concomitant medications  
• Routine physical examination  (including neurological examination) , including vital 
signs. Vital signs include measurement of pulse rate, respi[INVESTIGATOR_697], blood pressure 
and temperature, after the patient has been seated or in the supi[INVESTIGATOR_19636] 
5 minutes  
• 12-lead ECGs will be pe rformed prior to infusion of all IMPs  at all relevant visits   
o The ECGs should be performed in triplicate (keepi[INVESTIGATOR_346949]) and reviewed by [CONTACT_46874] a qualified 
designee for safety and quality  
o The QTc interval should be calculated for each ECG using the Frideric ia 
formula and averaged. Management of QT/QTc prolongation should be 
performed in accordance with institutional standard of care at the discretion of 
the treating physician  
o Digital and certified paper copi[INVESTIGATOR_346950] a future analysis  
• Blood samples drawn for:  
o Haematology: WBC count, differential WBC count, RBC, haemoglobin, 
haematocrit and platelets  
o Chemistry: sodium, potassium, magnesium, urea, creatinine, glucose, 
bicarbonate, chloride, uric acid, phosphate, total protein, albumin, adjusted 
calcium, total bilirubin, alkaline phosphatase, AST, ALT and LDH  
• IV administration of study drug:  
o Arm 1c: NUC -3373 + LV  
o Arm 1d: NUC -3373 + LV  
 
NuTide:302                                                                                                                        Version 4.2, 10 Aug 2022 
 
Confidentia l                                                            NuCana  plc 93 o Arm 2a: NUC -3373 + LV 
o Arm 2b: NUC -3373  + LV 
o Arm 2 c: NUC -3373 + LV  
o Arm 2 d: NUC -3373 + LV  
 
o Arm 3a: NUC -3373 + LV  
o Arm 3c: NUC -3373 + LV  
o Arm 3e: NUC -3373 + LV  
o Arm 3f: NUC -3373 + LV  + cetuximab  (if administered Q1W)  
o Arm 3g: NUC -3373 + LV + cetuximab  (if administered Q1W)  
• AE recording and causality assessment  
5.5.7 Each cycle, Day 15  (all cohorts)  
All procedures to be completed prior to dosing except study drug administration and applicable 
PK samples.  
• Recording of new or changes to concomitant medications  
• Routine physical examination  (including neurological examination) , including vital 
signs. Vital signs include measurement of pulse rate, respi[INVESTIGATOR_697], blood pressure 
and temperature, after the patient has been seated or in the supi[INVESTIGATOR_346951] 
5 minutes  
• 12-lead ECGs should be performed prior to infusion of all IMPs at all visits .  
o At Cycle 1  Day 1 5, Cycle 2 Day 15 (Part 3 only)  and Cycle [ADDRESS_431123] -infusion  of NUC -3373 .  
o The ECGs sh ould be performed in triplicate (keepi[INVESTIGATOR_346949]) and reviewed by [CONTACT_46874] a qualified 
designee for safety and quality  
o The QTc interval should be calculated for each ECG using the Fridericia  
formula and averaged. Management of QT/QTc prolongation should be 
performed in accordance with institutional standard of care at the discretion of 
the treating physician  
o Digital and certified paper copi[INVESTIGATOR_346952] a future analysis  
o Note:  Section 5.5. [ADDRESS_431124] dose, in addition to pre -infusion ECG 
measurements  
• Blood samples drawn for:  
o Haematology: WBC count, differential WBC count, RBC, haemoglobin, 
haematocrit and platelets  
NuTide:[ADDRESS_431125] c                                                             Confidential  94 o Chemistry: sodium, potassium, magnesium, urea, creatinine, glucose, 
bicarbonate, chloride, uric acid, phosphate, total protein, albumin, adjusted 
calcium, total bilirubin, alkaline phosphatase, AST, ALT and LDH  
• IV administration of study drug:  
o Arm 1a: NUC -3373 + LV 
o Arm 1b: NUC -3373 alone  
o Arm 1c: NUC -3373 + LV  
o Arm 1d: NUC -3373 + LV  
 
o Arm 2a: NUC -3373 + LV + oxaliplatin  
o Arm 2b: NUC -3373 + LV + irinotecan  
o Arm 2c: NUC -3373 + LV + oxaliplatin  
o Arm 2d: NUC -3373 + LV + irinotecan  
 
o Arm 3a: NUC -3373 + LV + oxaliplatin  + bevacizumab  
o Arm 3b: NUC -3373 + LV + oxaliplatin  + bevacizumab  
o Arm 3c: NUC -3373 + LV + irinotecan  + bevacizumab  
o Arm 3d : NUC -3373 + LV + irinotecan + bevacizumab  
o Arm 3e: NUC -3373 + LV + bevacizumab  
o Arm 3f: NUC -3373 + LV + oxaliplatin + cetuximab  
o Arm 3g: NUC -3373 + LV + irinotecan + cetuximab  
• AE recording and causality assessment  
• Blood samples for PK  measurements  (Cycle 1 only) - Refer to Section 7.2  for more 
details  
• Part 1 only : Blood samples for PD  measurements  (Cycle 1 only) - Refer to 
Section  7.3 for more details  
5.5.8 Each cycle, Day 22 (Q1W  cohorts only)   
All procedures to be completed prior to dosing with study drug:  
• Recording of new or changes to concomitant medications  
• Routine physical examination  (including neurological examination) , including vital 
signs. Vital signs include measurement of pulse rate, respi[INVESTIGATOR_697], blood pressure 
and temperature, after the patient has been seated or in the supi[INVESTIGATOR_346951] 
5 minutes  
• 12-lead ECGs should be performed prior to infusion of all IMPs  at all relevant visits  
o The ECGs should be performed in triplicate (keepi[INVESTIGATOR_346949]) and reviewed by [CONTACT_46874] a 
qualifie d designee for safety and quality  
NuTide:302                                                                                                                        Version 4.2, 10 Aug 2022 
 
Confidentia l                                                            NuCana  plc 95 o The QTc interval should be calculated for each ECG using the Fridericia  
formula and averaged. Management of QT/QTc prolongation should be 
performed in accordance with institutional standard of care at the discretion 
of the  treating physician  
o Digital and certified paper copi[INVESTIGATOR_346953] a future 
analysis  
• Blood samples drawn for:  
o Haematology: WBC count, differential WBC count, RBC,  haemoglobin, 
haematocrit and platelets  
o Chemistry: sodium, potassium, magnesium, urea, creatinine, glucose, 
bicarbonate, chloride, uric acid, phosphate, total protein, albumin, adjusted 
calcium, total bilirubin, alkaline phosphatase, AST, ALT and LDH  
• IV administration of study drug:  
o Arm 1c: NUC -3373 + LV  
o Arm 1d: NUC -3373 + LV  
 
o Arm 2a: NUC -3373 + LV 
o Arm 2b: NUC -3373 + LV 
o Arm 2 c: NUC -3373 + LV  
o Arm 2 d: NUC -3373 + LV  
 
o Arm 3a: NUC -3373 + LV  
o Arm 3c: NUC -3373 + LV  
o Arm 3e: NUC -3373 + LV  
o Arm 3f: NUC -3373 + LV + cetuximab  (if administered Q1W)  
o Arm 3 g: NUC -3373 + LV + cetuximab  (if administered Q1W)  
• AE recording and causality assessment  
NuTide:[ADDRESS_431126] c                                                             Confidential  96 5.5.9 PK sub -study (Part 2, Arm 2b): Cycle 1 and Cycle 2  D1/D2  ONLY  
Patient s participating in the PK sub -study in Part [ADDRESS_431127] the assessments detailed in this 
section during Cycle 1 and on Days 1 and 2 of Cycle 2. Following this, patients in the sub -study 
will continue with the normal assessments described for patients in Arm 2b ( Sections 5.5.2  to 
5.5.8 ).  
• Recording of new or changes to concomitant medications  (C1D1, C1D8, C1D15, 
C1D22 and C2D1)  
• Routine physical examination  (including neurological examination) , including vital 
signs. Vital signs include measurement of pulse rate, respi[INVESTIGATOR_697], blood pressure 
and temperature, after the patient has been seate d or in the supi[INVESTIGATOR_19636] 
5 minutes  (C1D1, C1D8, C1D15, C1D22 and C2D1)  
• Urinalysis: pH, specific gravity, ketones, leukocytes, protein, glucose, bilirubin, 
urobilirubin and occult blood. Dipstick testing is acceptable  (C1D1 and C2D1)  
• Urine pregnancy test for women of child -bearing potential. If any urine test result 
is positive, patient dosing will be postponed until the result is confirmed by a serum 
pregnancy test. Any patient with a positive serum test will not be allowed to receive 
any study treat ment  (C1D1 and C2D1)  
• ECOG performance status (C1D1 and C2D1)  
• Standard 12-lead ECGs should be performed prior to infusion of all IMPs on C1D1, 
C1D8, C1D15, C1D22 and C2D1. [ADDRESS_431128] -administration of all IMP s on C1D1 and C1D15  
o The ECGs should be performed in triplicate (keepi[INVESTIGATOR_346949]) and reviewed by [CONTACT_46874] a 
qualified designee for safety and quality  
o The QTc interval should be calculated for each ECG using the Frideric ia 
formula and averaged. Management of QT/QTc prolongation should be 
performed in accordance with institutional standard of care at the discretion 
of the treating physician  
o Digital and certified paper copi[INVESTIGATOR_346954] a future 
analysis  
• Holter  ECGs should be performed on C1D8 and C1D22, with continuous readings 
taken over [ADDRESS_431129]  5 minutes before, and during, the other PK draw timepoints (see  
Section  7.2.1 )  
o The ECG data should be transmitted for blinded central review  
• Blood samples drawn for:  
o Haematology: WBC count, differential WBC count, RBC, haemoglobin, 
haematocrit and platelets  (C1D1, C1D8, C1D15, C1D22 and C2D1)  
o Chemistry: sodium, potassium, magnesium, urea, creatin ine, glucose, 
bicarbonate, chloride, uric acid, phosphate, total protein, albumin, adjusted 
NuTide:[ADDRESS_431130], ALT and LDH  (C1D1, 
C1D8, C1D15, C1D22 and C2D1)  
o Coagulation parameters: PT/INR and aPTT  (C1D1 and C2D1)  
o Tumour markers (CEA)  (C1D1 and C2D1)  
• IV administration of study treatment  as follows:  
o Cycle 1 Day 1: LV + irinotecan  
o Cycle 1 Day 8: LV + NUC -3373  
o Cycle 1 Day 15: LV + irinotecan + NUC -3373*  
o Cycle 1 Day 22: LV + NUC -3373  
o Cycle 2 Day 1: LV + NUC -3373 + irinotecan*  
*Patients will be alternately assigned  to two groups (Group A and Group B) for 
treatment on Cycle 1 Day  15 and Cycle 2 Day 1 and will receive the study 
treatments in an order that has been pre -specified for each g roup (refer to Section 
7.2.1  for details).  
• Blood samples for PK  measurements  will be collected as follows:  
o Cycle 1 Day 1 & Day 2  
o Cycle 1 Day 8 & Day 9  
o Cycle 1 Day  15 & Day 16  
o Cycle 1 Day 22 & Day 23  
o Cycle 2 Day 1 & Day [ADDRESS_431131] be recorded  
Refer to Section 7.2.1  for more details . 
• AE recording and causality assessment  (C1D1, C1D2, C1D8, C1D9, C1D15, 
C1D16, C1D22, C1D23, C2D1 and C2D2)  
• For consenting patients with an accessible tumour  that is not a tar get lesion for the 
purposes of the study, obtain a n optional  fresh tumour specimen 3 -6 hours after 
study drug treatment on C1D8 or C1D15 . Patients should not be put at undue risk 
for collection of tumour samples. For sampling procedures, storage conditions , and 
shipment instructions, see the Laboratory Manual  
5.5.10  Every 8 weeks (±7 days) from Cycle 1 Day 1  until disease p rogression , initiation 
of a new treatment or d eath  
• Tumo ur imaging (CT , or MRI  of thorax , abdomen  and pelvis)  
NuTide:[ADDRESS_431132] c                                                             Confidential  98 5.5.11  End of Treatment Visit 
The a ssessments to be performed on discontinuation due to radiological disease progression or 
early treatment discont inuation for other reasons ( e.g., withdrawal of consent)  are summaris ed 
below . The End of Treatment  (EoT)  visit should  occur within a minimum of [ADDRESS_431133] administration of any study medication . During the 
EoT visit, the  following  items  will be assessed:  
• Recording of new or changes to concomitant medication  
• Routine physical examina tion (including neurological examination) , including vital 
signs . Vital signs include measurement of pulse rate, respi[INVESTIGATOR_697], blood pressure  
and temperature , after the patient has been seated or in the supi[INVESTIGATOR_19636] 
5 minutes, and temperature  
• Weight  
• ECOG performance status  
• 12-lead ECG   
o The 12-lead ECGs should be performed in triplicate (keepi[INVESTIGATOR_346955]) and reviewed by [CONTACT_46874] a 
qualified designee for safety and quality  
o The QTc interval should be calculated for each ECG using the Fridericia  
formula and averaged. Management of QT/QTc prolongation should be 
performed in accordance with institutional standard of care at the discretion of 
the treating physician  
o Digital and certif ied paper copi[INVESTIGATOR_346946] a future analysis  
• Blood samples drawn for: 
o Haematology: WBC count, differential WBC count, RBC, haemoglobin, 
haematocrit and platelets  
o Coagulation parameters : PT/INR and  aPTT  
o Chemistry: sodium, potassium, magnesium, urea, creatinine, glucose, 
bicarbonate, chloride, uric acid, phosphate, total protein, albumin, adjusted 
calcium, total bilirubin, alkaline phosphatase, AST, ALT and LDH  
o Pregnancy testing  for women of child -bearing potential  
o Tumour markers CEA  
• Urinalysis: pH, specific gravity, ketones, leukocytes, protein, glucose, bilirubin, 
urobil irubin and occult blood . Dipstick testing is acceptable  
• AE recording and causality assessment  
NuTide:[ADDRESS_431134]  v1.1 criteria  will continue to receive scans at regular intervals ( every 8 weeks 
[±7 days] from C1D1 ) until disease progression , initiation of a new treatment for CRC , or death 
(whichever comes first) to determine duration of overall response and PFS. 
All patients  will be followed up until withdrawal of consent,  lost to follow -up, death, or the 
overall end of study  has be en reached (defined in Section 3.6), whichever occurs first. 
During the COVID -19 pandemic, collection of follow -up data can be performed via a telephone 
call with the patient where possible ( e.g., for data regarding concomitant medications, AEs, 
and QoL). The data collected and the follow -up schedule remain a s per the schedule of events. 
Patients in follow -up who have not experienced radiological disease progression should 
continue to attend the clinic for planned radiologic scans; however, other follow -up data can 
be collected via telephone to limit patient v isits. 
NuTide:[ADDRESS_431135] c                                                             Confidential  100 6  PATIENT WITHDRAW AL 
6.1 End of Treatment  
Patients may continue on study until one of the following occurs:  
• Progressive Disease as defined by [CONTACT_393]  v1.[ADDRESS_431136]  v1.1 
• Unmanageable toxicity defined as an AE that is considered by [CONTACT_347023] -3373  including the following:  
o AE resulting in a dosing delay of more than 21 days i n starting the next cycle  
unless the patient is receiving clinical benefit  
o Clinically -significant treatment -related AE that recurs despi[INVESTIGATOR_346956].  Patients may continue to receive 
treatment if the Principal Investigator [CONTACT_1629] d Medical Monitor agree that the 
patient is receiving a clinical benefit and the toxicity is manageable, 
reversible or transient  
• Lack of further clinical benefit or unfavo urable risk/benefit profil e as judged by [CONTACT_3786]  
• Inter -current illness that prevents further administration of NUC -3373  
• Patient withdraws consent from further treatment or f or further data collection  
o If the patient withdraws consen t for further treatment, follow -up visits 
should continue  
o If the patient withdraws consent for further treatment and data collection, 
then no additional study visits or data collection should occu r 
• Patient requires use of a prohibited co ncomitant medication or therapy  
• Pregnancy  
• Changes in the patient’s condition , which in the opi[INVESTIGATOR_273554], make 
the patient  unsuitable for any further treatment  under the protocol ; note that at the 
Investigator ’s discretion, the patient may disc ontinue treatment with an agent in the 
prescribed combination , other than NUC -3373 , without requiring discontinu ation 
from the study  
• Patient n on-compliance  
• Lost to follow -up 
• Patient withdrawal of consent  
• Sponsor request  
All study  procedures outlined for the EoT visit are to be completed 30 days (+7 days)  after the 
last dose of study drug . The primary reason for study drug discontinuation is to be recorded in 
the CRF. 
NuTide:[ADDRESS_431137] 3 (or 6 in the case 
that an arm or dosing cohort is expanded on the basis of an earlier DLT) patients evaluable  for 
DLT in each arm or dose cohort within an arm.    
All patients who receive at least one dose of NUC -[ADDRESS_431138] 75% of planned treatment in that two -cycle period, and undergo a post -treatment objective 
disease assessment w ill be considered evaluable for response assessment.  
Patients enrolled in the PK sub -study will be considered evaluable for PK endpoints if they 
have received planned study treatment and had PK assessments up to at least C1D15. If patients 
discontinue study treatment or require dose modifications before C1D15, they will be 
considered non -evaluable and will be replaced.  
 
NuTide:[ADDRESS_431139] will be 
performed in women of child -bearing potential at the Screening visit. Laboratory tests may be 
performed either on the day of a treatment visit  (prior to study drug administration)  or during 
the three  days prior to a treatment visit.  
7.[ADDRESS_431140] be collected from a minimum of four patients per arm.  
Blood samples will be collected at the following visits:  
• C0D1, C0D 2 and C0D 3* (Arms  1a and 1b only)  
• Parts 1 , 2 and 3 : C1D1, C1D 2 and C1D 3* 
• Parts 1 , 2 and 3 : C1D15 and C1D 16  
* Optional 48 -hour PK sample  
PK endpoi nts will include assessments of , but are not limited to : 
• In plasma: NUC -3373,  5-FU, [ADDRESS_431141], FBAL  
• Part 1 only : In PBMCs : NUC -3373, FUDR -MP, FBAL, 5-FUTP , dTMP, and 
dUMP  
The PK sampling schedule , based on an NUC -3373 infusion duration of 2 hours  and 4 hours , 
is summaris ed in Table 15. 
Collection times for the ‘ During NUC -3373 Infusion’ PK samples (Samples 2 -4) should be 
adjusted proportionall y to the NUC -[ADDRESS_431142] through the infusion and 
Sample 4 at the end of the infusion.  
NuTide:302                                                                                                                        Version 4.2, 10 Aug 2022 
 
Confidentia l                                                            NuCana  plc 103 Table 15 PK sampling schedule  (Main study)  
Sample 
Number  Sample Collection Time   
(NUC -3373 2 -hour infusion)  Sample Collection Time   
(NUC -3373 4 -hour infusion)  Sample  Collection 
Window  
PRIOR TO NUC -3373 INFUSION  
1 Pre-dose Up to 30 minutes prior  
to starting infusion  
DURING NUC -3373 INFUSION  
2 T0 + 30 minutes  T0 + 60 minutes  
+/- 5 minutes  3 T0 + 60 minutes  T0 + 120 minutes  
4 T0 + 120 minutes  T0 + 240 minutes  
AFTER NUC -3373 INFUSION  
5 T1 + 15 minutes  
+/- 5 minutes  6 T1 + 30 minutes  
7 T1 + 60 minutes  
8 T1 + 90 minutes  
9 T1 + 120 minutes  +/- 15 minutes  
10 T1 + 240 minutes  + 4 hours  / - 15 minutes  
11 T1 + 24 hours  
+ 4 hours  12* T1 + 48 hours  
• T0 = Start of NUC -3373 infusion  
• T1 = End of NUC -3373 infusion  
• Sample 1, Pre -dose should be collected prior to infusion of all IMPs  
• Samples 2, 3, and 4 are triggered by [CONTACT_346997] a 2 -hour or a 4 -hour infusion 
duration. Collection times will be modified in alignment with infusion duration changes  
* Sample 12 = Optional 48 -hour PK sample  
Urine  samples will be collected  in Arms 1d and 3e only  at the following visits:  
• C1D1, C 1D2 and C 1D3* 
• C1D1 5 and C1D 16 
* Optional [ADDRESS_431143] urine 
samples at home. The samples will then be brought back when the patient attends for the Day  2 
or Day 16 (24 hours) or Day 3 (48 hours) blood samples. For logistical reasons ( e.g., if the 
patient lives far away) it may be necessary for the patient to stay overnight.  
Standard PK parameters for each compound of interest will then be derived  from the measured 
plasma , PBMC (Part 1 only) , and urine  concentrations . The PK samp les will be processed and 
analys ed at a central laboratory . Please refer to the PK Laboratory Manual for details regarding 
PK sample collection, processing and shippi[INVESTIGATOR_007].   
NuTide:[ADDRESS_431144] it would be beneficial 
to evaluate the PK relationship between NUC -3373, LV and irinotecan ( Figure 5). If 
conducted, a n additional 8 patients would  be enrolled in the NUFIRI Q1W cohort (Arm  2b). 
Inclusion into this sub -study will also involve individual patient genotypi[INVESTIGATOR_346957] -related toxicities. Genotypi[INVESTIGATOR_346958]. The genomic DNA will be analysed using 
pharmacogenomic protocols specific for individual genotypes for drug metabolising enzymes 
and drug transporters, e.g., TATA box polymorphism of the UGT1A1 p romoter region and 
NR1I2 -rs10934498 polymorphism, prior to admission to this sub -study  (Deyme et al,  2021 ). 
Genotypi[INVESTIGATOR_346948] a known UGT1A1 status from prior testing.   
 
 
Figure 5 PK sub-study schema  
 
In Cycle 1 of the sub -study, irinotecan and LV will be administered concurrently  on Day 1. On 
Day 8, NUC -3373 and LV will be administered  sequentially . On Day 15,  4 patients (Group A) 
will first be administered  irinotecan concurrently  with LV , followed by  [CONTACT_346982] -3373. Prior to 
the start of NUC -[ADDRESS_431145] -start of irinotecan /LV infusion  PK 
sample should be taken , which will also serve as th e pre -infusion  sample for NUC -3373 PK  
for Group A . The remaining 4  patients (Group B) will first be administered NUC -3373, 
followed by [CONTACT_346983] . On Day 15, the [ADDRESS_431146] be administered irinotecan concurrently  with LV, followed by [CONTACT_346982] -3373. 
Prior to the start of irinotecan /LV infusion on Cycle [ADDRESS_431147] -start of 
irinotecan/LV PK sample should b e taken, which will also serve as the pre -infusion sample for 
NUC -3373 PK for Group  B. Patients will be alternately  assigned to Group A or Group B.  
: DDI PK interaction Sub-Study
C1D15 C1D22 C2D1 C1D1 C1D8
Group A
n=4
Group B
n=4Irino
LV
90 minNUC
-3373LV
120 minNUC
-3373Irino
LVNUC
-3373
Irino
LVNUC
-3373LVNUC
-3373Irino
LVNUC
-3373LV
NUC
-3373LVIrino
LV
NUC
-3373Irino
LV120 min 120 min120 min 120 min 120 min
120 min 120 min 120 min 120 min120 min 120 min120 min
90 min
120 min90 min
120 min90 min
120 min90 min
120 min90 min
120 min
NuTide:[ADDRESS_431148] 5 minutes prior  to, and during, the other timepoints where PK draws are taken (as outlined 
in Figure 6) . All Holter ECG data should be transmitted for blinded central review.  
Plasma s amples will be collected for PK analysis on Cycle [ADDRESS_431149] be recorded.  
Following this, patients will continue on the treatment schedule outlined for Arm 2b .  
Group A  
      Timepoints (min post -first infusion)  
    Pre-
dose* 60 mins  
(+/- 5 mins) 120 mins  
(+/- 5 mins) 150 mins  
(+/- 5 mins) 180 mins  
(+/- 5 mins) 250 mins  
(+/- 5 mins) 280 mins  
(+/- 5 mins) 300 mins  
(+/- 5 mins) 360 mins  
(+/- 15 mins) 480 mins  
(+/- 15 mins) 24 hours  
(+/- 2 hours) 
C1D1 Infusion   Irinotecan + LV                 PK Draw X X X   X X   X X X X 
C1D8 Infusion   LV NUC -3373           PK Draw X       X X X X X X X 
C1D15 Infusion   Irinotecan + LV NUC -3373           PK Draw X X X   X X X X X X X 
C1D22 Infusion   LV NUC -3373           PK Draw X       X X X X X X X 
C2D1 Infusion   NUC -3373 Irinotecan + LV           PK Draw X X X X X X   X X X X 
*Pre -dose = up to 30 minutes prior to the administration of irinotecan + LV (C1D1, C1D15) or NUC -3373 (C1D8, C1D22, C2D1)               
Group B  
      Timepoints (min post -first infusion)  
    Pre-
dose* 60 mins  
(+/- 5 mins) 120 mins  
(+/- 5 mins) 150 mins  
(+/- 5 mins) 180 mins  
(+/- 5 mins) 250 mins  
(+/- 5 mins) 280 mins  
(+/- 5 mins) 300 mins  
(+/- 5 mins) 360 mins  
(+/- 15 mins) 480 mins  
(+/- 15 mins) 24 hours  
(+/- 2 hours) 
C1D1 Infusion   Irinotecan + LV                 PK Draw X X X   X X   X X X X 
C1D8 Infusion   LV NUC -3373           PK Draw X       X X X X X X X 
C1D15 Infusion   NUC -3373 Irinotecan + LV           PK Draw X X X X X X   X X X X 
C1D22 Infusion   LV NUC -3373           PK Draw X       X X X X X X X 
C2D1 Infusion   Irinotecan + LV NUC -3373           PK Draw X X X   X X X X X X X 
*Pre -dose = up to 30 minutes prior to the administration of irinotecan + LV (C1D1, C2D1) or NUC -3373 (C1D8, C1D15, C1D22)  
Figure 6 PK sub -study blood sampling schema  
PK endpoints will include plasma assessments of  (but are not limited to ): 
• NUC -3373, FUDR, NUC -3373 alanine phosphate intermediate  
• Irinotecan, SN -38, SN -38 glucuronide, APC and NPC   
NuTide:[ADDRESS_431150] will then be derived from the measured 
plasma  concentrations. The PK samples will be processed and analysed at a central laboratory. 
Please refer to the PK Laboratory Manual for details regarding PK sample collection, 
processing and shippi[INVESTIGATOR_007].   
7.3 Pharmacodynamics  (Part 1 only)  
The PD  schedule is designed to explore the relationship between NUC -3373 
pharmacodynamics and clinical activity.  
Blood samples will be collected at the following visits:  
• C0D1 (Arms 1a and 1b only)  
• C1D1 and C1D15  
PD endpoints will include assessments of:  
• Part 1 only : In PBMCs : TS - total, bound and unbound  
The PD sampling schedule is summarised in Table 16. 
Table 16 PD sampling schedule (Part 1 only)  
Sample Number  Sample Time   Sample  Collection Window  
PRIOR TO NUC -3373 INFUSION  
1 Pre-dose Up to 30 minutes prior  
to starting infusion  
AFTER  NUC -3373 INFUSION  
2 T1 + 30 minutes  +/- 5 minutes  
• Sample 1, Pre -dose should be collected prior to infusion of all IMPs  
• T1 = End of NUC -3373 infusion  
7.4 Exploratory Biomarkers  
Blood samples  (optional) will be collected for mRNA analyses ( e.g., PAX gene)  at baseline  or 
C1D1 pre-dose and at C3D1 . 
7.5 Tumour Tissue Sample Submission  
Tissue specimens will be collected from patients enrolled in  the study  for exploration of 
pharmacodynamic  biomarkers of biological activity and possible relationships between PK 
exposure, PD effects, safety and efficacy . An archival specimen will be collected from 
consenting patients for whom an  archival tissue exists; the specimen may be collected at any 
time during the study. A n optional  fresh tissue specimen also will be collected during the 
screening period and on treatment on C1D8  or C1D15  3-6 hours after study drug infusion  in 
consenting patients . The fresh tissue specimen should not be taken from a lesion to be 
designated a target lesion for the purposes of the study. Specific instructions on the collection 
and shipment of tissue samples will be provided in the Tumo ur Tissue Laboratory Manual.  
7.6 Labelling  and Confidentiality of Biological Samples  
All biological samples (including blood , PBMC  and tumo ur tissue ) sent to analytical 
laboratories will be labelled  with the study code,  patient study number and date/time taken . 
Samples  labels  must not contain any unique patient identifiers .  
NuTide:[ADDRESS_431151] already been 
processed and anonymised, it would not be possible to destroy such samples . 
NuTide:[ADDRESS_431152] is called ‘ NUC -3373 for infusion’  and is presented as a single -dose sterile 
liquid formulation for IV injection  of NUC -3373  in a clear glass vial . 
8.1.2 NUC -3373  Supplies and Study Drug Packaging  
‘NUC -3373  for infusion’  will be supplied to the pharmacy of the investigative clinical site in 
[ADDRESS_431153] outer carton.  
NUC -3373 saline -based formulation is prepared by  [CONTACT_347024] 
‘NUC -3373  for infusion’  from  the vial and adding it directly  to the saline infusion bag.  Please 
refer  to the dose preparation guidance  in the current version of the Pharmacy Manual and the 
Administration Guidelines for further information on the preparation of NUC -3373  
saline -based formulation s.  
8.1.3 Handling and Storage  of NUC -3373  
‘NUC -3373  for infusion’ must be stored in an appropriately secure investigational pharmacy 
at all times until dispensed for administration to patients on protocol. ‘NUC -3373 for infusion’ 
must be stored between 2 -8°C (36-46°F) in a temperature -monitored refrigerated unit . Only 
adequately trained pharmacy staff are permitted to handle ‘NUC -3373 for infusion’ . The study 
medication should not be removed from the pharmacy except for the purposes of dispensing to 
the patient for this protocol.  Study drug that has been quarantined for a ny reason must not be 
dispensed or administered to patients.  
If ‘NUC -3373 for infusion’ contacts the skin or the mucous membranes, it should be washed 
immediately and thoroughly. Please refer to the guidance in the current version of the Pharmacy 
Manual fo r further information on the preparation of NUC -3373  saline -based formulation s.  
8.1.4 Preparation  of NUC -3373  
As with other cytotoxic substances, applicable local procedures should be used in the 
preparation and administration of ‘NUC -3373  for infusion’ . Please refer to the administration 
guidance in the current version of the Pharmacy Manual and Administration Guidelines for 
further information on the preparation of NUC -3373  saline -based formulation . 
Due to known issues regarding DMA and compat ibility wit h polycarbonate, do not  use 
polycarbonate syringes or polycarbonate filter needles to withdraw  ‘NUC -3373 for infusion’.  
8.1.5 NUC -3373 Administration  
‘NUC -3373  for infusion’  will be administered to each patient based on body surface area (BSA ; 
calculated form pa tient’s height and weight ) at baseline  and/or height at baseline and weight at 
Day [ADDRESS_431154] operating practises . If a patient’s weight increases 
or decreases by ≥10% during the course of the study, the dose of ‘NUC -3373  for infusion’  
should be re -calculated. The Dubois & Dubois BSA calculation is the preferred method, 
however other standard calculations can also be used. Sites should document the method used 
in the electronic case report form ( eCRF ). 
NuTide:302                                                                                                                        Version 4.2, 10 Aug 2022 
 
Confidentia l                                                            NuCana  plc 109 Dubois & Dubois BSA calculation:  
BSA (m2) = 0.007184 × Height (cm)0.725 × Weight (kg)0.425  
The duration of infusion of NUC -3373 saline -based formulations should align with the 
guidance provided in Table 17.  Should a decision on dose modification be taken that increases 
or reduces the dose of ‘NUC -3373 for infusion’ administered to the patient, the duration of the 
infusion should also be checked and adjusted in accordance with the guidance provided.  
It is suggested that NUC -3373 at 1500 mg/m2 is infused over 120 minutes . The infusion 
duration for lower and higher doses of NUC -3373 should be adjusted relative to the 
1500  mg/m2 dose ( e.g., a 25% increase in dose requires a n approximately  25% increase in 
infusion duration), as shown in Table 17. 
Table 17 NUC -3373 infusion duration  guidance  
Dose of NUC -3373  Minimum Infusion Duration * 
1125  mg/m2 (-25%)  90 minutes  
1500 mg/m2 120 minutes  
1875 mg/m2 (+25%)  150 minutes  
2000 mg/m2 (+33%)  160 minutes  
2250 mg/m2 (+50%)  180 minutes  
2500 mg/m2 (+67%)  200 minutes  
*  - 5 to +15  minute window will be permitted on all infusion durations     
8.2 Other IMPs ( Agents to be used in C ombination with NUC -3373 ) 
All of the agents to be used in combination with NUC -3373 in the different arms of this study 
are commercially available and sh ould be sourced locally by [CONTACT_347025]. Descriptive 
information for these agents can be found in the package inserts.  These agents should  be stored 
according to the manufacturer’s instructions.  Further information can be found in the 
pharmacy  manual.  
For VEGF inhibitors, the preferred treatment option is Avastin; however, biosimilars may be 
used after discussion with the Sponsor. For EGFR inhibitors, the preferred treatment options 
are Erbitux ( cetuximab ) or Vectibix  (panitumumab ); however, i f biosimilars become available, 
their use may be discussed with the Sponsor.      
8.3    Administration  of NUC -3373 and other IMPs  
The sections below provide suggested administration times and order for each of the 
combination agents; however, each administration in Parts 1, 2, and 3 of the study  may be 
modified based on emerging safety and PK data (in line with local guidelines/relev ant 
Prescribing Information) with agreement from the DSMC . 
8.3.1 Part 1  
A total of 21  eligible and consenting ≥3rd-line patients were  randomis ed to either Arm 1a or 
Arm 1b and a further 17 patients  were  enrolled  to each of two dosing cohorts in Arm 1c. 
Arms  1a, 1b, and 1c are now complete. Following this, approximately 10 combination 
chemotherapy ineligible patients will be enrolled to a Q1W  administration schedule of 
NUC -3373 plus LV  (Arm 1d). Dose adjustments or dose delays are to be implemented within 
NuTide:[ADDRESS_431155] c                                                             Confidential  110 or between cycles based on drug -related toxicities. The dose modification scheme to be 
employed is detailed in Section 9  of this protocol.  
Arm  1a: SINGLE DOSE NUC -3373 / LV +  NUC -3373 COMBINATION  
At C0D1:   
• NUC -3373 IV over 120 minutes at an initial dose of 1500  mg/m2  
NUC -3373 monotherapy was given once followed by a 2 -week washout period.  
At C1D1 and beyond:  
• LV 400 mg/m2 IV (or equivalent levo -leucovorin) over 120 minutes prior to each 
NUC -3373 infusion  on Days 1 and 15 of each 28 -day treatment cycle  
• NUC -3373 IV over 120 minutes at an initial dose of 1500  mg/m2 on Days 1 and 
15 of each 28 -day treatment cycle  
Arm  1b: SINGLE DOSE NUC -3373  + LV / NUC -3373 MONOTHERAPY  
At C0D1:  
• LV 400 mg/m2 IV (or equivalent levo -leucovorin) over 120 minutes prior to 
NUC -3373 infusion   
• NUC -3373 IV over 120 minutes at an initial dose of 1500  mg/m2  
NUC -3373 + LV was given once followed by a 2 -week washout period.  
At C1D1 and beyond :  
• NUC -3373 IV over 120 minutes at an initial dose of 1500  mg/m2 on Days 1  and 
15 of each 28 -day treatment cycle  
Arm  1c: NUC -3373  + LV  COMBINATION  
At C1D1 and beyond :  
• LV 400 mg/m2 IV (or equivalent levo -leucovorin) over 120 minutes prior to each 
NUC -3373 infusion  on Days 1, 8, 15 and 22 of each 28 -day treatment cycle  
• NUC -3373 by [CONTACT_204108] 120 minutes at an initial dose of 1500 mg/m2 on Days 1, 8, 
15 and 22 of each 28 -day treatment cy cle 
Starting doses for subsequent cohorts will be determined during the study by [CONTACT_6802] . 
Arm 1 d: NUC -3373 + LV (combination chemotherapy ineligible patients)  
At C1D1 and beyond :  
• LV 400 mg/m2 IV (or equivalent levo -leucovorin) over 120 minutes prior to each 
NUC -3373 infusion  on Days 1, 8, 15 and 22 of each 28 -day treatment cycle  
• NUC -3373 IV over 200 minutes at a dose of 2500 mg/m2 on Days 1, 8, 15 and 22 
of each 28 -day treatment cycle  
NuTide:302                                                                                                                        Version 4.2, 10 Aug 2022 
 
Confidentia l                                                            NuCana  plc 111 8.3.2 Part 2  
Eligible consenting patients in Part 2 will receive one of the combinations listed below, as 
determined by [CONTACT_347026].  Patients will 
continue to receive NUC -3373 + the combination drug(s) until the occurrence of radiological 
disease progression using RECIST v1.1 or unmanageable drug -related AEs despi[INVESTIGATOR_58349]. G uidelines for dose modifications and discontinuatio ns due to AEs will be 
provided.  
The order of administration of each of the agents  in Part 2 may be modified with approval from 
the DSMC , so that NUC -3373 + LV is infused first followed by [CONTACT_346990] (Arms 2a 
and 2c) or irinotecan (Arms 2b and 2d).  Alternate infusion parameters may be implemented 
with approval from the DSMC.  
Arm  2a: NUFOX  Dose Escalation  Q1W (≥3rd-line patients)  
C1D1 and beyond:  
• LV 400 mg/m2 IV (or equivalent levo -leucovorin) over 120 minutes prior to 
NUC -3373 infusion  
• Oxaliplatin 85 mg/m2 IV over 120 minutes prior to NUC -3373 infusion   
• NUC -3373 IV over 120 minutes at the combination dose as determined at the 
DSMC  meeting for Part 1  
NUC -3373  + LV is given on Days 1, 8, 15 and 22 in each 28 -day treatment cycle  (Q1W) . 
Oxaliplatin is given on Days 1 and 15 in each 28 -day treatment cycle  (Q2W ), as per the 
Prescribing Information .  
Arm 2b: NUFIRI  Dose Escalation  Q1W  (≥3rd-line patients)  
C1D1 and beyond:  
• LV 400 mg/m2 IV (or equivalent levo -leucovorin) over 120 minutes prior to 
NUC -3373 infusion  
• Irinotecan  180 mg/m2 IV over 120 minutes prior to NUC -3373 infusion   
• NUC -3373 IV over 120 minutes at the combination dose as determined at the 
DSMC meeting for Part 1  
NUC -3373 + LV is given on Days 1, 8, 15 and 22 in each 28 -day treatment cycle  (Q1W) . 
Irinotecan is given on Days 1 and 15 in each 28 -day treatment cycle ( Q2W ), as per the 
Prescribing Information .  
The MTD for NUFIRI has been established in Arm 2b and was d etermined to be 1500 mg/m2 
NUC -3373 + 400 mg/m2 LV + 180 mg/m2 irinotecan.   
NuTide:[ADDRESS_431156] c                                                             Confidential  112 PK sub -study (Arm 2b): NUFIRI  Q1W  
C1D1:  
• LV (400 mg/m2 IV; or equivalent levo -leucovorin) over 120 minutes concurrently 
with i rinotecan (180 mg/m2 IV) over 90 minutes  
C1D 8: 
• LV (400 mg/m2 IV; or equivalent levo -leucovorin) over 120 minutes  
• NUC -3373 (1500 mg/m2 IV) over 120 minutes  
C1D 15 (Arm A) : 
• LV (400 mg/m2 IV; or equivalent levo -leucovorin) over 120 minutes concurrently 
with i rinotecan (180 mg/m2 IV) over 90 minutes  
• NUC -3373 (1500 mg/m2 IV) over 120 minutes  
C1D 15 (Arm B) : 
• NUC -3373 (1500 mg/m2 IV) over 120 minutes  
• LV (400 mg/m2 IV; or equivalent levo -leucovorin) over 120 minutes concurrently 
with i rinotecan (180 mg/m2 IV) over 90 minutes  
C1D 22: 
• LV (400 mg/m2 IV; or equivalent levo -leucovorin) over 120 minutes  
• NUC -3373 (1500 mg/m2 IV) over 120 minutes  
C2D1 (Arm A) : 
• NUC -3373 (1500 mg/m2 IV) over 120 minutes  
• LV (400 mg/m2 IV; or equivalent levo -leucovorin) over 120 minutes concurrently 
with i rinotecan (180 mg/m2 IV) over 90 minutes  
C2D1 (Arm B) : 
• LV (400 mg/m2 IV; or equivalent levo -leucovorin) over 120 minutes concurrently 
with i rinotecan (180 mg/m2 IV) over 90 minutes  
• NUC -3373 (1500 mg/m2 IV) over 120 minutes  
 
Arm  2c: NUFOX Dose Expansion  Q1W  (2nd-/3rd-line patients)  
C1D1 and beyond:  
• LV 400 mg/m2 IV (or equivalent levo -leucovorin) over 120 minutes prior to 
NUC -3373 infusion  (concurrently with oxaliplatin)  
• Oxaliplatin  85 mg/m2 IV over 120 minutes prior to NUC -3373 infusion  
(concurrently with LV)  
• NUC -3373 IV at the combination dose as determined at the DSMC meeting for 
Part 2 dose escalation  
NUC -3373  + LV is given on Days 1, 8, 15 and 22 in each 28 -day treatment cycle  (Q1W) . 
Oxaliplatin is given on Days 1 and 15 in each 28-day treatment cycle ( Q2W ), as per the 
Prescribing Information .  
NuTide:302                                                                                                                        Version 4.2, 10 Aug 2022 
 
Confidentia l                                                            NuCana  plc 113 Arm  2d: NUFIRI Dose Expansion  Q1W (2nd-/3rd-line patients)  
C1D1 and beyond:  
• LV 400 mg/m2 IV (or equivalent levo -leucovorin) over 120 minutes prior to 
NUC -3373 infusion  (concurrently with irinotecan)  
• Irinotecan 180 mg/m2 IV over 120 minutes prior to NUC -3373  infusion 
(concurrently with LV)  
• NUC -3373 1500 mg/m2 IV over 120 minutes  
NUC -3373 + LV is given on Days 1, 8, 15 and 22 in each 28 -day treatment cycle  (Q1W) . 
Irinotecan is given on Days 1 and 15 in each 28 -day treatment cycle ( Q2W ), as per the 
Prescribing Information .  
Guidance on combination agent infusion time and order has been provided above ; however , in 
all instance’s combination agents may be administered in accordance with local and national 
guidelines  for FOLFOX and FOLFIRI regimens . 
For patients experiencing toxicity related to NUC -3373 in the NUFOX and NUFIRI cohorts, 
initially the NUC -3373 dose modification guidelines in Section 9 should be followed. The 
doses of oxaliplatin and irinotecan may be adjusted (through agreement with the DSMC) based 
on, but not limited to, safety and PK da ta generated in patients receiving treatment with 
NUFOX and NUFIRI regimens. If oxaliplatin or irinotecan -related AEs are observed, dose 
de-escalation should be performed as per the respective Prescribing Information  or standard 
local practice . The modifie d dose of oxaliplatin or irinotecan (in combination with NUC -3373) 
will be assessed in approximately  [ADDRESS_431157]. 
Following this , Q2W arms and/or cetuximab combination cohorts may  be opened, depending 
on emerging data . In addition, patients qualifying for maintenance therapy may receive 
NUC -3373  + LV  in combination with bevacizumab.  
Eligible consenting patients in Part [ADDRESS_431158] v1.1 or unmanageable drug -related AEs despi[INVESTIGATOR_58341]. Guidelines for 
dose modifications and discontinuations due to AEs will be provided.  
Alternate infusion parameters may be implemented with approval from the DSMC.  
Arm  3a: NUFOX + bevacizumab  Q1W  (2nd-line patients)  
C1D1 and beyond:  
• Bevacizumab  5 mg/kg : 
o [ADDRESS_431159] dose  
o 60 minutes for the second dose ( if first dose is tolerated)  
o 30 minutes for subsequent doses (if second dose is tolerated)  
• LV 400 mg/m2 IV (or equivalent levo -leucovorin) over 120 minutes prior to 
NUC -3373 infusion  (concurrently with oxaliplatin)  
NuTide:[ADDRESS_431160] c                                                             Confidential  114 • Oxaliplatin 85 mg/m2 IV over 120 minutes prior to NUC -3373 infusion  
(concurrently with LV)  
• NUC -3373 IV at the combination dose  and infusion duration  determined at the 
DSMC meeting for Part 2 dose escalation  
NUC -3373 and LV are given on Days 1, 8, 15 and 22 in each 28 -day treatment cycle  (Q1W) . 
Oxaliplatin  and bevacizumab are  given on Days 1 and 15 in each 28 -day treatment cycle 
(Q2W ), as per the respective Prescribing Information .  
Arm  3b: NUFOX + bevacizumab  Q2W  (2nd-line patients)  
C1D1 and beyond:  
• Bevacizumab  5 mg/kg:  
o [ADDRESS_431161] dose  
o 60 minutes for the second dose (if first dose is tolerated)  
o 30 minutes for subsequent doses (if second dose is tolerated)  
• LV 400 mg/m2 IV (or equivalent levo -leucovorin) over 120 minutes prior to 
NUC -3373 infusion  (concurrently with oxaliplatin)  
• Oxaliplatin 85 mg/m2 IV over 120 minutes prior to NUC -3373 infusion  
(concurrently wit h LV)   
• NUC -3373 IV at the combination dose  and infusion duration  determined at the 
DSMC meeting for Part 2 dose escalation  
NUC -3373 , LV, oxaliplatin  and bevacizumab  are given on Days 1 and 15 in each 28 -day 
treatment cycle ( Q2W ).  
Arm  3c: NUFIRI + bevacizumab  Q1W  (2nd-line patients)  
C1D1 and beyond:  
• Bevacizumab  5 mg/kg:  
o [ADDRESS_431162] dose  
o 60 minutes for the second dose (if first dose is tolerated)  
o 30 minutes for subsequent doses (if second dose is tolerated)  
• LV 400 mg/m2 IV (or equivalent levo -leucovorin) over 120 minutes prior to 
NUC -3373 infusion  (concurrently with irinotecan)  
• Irinotecan  180 mg/m2 IV over 120 minutes  prior to NUC -3373  infusion 
(concu rrently with LV)  
• NUC -3373 1500 mg/m2 IV over 120 minutes  
NUC -3373 and LV are given on Days 1, 8, 15 and 22 in each 28 -day treatment cycle  (Q1W) . 
Irinotecan  and bevacizumab are  given on Days 1 and 15 in each 28 -day treatment cycle ( Q2W ), 
as per the respective Prescribing Information .  
NuTide:302                                                                                                                        Version 4.2, 10 Aug 2022 
 
Confidentia l                                                            NuCana  plc 115 Arm  3d: NUFIRI + bevacizumab  Q2W  (2nd-line patients)  
C1D1 and beyond:  
• Bevacizumab  5 mg/kg:  
o [ADDRESS_431163] dose  
o 60 minutes for the second dose (if first dose is tolerated)  
o 30 minutes for subsequent doses (if second dose is tolerated)  
• LV 400 mg/m2 IV (or equivalent levo -leucovorin) over 120 minutes prior to 
NUC -3373 infusion  (concurrently with irinotecan)  
• Irinotecan  180 mg/m2 IV over 1 20 minutes prior to NUC -3373  infusion 
(concurrently with LV)  
• NUC -3373  1500 mg/m2 IV over 120 minutes  
NUC -3373 , LV, irinotecan  and bevacizumab  are given on Days 1 and 15 in each 28 -day 
treatment cycle ( Q2W ).  
Arm  3e: NUC -3373 + bevacizumab  Q1W  (Maintenance patients)  
C1D1 and beyond:  
• Bevacizumab  5 mg/kg:  
o [ADDRESS_431164] dose  
o 60 minutes for the second dose (if first dose is tolerated)  
o 30 minutes for subsequent doses (if second dose is tolerated)  
• LV 400 mg/m2 IV (or equivalent levo -leucovorin) over 120 minutes prior to 
NUC -3373 infusion  
• NUC -3373 2500 mg/m2 IV over 200 minutes  
NUC -3373 and LV are given on Days 1, 8, 15 and 22 in each 28 -day treatment cycle  (Q1W) . 
Bevacizumab is  given on Days 1 and 15 in each 28 -day treatment cycle ( Q2W ), as per the 
Prescribing Information .  
Arm  3f: NUFOX + cetuximab  Q1W or Q2W  (2nd-line patients)  
C1D1 and beyond:  
• Cetuximab infusion to be completed 1  hour prior to  NUFOX infusions : 
o First dose: 400 mg/m2 IV over 120 minutes  
o Subsequent doses: 250 mg/m2 IV over 60 minutes  
• LV 400 mg/m2 IV (or equivalent levo -leucovorin) over 120 minutes prior to 
NUC -3373 infusion  (concurrently with oxaliplatin)  
• Oxaliplatin 85 mg/m2 IV over 120 minutes prior to NUC -3373 infusion  
(concurrently with LV)  
• NUC -3373 IV at the combination dose  and infusion duration  determined at the 
DSMC meeting for Part 2 dose escalation  
The NUC -3373 + LV administration schedule may be Q1W or Q2W, depending on emerging 
data.  
NuTide:[ADDRESS_431165] c                                                             Confidential  116 Oxaliplatin is  given on Days 1 and 15 in each 28 -day treatment cycle ( Q2W ) and cetuximab is 
given on Days 1, 8, 15 and 22 in each 28 -day treatment cycle (Q1W), as per the respective 
Prescribing Information .  
Arm  3g: NUFIRI + cetuximab  Q1W or Q2W  (2nd-line patients)  
C1D1 and beyond:  
• Cetuximab infusion to be completed 1  hour prior to NUFIRI infusions : 
o First dose: 400 mg/m2 IV over 120 minutes  
o Subsequent doses: 250 mg/m2 IV over 60 minutes  
• LV 400 mg/m2 IV (or equivalent levo -leucovorin) over 120 minutes prior to 
NUC -3373 infusion  (concurrently with irinotecan)  
• Irinotecan 180 mg/m2 IV over 120 minutes prior to NUC -3373  infusion 
(concurrently with LV)  
• NUC -3373 1500 mg/m2 IV over 120 minutes  
The NUC -3373 + LV administration schedule may be Q1W or Q2W, depending on emerging 
data.  
Irinotecan is  given on Days 1 and 15 in each 28 -day treatment cycle ( Q2W ) and cetuximab is 
given on Days 1, 8, 15 and 22 in each 28 -day treatment cycle (Q1W), as per the respective 
Prescribing Information .  
In all bevacizumab -containing arms, NUC -3373 dose adjustments may occur depending on 
emerging data.  
Guidance on combinatio n agent infusion time has been provided above ; however , in all 
instance’s  combination agents may be  administered in accordance with local and national 
guidelines . 
Panitumumab combination arms may also be opened  (~10 2nd-line patients) , depending on 
emerging data.  
Cohorts of rapid progressors may also be opened (~10 patients), depending on emerging data.  
8.4    NUC -3373 Drug Destruction  
Used vials  of NUC -3373 should be destroyed in accordance with local procedures and 
documented in the drug accountability  and drug destruction log .  A copy of the disposal 
certificates should be kept in the study file.  
8.5  NUC -3373 Study Drug Accountability  
The US Food and Drug Administration ( FDA ) and other applicable regulatory authorities 
require accounting of all study drug  received by [CONTACT_347027] . Records of drug disposition 
required include  the date received by [CONTACT_347028] , date administered, quantity administered, and 
the patient to whom  study drug was administered . The Investigator is responsible for the 
accountability of all used and unused study drug co ntainers and unused study drug . Each study 
centre  is to use a study drug accountability log to document study drug disposition . All ite ms 
on this for m are to be completed in full.  
The I nvestigator identification number and patient initials (as allowed by [CONTACT_427]) and 
identification number are to be recorded on each study drug accountability log . Each time study 
personnel dispens e study drug for a patient, he or she is to record the date dispensed, amount 
NuTide:302                                                                                                                        Version 4.2, 10 Aug 2022 
 
Confidentia l                                                            NuCana  plc 117 of study drug dispensed, Lot number, and the dispenser ’s initials . Study personnel are to 
monitor the inventory of clinical supplies and maintain a count of all used and unused s tudy 
drug. The Sponsor’s designated site monitor will review study drug accountability records and 
remaining drug supplies during routine monitoring visits.  
8.6   Management of Overdose  of NUC -3373  
The initial dose of NUC -3373  intended for use on this protocol is 1500  mg/m2.  In the Phase I , 
first-in-human  study, the highest dose studied at the time of writing this protocol has been 
3250  mg/m2. Should a  substantial  overdose occur, there is no known antidote .  
In the event of a substantial overdose of any of the agents used in the prescribed  combinations 
(LV, oxaliplatin, irinotecan, bevacizumab , cetuximab , panitumumab ), the management should 
follow guidance  in the Prescribing Information  or standard local practice . 
Any patient  who inadvertently receives a dose  of any agent in this study higher  than intended 
should be monitored closely, managed with appropriate supportive care , including transfusion 
and h aematopoietic growth factors as needed, until recovery . Such overdoses should  be 
recorded as follows:  
1. If an overdose occurs in the course of the study, site personnel must inform the 
Investigator and monitor immediately upon discovery of the event . An overdose 
will be recorded on the treatment CRF page and any associated AEs/SAEs w ill be 
recorded as the AE diagnosis/symptoms on the relevant AE/SAE page in the CRF . 
An overdose with no associated symptoms is only reported on the treatment CRF.  
2. All overdoses should be tracked  as a viol ation.  
NuTide:[ADDRESS_431166] c                                                             Confidential  118 9 DOSE MODIFICATIONS  
Adverse events may be managed by [CONTACT_347029]/or dose reductions  according to the 
clinical situation . For patients experiencing toxicity related to NUC -[ADDRESS_431167] be 
continued for the patient  to remain on treatment for the purposes of this protocol.  
Table 18 Dose reduction guidelines for Part 1, Arms 1a and 1b  
Reduction  NUC -3373  
Days 1 and 15 eve ry 28 days  LV 
Day 1 and 15  
1 75% of starting dose1 100% of starting dose2 
2 50% of starting dose1 100% of starting dose2 
1  Two dose reductions allowed  
2   LV dose should be maintained but may be reduced at the disc retion of the Investigator,  with 
confirmation from the Medical Monitor and Sponsor 
 
Table 19 Dose reduction guidelines for Part 1, Arm 1c  and 1d  
Reduction  NUC -3373  
Days 1, 8, 15 and 22 every 28 days  LV 
Days 1, 8, 15 and 22 every 28 days  
1 75% of starting dose1 100% of starting dose2 
2 50% of starting dose1 100% of starting dose2 
1  Two dose reductions allowed  
NuTide:302                                                                                                                        Version 4.2, 10 Aug 2022 
 
Confidentia l                                                            NuCana  plc 119 2  LV dose should be maintained but may be reduced at the disc retion of the Investigator, with 
confirmation from the Medical Monitor and Sponsor  
 
Table 20 Dose reduction guidelines for Part 2  and Part 3  
Reduction  NUC -3373  LV Combination agent  
1 75% of Starting Dose1 100% of starting dose2 Per Prescribing 
Information3 
2 50% of Starting Dose1 100% of starting dose2 Per Prescribing 
Information3 
1 Two dose reductions allowed. Minimum 25% reduction per reduction  
[ADDRESS_431168] meet ALL of the following criteria prior to receiving a dose of study treatment : 
• ANC  ≥1.5×109/L (growth factor s upport permitted after Cycle  1) 
• Platelet count ≥ 75×109/L without platelet transfusion  (platelet transfusion permitted 
after Cycle 1)  
• No evidence of disease progression (based on radiographic assessment)  
• Recovery from all clinica lly significant toxicities to ≤ Grade 2 or to baseline grade 
present at study entry  
Administration of study drug should be held until all of the re -treatment criteria are met. Any 
missed dose(s) should not be made up if treatment delay exceeds 24 hours. If treatment delay 
is <24  hours, subsequent schedul ed dose(s) may be administered.  If a DLT occurs during a 
cycle, doses of study drug will be withheld for the remainder of the cycle and subsequent cycles 
will be administered at the previously tested next lower dose level.  
9.2 Dose Modifications ( Dose Delays and Dose Reductions)  
Treatment between cycles can be delayed for up to [ADDRESS_431169] severe toxicity. A patient who 
experiences a toxicity meeting the definition of DLT (during any cycle ) but whose toxicity 
recovers within [ADDRESS_431170] one further dose reduction . Patients who continue to experience 
clinically significant toxicity despi[INVESTIGATOR_346959] a Q2W schedule, if the timecourse of the toxicity indicates 
that a different schedule may i mprove tolerability .  A patient receiving clinical benefit will not 
require discontinuation and treatment guidelines for such patient will be decided in discussion 
NuTide:[ADDRESS_431171] completed the DLT period may be switched from a Q1W to a Q2W schedule 
if they experience drug -relate d toxicity (other than fatigue) that would otherwise lead to 
treatment discontinuation. In addition, patients who have completed the DLT period may move 
from a Q2W to a Q1W schedule. The decision to switch schedules must be discussed with and 
approved by t he Sponsor on an individual patient basis.   
General g uidance for dose modifications  of NUC -3373 is provided in Table 21. 
Table 21 Dose modifications for Cycle 2 onwards and for non -DLT  toxicities within 
Cycle 1   
Toxicity Grade  Recommended immediate action 
with NUC -3373  Recommendation for dose modification of 
NUC -3373 at start of a new cycle  
Mucositis  
Grade 2  No immediate action  Continue current dose level with appropriate 
mouth care . 
Grade 3 or 4  Hold  If resolved to ≤Grade 2 within 14 days reduce by 
1 dose level. If mucositis has not resolved to 
≤Grade 2 within 14 days, permanently stop 
treatment . 
Febrile n eutropaenia  
Grade 3 or 4  Hold  If neutropaenia resolved to ≤Grade 1, reduce by 1 
dose level. If not resolved to ≤Grade 1 within 14 
days, permanently stop treatment . 
Neutropaenia  
Grade 2  Hold only if starting a new cycle 
[delay of max 14 days allowed until 
ANC≥1.5 x 109/L]. If within a cycle, 
no immediate action required.  If study drug held at the start of new cycle, 
continue current dose level once neutropaenia 
resolved to ≤Grade 1 (ANC≥1.5 x 109/L). 
Grade 3 or 4  Hold, consider growth factor 
support.  If held at the start of new cycle  continue at the 
next lower dose level if neutropaenia resolved to 
≤Grade 1 within 14 days.  
If study drug held within a cycle , if neutropaenia 
resolved ≤Grade 2 within 14 days, continue at 
next lower dose level.  
If neutropaenia has not resolved to ≤Grade 2 
within 14 days, permanently stop treatment . 
Thrombocytopaenia  
Grade 2  Hold  if starting or within a cycle 
[delay of max 14 days allowed until 
platelets ≤ Grade 1]  If held at the start or within cycle  continue at 
the next lower dose level if thrombocytopaenia 
resolved to ≤Grade 1 within 14 days.  
If thrombocytopaenia has not resolved to ≤Grade 
1 within 14 days, permanently stop treatment . 
NuTide:302                                                                                                                        Version 4.2, 10 Aug 2022 
 
Confidentia l                                                            NuCana  plc 121 Toxicity Grade  Recommended immediate action 
with NUC -3373  Recommendation for dose modification of 
NUC -3373 at start of a new cycle  
Grade 3 or 4  Hold and follow treatment 
guidelines  When thrombo cytopaenia resolved to ≤Grade 1, 
continue current study at the next lower dose 
level . 
If thrombocytopaenia has not resolved to ≤Grade 
1 within 14 days, permanently stop treatment .  
Diarrhoea  
Grade 2  Hold if starting or within a cycle 
[delay of max 14 days allowed until 
platelets ≤Grade 1]  Refer to Appendix 4  
Grade 3 or 4  Hold and follow treatment 
guidelines  Refer to Appendix 4  
9.3 Suggested Management of Toxicity  
9.3.1 Nausea and Vomiting  
• Consider anti -emetic medications, e.g., granisetron, dexamethasone, cyclizine  
• Maintain adequate hydration, including use of intravenous fluids if indicated  
• Supplement electrolytes, particularly potassium and magnes ium, to recommended 
levels  
• Discontinue any concomitant medications that could co ntribute to nausea and 
vomiting  
• Rule out other potential aetiologies ( e.g., gastrointestinal tract obstruction)  
• Consider prophy lactic anti -emetic medications per ASCO guidelines for 
chemotherapy r egimens  of moderate emetic risk  prior to next scheduled treatment  
9.3.2 Diarrhoea  
• All available anti -diarrhoeal medications, including loperamide and opi[INVESTIGATOR_346960], sho uld be considered for treatment  
• Maintain adequate hydration, including use of intravenous fl uids if indicated  
• Supplement electrolytes, particularly potassium and m agnesium, to recommended 
levels  
• Avoid oral supplement ation of electrolytes since diarrhoea could be exacerbated in 
some c ases 
• Rule out other potential causes, including infec tious aetiologies  
• Discontinue any concomitant medications that could exacerbate diarrhoea  
• Avoid the use of diuretics and laxatives  
• Refer to Appendix 4 for further guidance  
NuTide:[ADDRESS_431172] c                                                             Confidential  122 9.3.3 Mucositis  
• Encourage good oral hygiene, including cleaning teeth after each meal and at 
bedtime, us ing soft -bristled toothbrush  
• Rinse mouth using chlorhexidine (or similar) mouthwash after brushing teeth, afte r 
mealtimes and in the evenings  
• Careful dental flossing once daily; avoid visits to de ntal hygienist during treatment  
• Dentures cleaned aft er each meal and soaked  overnight in cleaning solution  
• Avoidance of spi[INVESTIGATOR_70329], rough or crunchy foods  
• Manage pain from mucositis with benzydamine mouthwash (Difflam), systemic 
analgesics such as dis persible paracetamol or aspi[INVESTIGATOR_248]  
• For ulcers, local analgesia in cluding Mucaine equivalent 10  mL qds, lidocaine 1% 
gel, topi[INVESTIGATOR_346961] 3 hours, buccal hydrocortisone (2.5  mg) tablet s 4x 
daily or orabase ointments  
• Sucralfate suspension 5  mL qds rinsed around the mouth  
• For patients  with G rade 3/4 mucositis, use low dose opi[INVESTIGATOR_858] ; consider rinsing with 
Gelcair oral gel (15  mL sachets)  
9.3.4 Palmar -Plantar Erythrodysesth aesia (hand -foot syndrome ) 
• For Grade 1 or above, consider starting pyridoxine 50  mg tds  
9.3.5 Dermatologic Toxicity  
Severe acneiform rash can occ ur with exposure to an EGFR inhibitor .  Recommended dose 
modifications for severe (CTC AE v5.0 Grade 3 or 4) acneiform rash are specified in Table 22.  
Table [ADDRESS_431173] dose  
No improvement  Discontinue  
Second  Delay treatment  1-2 weeks  Improvement  Continue at 80% of the dose  
No improvement  Discontinue  
Third  Delay treatment  1-2 weeks  Improvement  Continue at 60% of the dose  
No improvement  Discontinue  
Fourth Discontinue  
In general , patients should be treated as per local standards of care for EGFR  inhibitor -related rash.  
However, the following guidance should also be considered:  
NuTide:[ADDRESS_431174] -spectrum sunscreen of SPF ≥30 when going outside is 
recommended in all patients, since the rash is accompanied by [CONTACT_347030].  
Prevention of acneiform rash caused by [CONTACT_347031][INVESTIGATOR_11930] ( e.g., 
hydrocortisone 2.5%, alclometasone) and oral antibiotics ( e.g., minocycline, doxycycline, or antibiotics 
covering skin flora) twice daily for at least the first [ADDRESS_431175] should be consulted . Potential treatment options 
include:  
In patients who have already developed Grade 1/2 rash : topi[INVESTIGATOR_11930] ( e.g., hydrocortisone 
2.5%, alclometasone) and oral antibiotics ( e.g., minocycline, doxycycline, or antibiotics cov ering skin 
flora) twice daily for at least 4 weeks is recommended.  
In cases where secondary infections are suspected : a bacterial swab culture should be performed in 
order to institute oral antibiotic therapy based on sensitivities . 
9.3.6 Infusion Reactions  
Infusion reactions may occur with any of the study drugs . Infusion reactions should be managed 
as follows:  
• Reduce infusion rate by 50% in patients experiencing a mild or moderate ( Grade 1 
or 2) infusion reaction for the duration of that infusion  
• Terminate  the infusion in patients experiencing severe infusion reactions. 
Depending on the severity and/or persistence of the reaction, permanently 
discontinue the combination agent.   
9.3.7 Ocular Toxicity  
Patients presenting with signs or symptoms suggestive of eye disorders such as acute or 
worsening eye inflammation, lacrimation, light sensitivity, blurred vision, eye pain and/or red 
eye should be referred promptly to an ophthalmology specialist for evalu ation.  
9.3.[ADDRESS_431176] efforts that include supportive care and carefully considered dose reductions of 
all or some of the agents within a treatment regimen can be considered.  Changes in dose for 
any agent should be discussed with the medical monitor prior to implementation.  
9.3.9 Combination Therapi[INVESTIGATOR_346962] 2 and 3 of the study should be 
managed as outlined in the sections below.  
[IP_ADDRESS]  Oxaliplatin  
Serious and fatal hypersensitivity reactions, including anaphylaxis, can occur with oxaliplatin 
within minutes of administration and during any cycle of treatment. Oxaliplatin should be 
discontinued in patients who experience severe hypersensiti vity reactions  which are not 
manageable with dose reductions, infusion time adjustments and prophylactic treatment  with 
steroids and histamine receptor antagonists .  
NuTide:[ADDRESS_431177] c                                                             Confidential  124 For patients experiencing oxaliplatin -related toxicities in NUFOX cohorts, t he dose of 
oxaliplatin may be adjusted (through agreement with the DSMC) based on safety events.  
If oxaliplatin -related AEs are  observed, dose de -escalation should be performed as per the 
Prescribing Information  or standard local practice .  
For a complete overview of oxaliplatin -related AEs, refer to the Prescribing Information.  
[IP_ADDRESS]  Irinotecan  
Early and late diarrhoea can occur with irinotecan. Early diarrhoea may be accompanied by 
[CONTACT_347032], which may be prevented or ameliorated by [CONTACT_347033][INVESTIGATOR_050]. Late diarrhoea can 
be life -threatening and should be treated promptly with loperamide. Patients with diarrhoea 
must be monitored and given fluid and electrolytes as needed. Antibiotic therapy should be 
initiated if patients develop ileus, fever or severe neutropaenia.   
For patients experiencing irinotecan -related toxicities in the NUFIRI cohorts, t he dose of 
irinotecan may be adjusted (through agreement with the DSMC) based on safety events.  
If irinotecan -related AEs are observed, dose de -escalation should be performed as per the 
Prescribing Information  or standard local practice .  
For a complete overview of irinotecan -related AEs, ref er to the Prescribing Information.  
[IP_ADDRESS]  Bevacizumab  
Infusion reactions reported across clinical studies and post -marketing experience include 
hypertension, hypertensive crises associated with neurologic signs and symptoms, wheezing, 
oxygen desaturation, Grade [ADDRESS_431178] pain, headaches, rigors, and diaphoresis. 
Discontinue bevacizumab  in patients who develop a severe infusion reaction and administer 
appropriate medical therapy ( e.g., epi[INVESTIGATOR_238], corticosteroids, intravenous antihistamines, 
bronchodilators and/or oxygen).  
The incidence of severe hypertension is increased in patients receiving bevacizumab  as 
compared to patients receiving chemotherapy alone. Across clinical studies, th e incidence of 
Grade 3 -4 hypertension ranged from 5% to 18%. Monitor blood pressure every two to three 
weeks during treatment with bevacizumab . Treat with appropriate anti -hypertensive therapy 
and monitor blood pressure regularly.  
Bevacizumab  treatment must be discontinued in patients with gastrointestinal perforations or 
wound healing complications requiring medical intervention.  
For patients undergoing elective surgery, bevacizumab  must be withheld for at least [ADDRESS_431179] local practice . 
For a complete overview of bevacizumab -related AEs, refer to the Prescribing Information.  
[IP_ADDRESS]  EGFR inhibitors  
EGFR inhibitors  can cause serious and fatal infusion reactions and must be disco ntinued in 
patients who experience serious infusion reactions.  
NuTide:[ADDRESS_431180] efforts should 
be given to maintaining a patient receiving clinical benefit on study.  
NuTide:[ADDRESS_431181] c                                                             Confidential  126 10 OTHER TREATMENTS (NON -IMP)  
All prescription and non -prescription medications and therapi[INVESTIGATOR_014], including phar macologic 
doses of vitamins, herbal medicines or other non -traditional medicines, taken from [ADDRESS_431182] be recorded in the 
CRF.  
10.1 Support Medication  
Patients may receive prophylactic  medical treatment  at the Investigator’s discretion  to 
prevent  AEs common to the administration of anti -cancer agents  including, but not restricted 
to, anaphylaxis,  nausea and vomiting. All support medication s must be recorded in the CRF.  
Support medications should be administered according to the Prescribing Information or 
standard local practice for the relevant combination agents. The following support  medications 
are recommended: anti-emetics ( palonosetron, granisetron, aprepi[INVESTIGATOR_053], dexamethasone, 
metoclopramide, domperidone, cyclizine ); anti-histamines ; atropi[INVESTIGATOR_050] ( e.g., for irinotecan -
containing regimens) ; sunscreen  of ≥SPF 30; topi[INVESTIGATOR_11930] ( e.g., hydrocortisone 2.5%, 
alclometasone) ; and oral antibiotics ( e.g., minocycline, doxycycline, or antibiotics covering 
skin flora)  for cetuximab -containing regimens .  
10.2 Haematopoietic Growth Factor Support  
The prophylactic use of haematopoietic growth factors ( e.g., G-CSF) is not permitted in the 
first cycle  in patients being evaluated for DLT . However, the Investigator may include 
haematopoietic growth factor support according to local protocols and as prophyla xis after any 
febrile neutropaenic epi[INVESTIGATOR_346963] [ADDRESS_431183] be a barrier method.  
• True a bstinence  is defined as refraining from sexual intercourse. True abstinence is only 
acceptable if this practice is in line with the patient’s preference and usual lifestyle. 
Periodic abstinence ( e.g., calendar, ovulation, symptothermal, post -ovulation methods), 
declaration of abstinence for the duration of exposure to the investigational drug, and 
withdrawal are not acceptable methods of contraception.  
• Surgical sterilisation (males)  
• Intrauterine devic e or intrauterine system  
• Oral contraception plus a barrier method  
NuTide:302                                                                                                                        Version 4.2, 10 Aug 2022 
 
Confidentia l                                                            NuCana  plc 127 • Double -barrier method ( e.g., male condom or a diaphragm plus a vaginal spermicidal 
cream)  
These forms of contraception must be used from the time of signing consent, throughout the 
treatment  period, and for [ADDRESS_431184] -menopausal (12 months of amenorrhea) or surgically sterile.  
10.3.2  Prohibited Therapy  
Except as included in the specific arms and d osing regimens of this study, use of the following 
therapi[INVESTIGATOR_346964]:  
• Other cytotoxic chemotherapy  
• Radiotherapy , excluding a short cycle of palliative radiotherapy (e.g., for bone pain ) 
• Immunotherapy including immunosuppressive therapy  
• Radioimmunotherapy  
• Hormone therapy (other than contraceptives, hormone -replacement therapy, or 
megestrol acetate)  
• Other biologic agents intended for the treatment of CRC  (other than haematopoietic 
growth factors, which are allowed  if clinically indicated and used in accordance with 
instructions provided in the package inserts)  
• Any therapi[INVESTIGATOR_346965] , whether approved by [CONTACT_347034]  
• Drugs that are known to prolong QTc interval (refer to Appendix 3 ) 
• Strong inducers of CYP3A4 , including but not limited to  phenytoin, phenobarbital, 
carbamazepi[INVESTIGATOR_050], rifampin, rifabutin or St. John’s wort  
• Strong inhibitors of CYP3A4 , including but not limite d to ketoconazole, 
clarithromycin, indinavir, itraconazole, lopi[INVESTIGATOR_054], nefazodone, nelfinavir, ritonavir, 
saquinavir,  or atazanavir  
• Live vaccines (must also be avoided for six weeks after last dose  of study medication ) 
• Diuretics and laxatives should be avoided in patients experiencing treatment -related 
diarrhoea and cholinergic reactions  
• Patients in bevacizumab -containing arms should not receive full -dose anti -coagulation 
therapy , with the exception of patients who have been on stable doses for at least [ADDRESS_431185] tolerated prior bevacizumab treatment  
10.3.3  Therapy to be Used with Caution  
The following warnings and precautions regarding concomitant medications apply to 
irinotecan containing dose combinations:  
• Strong inhibitors of UGT1A1 , including but no t limited to ketoconazole, indinavir, 
itraconazole, lopi[INVESTIGATOR_054], nelfinavir, ritonavir, saquinavir, atazanavir, or gemfibrozil, 
should not be administered with irinotecan.  Strong inhibitors of UGT1A1 should be 
discontinued at least 1 week prior to starting irinotecan.  Do not administer strong 
NuTide:[ADDRESS_431186] the Medical Monitor before concomitant administration of strong 
UGT1A1 inhibitors and irinotecan  
• Interaction betw een irinotecan and neuromuscular blocking agents cannot be ruled out. 
Irinotecan has anti -cholinesterase activity, which may prolong the neuromuscular 
blocking effects of suxamethonium and the neuromuscular blockade of non -
depolarising drugs may be antagon ised.  Caution should be used when using 
neuromuscular blocking agents with irinotecan  
For patients in all parts and arms of the study, w arfarin and other types of long acting 
anti-coagulants (such as phenproc oumon and anti ‑Xa inhibitors with a half ‑life o f >12 hours) 
is prohibited within [ADDRESS_431187] dose of study treatment.  Patients requiring anti -
coagulant treatment should switch to low molecular weight heparin or anti ‑Xa inhibitors with 
a half ‑life of ≤12 hours . 
Refer to the NUC -3373 IB for cur rent information on potential drug interactions.  
10.3.4  COVID -19 Vaccinations  
A risk assessment performed in accordance with MHRA guidance ‘Managing clinical trials 
during COVID -19’ (MHRA, 2021 ) concluded that a COVID -[ADDRESS_431188] to administration 
of NUC -3373 and the other combination agents used in this  study.  
NuTide:[ADDRESS_431189] v1.1 criteria , with target and non -target 
lesions identified , measured  and followed throughout the study (Appendix 1 ).  Biopsied lesions 
should not be designated as target lesions for the purposes of RECIST  v1.1 and a target lesion 
should not be biopsied during the study unless medically necessary.  
Whenever possible, the same qualified physician will interpret results to reduce variability. 
Radiographic images will be maintained at the study centre  and Investigator’s assessments  will 
be filed in the patient’s source doc uments.  
Tumo ur measurements and  disease response assessments are to be performed  every  8 weeks 
(±7 days) from C ycle 1 Day 1. If the patient stops study treatment for re asons other than 
radiologically -confirmed progressive disease , tumo ur measurements and disease response 
assessments  should contin ue every 8 weeks  (±7 days ) from C ycle 1 Day 1 until progressive 
disease  is radiologically confirmed.  
Tumo ur measurements and disease response assessments should  be performed a ny time disease 
progression is suspected .  Patients should not discontinue treatment  because of clinical signs 
of progression  until it has been radiologically confirmed by [CONTACT_347035] . 
Complete responses ( CRs) and partial responses  (PRs) must be confirmed by [CONTACT_347036] [ADDRESS_431190] once after study entry 
at a minimum interval of not less than 7 weeks  after the start of study treatment . 
NuTide:[ADDRESS_431191] c                                                             Confidential  130 12 SAFETY REPORTING  
This study evaluates NUC -3373 in combination with a variety of agents commonly used in 
treatment of advanced CRC , including LV, oxaliplatin, irinotecan, bevacizumab , cetuximab , 
and panitumumab . In considering safety assessments and reporting, it is anticipated that some 
safety findi ngs may be attri butable to a specific agent in a  combination regimen , while others 
may not be attributable to a specific agent.  In this section, the term “study drug(s)” refers to 
any of the agents administered to the patient in the arm of the study to wh ich he/she was 
enrolled.  
12.1 Definitions  
The Investigator is responsible for reporting all AEs that are observed or reported during  the 
study, regardless of relationship to study drug (s) or clinical significance.  
An AE is defined as any untoward medical occurrence in a patient enrolled into this study 
regardless of its causal relationship to study drug (s). Patients or their legally authoris ed 
representatives will be instructed to contact [CONTACT_91564] -Investig ator at any time 
after signing the ICF if any symptoms develop.  
A TEAE  is defined as any event not present before exposure to study drug (s) or any event 
already present that worsens in either intensity or frequency after exposure to study drug (s). 
A SAE  is defined as any event that:  
• Results in death  
• Is immediately life -threatening  
• Requires inpatient hospi[INVESTIGATOR_346966]  
• Results in persistent or si gnificant disability/incapacity  
• Is a congenital anomaly/ birth  defect  
• Is a s ignificant medical event in the Investigator 's judgment ( e.g., may jeopard ise 
the patient or may require medical/surgical intervention to prevent one of the 
outcomes listed above)  
Disease progression  and disease -related death will not be consi dered an AE or SAE.  
An adverse drug r eaction (ADR)  is an AE  which is considered to be causally related to any 
dose of study drug(s).  This means that a causal relationship between study drug(s) and the AE 
is at least  a reasonable possibility, i.e., the rel ationship cannot be ruled out.  
An unexpected drug r eaction is an ADR , the nature or severity of which  is not consistent with 
applicable product information .  For NUC -3373 , please refer to the IB Reference Safety 
Information ( RSI).  For the other agents used in combination with NUC -3373, please refer to 
the applicable Summary of Product Characteristics (S mPC), which serve as their RSI . 
A suspected unexpected serious adverse r eaction (S[LOCATION_003]R)  is a serious ADR , the nature or 
severity of whic h is not consistent with the applicable product information ( e.g., IB for an 
unapproved IMP). 
An important medical event  that m ay not result in death, be life -threatening, or require 
hospi[INVESTIGATOR_346967], based upon appropriate medical judgment, it 
may jeopard ise the patient and may require medical or surgical intervention to prevent one of 
the outcomes listed in this definition . Examples of such medical events include a llergic 
NuTide:[ADDRESS_431192] been hospi[INVESTIGATOR_346968], had 
any accidents, used any new medications, or changed concomitant medication regimens (both 
prescription and over -the-counter medications) . In addition to patient observations, AEs will 
be documented from any data collected on the CRF or other documen ts that are relevant to 
patient safety . Any allergic reaction to the agents administered  as study drug treatment must be 
reported as an AE.  
After informed  consent has been obtained, but prior to initiation of study drug, only AEs and 
SAEs caused by a protocol -mandated intervention will be reported.  Thereafter, all AEs 
occurring up to and including  [ADDRESS_431193]  be reported in detail on the AE CRF . Disease progression in the medical opi[INVESTIGATOR_346969]/or disease -related morbidity and mortality as a study endpoint will not be 
considered an AE or SAE but should be captured on the Death CRF . Information to  be collected 
for each AE includes onset date, type of event, aetiology , Investigator -specified assessment of 
severity and relationship to study drug, seriousness, any required treatment or evaluations, 
outcome and date of resolution . AEs resulting from co ncurrent illnesses, reactions to 
concurrent illnesses, reactions to concurrent medications, or progression of disease states must 
also be reported . All AEs will be followed for 30 days after the  patient’s last dose  or until 
resolution, whichever comes firs t. 
Pre-existing  conditions (present before the start of the AE collection period) are considered 
concurrent medical conditions and should not be recorded as AEs . However, if the patient 
experiences a worsening or complication of such a concurrent condition, the worsening or 
complication should be recorded as an AE . Pre-existing AEs that worsen should be followed 
until 30 days after the patient’s last dose or resolution to the grade or  level present at study 
entry. Investigators should ensure that t he AE term recorded captures the change in the 
condition ( e.g., “worsening of [condition]”).  
Insufficient clinical response, efficacy, or pharmacological action should NOT be recorded as 
an AE . The Investigator must make the distinction between exacerbatio n of pre-existing  illness 
and lack of therapeutic efficacy . Progressive disease  is NOT an AE; however, some sequelae 
of progressive disease  (i.e., pain, neurologic impairment) may be reported as AEs (generally 
not related to study drug(s) ). 
Abnormal labora tory values or test results constitute AEs only if they induce clinical signs or 
symptoms, are considered clinically significant, require therapy or further diagnosis beyond 
repeat testing for confirmation, or (if not associated with clinical signs or symp toms) remain at 
levels consistent with severe abnormalities despi[INVESTIGATOR_346970] . It is 
requested that when reporting AEs for which potentially redundant CTCAE terms exist, the 
Investigator uses the more clinically -oriented terminology (for example, ‘an aemia’ is 
preferable to ‘h aemoglobin decreased’).  
It is also requested that in the setting of an allergic reaction or suspected allergic reaction 
considered by [CONTACT_66325](s) , the Investigator reports both the 
specific symptoms associated with the reaction ( i.e., ‘urticaria’, ‘ dyspnoea ’) and also report the 
NuTide:[ADDRESS_431194] c                                                             Confidential  132 appropriate term indicating the allergic reaction (‘allergic reaction’ or ‘anaphylaxis’ if 
appropriate [Immune System Diso rders; CTCAE v5.0]). 
12.3 Assessment of Causality  to Study Drug(s)  
The Investigator’s assessment of an AE's relationship to  study drug(s) i s part of the 
documentation process, but it is not a factor in determining what is or is not reported in the 
study . If the re is any doubt as to whether a clinical observation is an AE, the event should be 
reported.  
The relationship of an AE to study drug(s) in this study should be classified using the following 
guidelines:  
Definitely Related: There is clear evidence to suggest a causal relationship and other possible 
contributing factors can be ruled out.  
Probably Related: There is evidence to suggest a causal relationship and the influence of other 
factors is unlikely.  
Possibly Related: There is some evidence to suggest  a causal relationship ( e.g., because the 
event occurs within a reasonable time after administration of the study drug). However, the 
influence of other factors may have contributed to the event ( e.g., the patient’s clinical 
condition, other concomitant tr eatments).  
Unlikely Related: There is little evidence to suggest a causal relationship ( e.g., the event did 
not occur within a reasonable time after administration of the study drug). There is another 
reasonable explanation for the event ( e.g., the patient ’s clinical condition, other concomitant 
treatments).  
Not Related: There is no evidence of any causal relationship. N.B. An alternative cause for 
the AE should be given.  
12.4 Assessment of Severity  
The severity of each AE is to be assessed by [CONTACT_737] a ccording to CTCAE, v5.0. If the 
AE is not included in the CTCAE, then the Investigator should  determine the intens ity of the 
AE according to the  criteria  described in Table 23. 
Table 23 Intensity of adverse events not included in CTCAE  
Intensity  Criteria  
Mild (Grade 1)  AE that disappears or is easily tolerated on continuation of study 
drug 
Moderate (Grade 2)  AE is sufficiently discomforting to cause interference with usual 
work activities  
Severe (Grade  3) AE that is incapacitating, with inability to work or perform daily 
activities  
Life-Threatening (Grade 4)  AE that is potentially  life-threatening * 
Death (Grade 5)  Death related to AE  
*  If a life -threatening (Grade  4) AE is immediately  life-threatening, the event is by [CONTACT_347037] 12.6 and 12.7. 
NuTide:[ADDRESS_431195] administration of study drug (s) through [ADDRESS_431196] details  
Email  Nucana@ primevigilance.com  
If the patient is hospi[INVESTIGATOR_346971], then a copy of the 
hospi[INVESTIGATOR_44458] (if available) should be  provided in an SAE follow -up report  in 
the EDC or, if needed, using the contact [CONTACT_347038] 24 as soon as it becomes 
available .  
NuCana  will notify appropriate regulatory autho rities of any unexpected, fatal  or 
life-threatening experienc e that is determined to be related  to the use of the study drug(s).  R efer 
to Section 12.[ADDRESS_431197]/ethics committee ( IRB/EC ).  Copi[INVESTIGATOR_346972] -Investigator s, governing authorities, ethics committees, and the Sponsor 
(or sponsor designee)  must be submitted for filing.  
A patient experiencing one or more SAE s will receive treatment and follow -up evaluations by 
[CONTACT_137996] -Investigator  or will be referred to another appropriate physician for 
treatment and follow -up. All SAEs must be followed to resolution or, if res olution is unlikely, 
to stabilis ation. 
Study endpoints in patients with cancer, including CRC , include disease -related mortality and 
morbidity ; as study endpoints, these will not be reported as expedited Investigational New Drug 
(IND) safety reports, unless there is a serious and unexpect ed event with evidence of a causal 
relationship between  study drug(s) and the event . As appropriate and based on the frequency 
of occurrence, SAEs in the study will be reported to  the relevant regulatory authorities  at an 
appropriate interval, such as incl usion in the development safety update  report .  
The following SAEs will not be reported individually in an expedited manner because they are 
anticipated to occur in the CRC  study population receiving standard of care treatment at some 
frequency independent of study drug exposure:  
• Progress ion of disease  
• Death as a consequence of the underlying malignancy  
NuTide:[ADDRESS_431198] c                                                             Confidential  134 12.6  Expedited Reporting of SAEs  
The following SAE reporting requirements apply regardless of the Investigator’s assessment 
of the causality or expectedness of the SAE . If an SAE occurs that requires reporting, a n SAE 
Report Form should be completed in the EDC and communicated  within [ADDRESS_431199] be reported  to the responsible Regulatory Authorities and IRBs/ECs within 
the required timelines:  
• Fatal or life threatening S[LOCATION_003]Rs will be reported within [ADDRESS_431200] report.  
• All other S[LOCATION_003]Rs will be reported within [ADDRESS_431201] of the study.  
The Sponsor  will notify appropriate regulatory authorities of any fatal  or life -threatening 
experience that is determined to be related to the use of the study drug (s) (expedited report) as  
soon as possible but no later than 7 calendar days after the initial receipt of the information . 
Initial notification will be followed by a written report within 15 calendar days .  
For unexpected events associated with the use of the study drug (s) which a re not fatal or life 
threatening, the Sponsor  will notify the regulatory authorities as soon as possible and no later 
than 15  days of the initial receipt of information .  
The Investigator is responsible for informing the IRB/EC .  Copi[INVESTIGATOR_346973] -Investigators, regulatory  authorities, IRBs/ECs and the Sponsor must 
be submitted for filing.  
12.[ADDRESS_431202] also be reported as an SAE .  
Examples of pregnancy outcomes that are SAEs include reports of:  
• Congenital anomalies or developmental delay, in the foetus  or the child  
• Foetal  death and  spontaneous abortion  
• Suspected adverse reactions in the neonate  that are classified as serious  
NuTide:302                                                                                                                        Version 4.2, 10 Aug 2022 
 
Confidentia l                                                            NuCana  plc 135 12.10  Events Exempt from being R eported as AE/SAEs  
12.10.1   Progression of Underly ing Disease  
Disease progression and resultant death will be captured on the CRF . AEs including 
hospi[INVESTIGATOR_346974]/SAEs . Clinical symptoms of disea se progression will only be reported as AEs if 
the symptom cannot be deter mined as exclusively due to progressi on of the underlying 
malignancy  or does not fit the expected pattern of progression for the disease under study.  
Every effort should be made to d ocument the objective progression of underlying malignancy . 
In some cases, the determination of clinical progression may be based on symptomatic 
deterioration. For example, progression may be  evident from clinical symptoms  but is not 
supported by [CONTACT_347039]. Or  the disease prog ression is so evident that the 
Investigator may elect not to perfo rm further disease assessments.  
12.10.[ADDRESS_431203] supportive care are not 
SAEs  and do not require SAE reporting .  
12.11  Informing  Investigators of New Safety Information  
The sponsor  will en sure that all Investigators are  informed  in a timely manner  of new safety 
information  regarding NUC -3373  that becomes available . Investigators are responsible for 
briefing their study team as appropriate.  
12.12  Reference Safety Information (RSI) for Assessment of Expectedness  
12.12.1     NUC -3373  
The Investigator Brochure (IB) supplied by [CONTACT_347040] -3373 contains the NUC -3373 
RSI for this study.  Only the IB version with current regulatory and IRB/EC approval for use 
in the study will be used to assess S AE reports to identify S[LOCATION_003]Rs.  
• Significant Changes to the RSI : If patient safety or the risk/benefit assessment has 
changed or new expected reactions have been added, then approval of the updated IB 
by [CONTACT_347041]/ECs will be sought . If new expected 
reacti ons have been added to the IB or events have been down -graded to ‘expected’, a 
justification for the changes will be included in the amendment request. Changes to the 
IB that impact on patient safety or alter the risk/benefit assessm ent may require changes  
to study documentation , such as the ICF . The sponsor will identify any  required changes 
and ensure ICF revisions are made and approved by [CONTACT_347042]/ ECs, and patients re -consented as applicable . Significant updates to the I B 
shall be attached to the development safety update report ( DSUR ) (once approved by 
[CONTACT_347041]/ ECs); however , the IB in effect at the start 
of the DSUR reporting period serves at the RSI during the reporting period .  
NuTide:[ADDRESS_431204] c                                                             Confidential  136 • Non-Significant Changes to the IB: If changes to the IB are minor and do not include 
new/removed  expected reactions, do not impact on patient safety or alter the benefit/risk 
assessment, then sites will not receive the updated IB until the end of the DSUR 
reporting period . 
If the non -significant updated IB is to be implemented in the new DSUR reporti ng period, then 
Regulatory Authority and IRB/EC should be informed of the intention to implement the 
updated IB after the DSUR reporting period ends . The updated IB will be attached to the 
DSUR . If new expected reactions have been added to the IB or events  have downgraded to 
‘expected’, then the updated IB must receive approval before it is implemented . The IB will be 
sent to the study sites with a covering letter documenting the changes . This will be circulated 
after the DSUR has been submitted at the star t of the new DSUR reporting period.  
12.11.2   Other Agents to be Used in Combination with NUC -3373  
The SmPC  of each individual  agent  intended to be  administered in conju nction with NUC -3373 
in this study will serve  as their own RSI.  Representative  SmPC s for each agent are provided 
in the NUC -3373 IB (Section 8.1) for ease of reference .  
12.13  Data Safety Monitor ing Committee (DSMC ) 
The DSMC  will review ongoing and cumulative  safety, dosing intensity, PK, PD and clinical 
activity data from each cohort.  In all cohorts, the DSMC will  determine  if the dose  
levels/schedules are safe and tolerable  and if an arm should be expanded, if other dose 
levels/schedules should be explored, or if the cohort should be stoppe d.   
The DSMC will review all data in accordance with the European Medicines Agency ( EMA ) 
guideline on strategies to identify and mitigate risks for first -in-human and early clinical trials 
with investigational medicinal products  (EMEA/CHMP/SWP/[ZIP_CODE]/07 Re v. 1, EMA 01 Feb 
2018 ). 
Members of the DSMC  will include  (at a minimum) :  
• Chief Investigators from US and Europe  
• Medical Monitors  
• Sponsor’s  Medical Director  
• Sponsor’s s tudy management staff  
NuTide:302                                                                                                                        Version 4.2, 10 Aug 2022 
 
Confidentia l                                                            NuCana  plc 137 13 STATISTICAL CONSIDERATIONS  
A Statistical Analysis P lan (SAP) will be finalis ed before database lock and conduct of the 
final analysis is undertaken . Only the main features of the planned statistical analysis are 
included below.  
All statistical analyses will be performed using SAS®, Version 9.3 or higher.  
Unless specified otherwise, all data from each study part will be presented separately in the 
tables, figures and l istings.  Furthermore, for Part s 2 and 3 , data for each cohort will be 
presented separately.  
The study database will be locked prior to the p rimary analyses for inclusion in the clinical 
study report ( CSR ). However, interim data will be made available to the DSMC  to assist with 
the identification of DLTs and enable dose escalation decisions whilst the study  is ongoing.  
13.1 Sample Sizes 
The study is not formally powered, but has been designed to estimate the safety and tolerability 
of NUC -3373 when given with the combination agents described in Section 3.3. For the dose 
escalation phases, a modified 3+[ADDRESS_431205] limiting the number of patients exposed to experimental treatment and 
procedures.  
13.2 Missing, Unused  and Spurious Data 
In general, missing data will remain missing and will not be included in data summaries.   
Exceptions are described below.  
Missing baseline data (safety data)  
If a baseline value is not available and a screening value is available for the same parameter, 
then the last screening value will be used as baseline.  This value will also be used for 
calculations of changes from baseline. Unless otherwise defined, baseline will be defined as 
C0D1 for Part 1 Arm 1a & 1b , or C1D1 for all other cohorts.  
13.[ADDRESS_431206] 1 dose of NUC -3373  and will be the primary analysis set for the 
assessment of safety and tolerability in the study.  
For the purpose of data summaries, patients will be included in the Sa fety Population according 
to the treatment cohort and dose level initially received, regardless of any subsequent dose 
adjustments.  
NuTide:[ADDRESS_431207] c                                                             Confidential  138 13.3.2  Full Analysis Set 
For all study parts and cohorts, the Full Analysis Set (FAS) is based on the intention -to-treat 
principles and includes all patients who received at least one dose of NUC -3373. Patients will 
be included in the FAS based on the dose of NUC -3373 initially received, regardless of any 
subsequent dose adjustments.  
The FAS will be used t o assess PFS and the PD markers.  
13.3.3  Evaluable for Response Set 
The Evaluable for Response (EFR) set is defined as a subset of the FAS with measurable 
disease at baseline  and who have undergone at least two cycles of treatment, received at least 
75% of planned  treatment over the two cycles, and undergone a post -treatment objective 
disease assessment.  
The EFR set  will be the primary analysis set used to assess tumour size, ORR , DCR, DoR  and 
DoSD  in all study parts.  
13.3.4  PK Analysis Set 
The PK Population contains all  patients who received NUC -3373 as per protocol ( i.e., intended 
dose) and provided at least one usable PK pro file. All PK data will be analys ed according to 
treatment received.   
This population will comprise all data from patients who received study treatment as per 
protocol (i.e., intended dose ) and did not violate or deviate from the protocol and planned 
dosing regimen in ways that would significantly affect the PK analyses (for example skippi[INVESTIGATOR_346975], or taking reduced doses or taking concomitant medications with the potential to cause a 
drug-drug interaction) during the PK sampling period. Patients who did deviate from the 
planned dosing regimen  may still provide some d ata for inclusion in the PK set  if they have at 
least one usable PK profile. The populatio n and decisions rega rding which prof iles are usable  
will be defined by [CONTACT_3476] , pharmacokineticist and statistician prior to any analyses 
being performed.  
13.4 Patient Disposition  
The disposition of patient s will be summaris ed presenting the number of patients enrolled, the 
number of patie nts treated, the number of patients for whom the study drug was discontinued 
with the reasons for discontinuation, and the number of patients who discontinued participation 
in the study.  
The number and percentage of patients included in each analysis popu lation (as defined in 
Section  13.3) will be presented.  
Patients with major protocol deviations or other significant deviations as defined in the SAP 
will be listed and summarised by [CONTACT_347043].  
NuTide:[ADDRESS_431208] atus wi ll be listed and summaris ed using appropriate 
descriptive statistics.  
Baseline disease characteristics including, but not limited to, primary diagnosis, primary 
tumo ur location and disease status at baseline will also be listed and summaris ed using 
appropr iate descriptive statistics.  
Relevant medical history and prior treatment for CRC, including, but not limited to systemic 
therapi[INVESTIGATOR_014], radiation and surgeries, will be listed and summaris ed using appropriate descriptive 
statistics. Full details will be provi ded in the SAP.  
13.5.2  Concomitant Medications  
Concomitant medication s, coded using World Health Organisation Drug Dictionary ( WHO 
DD) by [CONTACT_347044], therapeutic, chemical class and preferred term will be listed.  
Summaries may be produced for concomitant medications of specific interest, as determined 
by [CONTACT_347045], for example use of haematopoietic  growth factors and 
transfusions.  
13.5.[ADDRESS_431209] clearly enumerate rates of toxicities and to define 
further the safety profile of NUC -3373  and/or any of the proposed combinations . 
[IP_ADDRESS]  Adverse Events  
AEs will be considered treatment -emergent (TEAE) if they start on or after the time of the first 
dose of study treatment and up to [ADDRESS_431210] dose of study treatment. AEs will be 
summaris ed by [INVESTIGATOR_307692] D ictionary for Regulatory Activities ( MedDRA )™, Version 18.1 (or 
higher), System Organ Class (SOC) and preferred term. The sever ity of AEs will also be 
summaris ed by [CONTACT_3989] v5.0 (or higher), G rade. Non -treatment -emergent AEs will be included 
in the patient l istings and flagged as such but will not be included in the summary tables. Where 
an AE date is partial or missing, and it is unclear whether the AE is treatment -emergent, the 
AE will be assumed to be treatment -emergent.  
NuTide:[ADDRESS_431211] c                                                             Confidential  140 The following summaries will be produced by [CONTACT_347046]:  
• An overview table of the incidence of TEAEs, Grade 3+ TEAEs, SAEs, treatment -
related TEAEs, TEAEs leading to treatment discontinuation , TEAEs leading to 
treatment interruption,  and TEAEs leading to death, by [CONTACT_347047]  
• Summary of TEAEs by [CONTACT_9315]: Both the number and percentage 
of patients in each category (patient -level summary) and the number of e pi[INVESTIGATOR_1841] 
(epi[INVESTIGATOR_1865] -level summary)  
• Summary  of treatment -related TEAEs by [CONTACT_9315]  
• Summary of TEAEs occurring in at least 10% of patients, sorted in descending 
order of frequency ( i.e., most frequent event shown first). The order of frequency 
will be determined by [CONTACT_347048].  
• Summary of CTCAE Grade 3 an d above TEAEs by [CONTACT_11702]  
• Summary of TEAEs leading to NUC -3373 interruptions by [CONTACT_9315]  
• Summary of TEAEs leading to treatment discontinuation by [CONTACT_347049] h study treatment  
• Summary of TEAEs by [CONTACT_2946], preferred term and maximum severity  
• Summary of TEAEs by [CONTACT_2946], preferred term and worst -case relationship attribution  
• Summary of SAEs by [CONTACT_9315]  
• Summary of SAEs by [CONTACT_347050], the following will be listed:  
• All AEs, listed with date of onset, study day, dose at onset, treatment status at onset 
(pre-treatment, ongoing or post -treatment) and Investigator’s assessment of severity 
and relationship to study drug . 
• AEs with outcome of death along with the date of onset, study day, dose at onset, 
treatment status at onset (pre -treatment, ongoing or post -treatment) and 
Investigator ’s assessment of severity  and relationship to study drug  
• All SAEs along with the date of onset, study day, dose at onset, treatment status at 
onset (pre -treatment, ongoing or post -treatment), date of resolution (if SAE is 
resolved), Investigator ’s assessment of severity  and relationship to study drug (s) 
• AEs leading to discontinuation of study medication, listed along with the date of 
onset, study day, dose at onset, treatment status at onset (pre -treatment, ongoing or 
post-treatment) and Investigator ’s assessment of severity and relationship to study 
drug 
• AEs leading  to treatment interruptions, listed along with the date of onset, study 
day, dose at onset, treatment status at onset (pre -treatment, ongoing or post -
treatment) and Investigator’s assessment of severity and relationship to study drug  
If an AE is reported m ore than once during the study period the greatest severity and the 
worst -case attribution will be presented in summary tables. Any AEs commencing >30 days 
after discontinuation of study treatment will not be included in the tabulations of AE da ta 
NuTide:302                                                                                                                        Version 4.2, 10 Aug 2022 
 
Confidentia l                                                            NuCana  plc 141 [IP_ADDRESS]  Laborato ry Parameters  
Clinical laboratory data (actual and change from baseline) for continuous parameters at each 
sched uled assessment will be summaris ed using descriptive statistics including number of 
observations, mean, standard deviation, interquartile range  (for overall only) , minimum, 
median and maximum values. For categorical laboratory assessments, shift from baseline will 
be summarised using frequency and proportion at each scheduled assessment time.  
Additionally, data may be displayed graphically. Full details will be provided in the SAP.  
All clinical laboratory data for individual  patient s will be listed.  
[IP_ADDRESS]  Vital Signs 
Actual values at baseline and each scheduled visit and change from baseline at each post -
baseline  scheduled visit of vital signs (including pulse, respi[INVESTIGATOR_1516], systolic and diastolic blood  
pressure, oral temperature, and weight) will be summarised with descriptive statistics by [CONTACT_347051]. A ll data will also be listed .  
[IP_ADDRESS]  ECOG Performance Status  
ECOG perfor mance status will be summarised and listed . The ECOG Performance Scale is 
provided in Appendix 2 . 
[IP_ADDRESS]  Physical Examination  
Listings  will be provided for physical examination parameters.  
[IP_ADDRESS]  ECGs  
[IP_ADDRESS].[ADDRESS_431212] -baseline scheduled visit in ECG endpoints will be summarised with  
descriptive statistics by [CONTACT_347052]. Additionally, abnormal results will be  
summarised with frequencies and percentages by [CONTACT_347053], treatment group, and  
time point. All ECG data will be displayed in a data listing.  
[IP_ADDRESS].2  Holter ECGs  (PK sub -study)  
Holter  ECG monitoring will be implemented for patients in the PK sub -study (Arm 2b) to 
collect QT/QTc data to allow robust analysis of  ECG parameters. Holter monitoring will be 
performed on C1D8 and C1D22, when patients receive NUC -3373 + LV only.  
ECGs will be centrally evaluated. The analysis of ECG parameters for QT/QTc evaluation will 
be outlined in a separate QT SAP.  
 
 
NuTide:[ADDRESS_431213] c                                                             Confidential  142 [IP_ADDRESS]  Pharmacokine tics 
The PK of single and multiple -dose NUC -3373  will be assessed, including:  
• Cmax 
• AUC  
• t1/2 
• Vd 
• CL 
PK of the following will be measured , but are not limited to : 
• In plas ma: NUC -3373, [ADDRESS_431214] , FBAL  
• Part 1 only : In PBMCs : NUC -3373, FUDR -MP, FBAL, 5-FUTP , dTMP and 
dUMP  
All ab ove PK parameters will be analys ed in the PK population.  
[IP_ADDRESS]  Exploratory Endpoints  
Genomic, transcriptomic and proteomic biomarkers of biological activity will be analysed in a 
pre-treatment tumour sample and pre - and on -treatment blood and PBMC  (Part 1 only)  samples 
from patients i n the intention -to-treat population.  The SAP will specify candidate biomarkers 
where known as well as the exploratory nature of the biomarker studies to be conducted and 
exploration of possible relationships, if evident, of relationships between PK exposure, PD 
effects, safety and clinical a ctivity.  
13.5.5  Efficacy Analysis  
The primary efficacy endpoints and methods of analysis are defined below:  
[IP_ADDRESS]  Change from Baseline in Tumo ur Size  
The percentage change from baseline in tumo ur size at 8-week intervals  (%ΔTS timepooint ) will 
be defined as follows:  
• Baseline tumo ur size (TS baseline ): sum of longest diameters of target lesions at 
baseline  
• On-study  TS (TS timepoint ): sum of longest diameters of target lesions at a post-
treatment disease assessment  timepoint  
 
%∆TS𝑡𝑖𝑚𝑒𝑝𝑜𝑖𝑛𝑡 =TS𝑡𝑖𝑚𝑒𝑝𝑜𝑖𝑛𝑡 − TS𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒
TS𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒 × [ADDRESS_431215] percentage change from baseline in tumo ur size (%ΔTS best) across all timepoints will 
be calculated and presented using waterfall plots .  
The %ΔTS best will be defined as follows:  
• Baseline tumour size (TS baseline ): sum of longest diameters of target lesions at 
baseline  
NuTide:302                                                                                                                        Version 4.2, 10 Aug 2022 
 
Confidentia l                                                            NuCana  plc 143 • Best TS  (TSbest):  smallest sum of longest diameters of target lesions observed at 
any timepoint , regardless of whether the assessment was scheduled or unscheduled,  
after first dose and prior to disease progression  
 
%∆𝑇𝑆𝑏𝑒𝑠𝑡 =TS𝑏𝑒𝑠𝑡 − TS𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒
TS𝑏𝑎𝑠𝑒𝑙𝑖𝑛𝑒 × [ADDRESS_431216] -dose target lesion data , then they 
will be excluded from the waterfall plot of %ΔTS best.  
Tumo ur size (%ΔTS Wk8 and %ΔTS best) will be presented graphically using waterfall plots for 
presenting each patient’s percentage change in tumo ur size as a separate bar with the bars 
ordered from the largest increase to the largest decrease.  Reference lines at the +20% and –
30% change in tumo ur size levels will be added to the plots, which correspond with the 
definitions of disease progression and PR, respectively.   
[IP_ADDRESS]  Objective Response Rate (ORR)  
ORR is defined as the number of pati ents achieving a confirmed response (CR or PR), defined 
in accordance with RE CIST v1.1 (see Appendix 1 ). The number and percentage of patients in 
each RECIST v1.1 response category (CR, PR, SD, progressive disease  or not evaluable [ NE]), 
as well as the ORR  will be presented.  
All data will be listed.  
[IP_ADDRESS]  Disease Control Rate (DCR)  
DCR is defined as the number of patients achieving confirmed response (CR and PR) or SD as 
a best overall response.  
DCR may be summari sed if there are a number of patients achieving SD or response.  
[IP_ADDRESS]  Duration of Response (DoR)  
DoR is defined for the subset  of the EFR population categoris ed as responders for the 
assessment of ORR. DoR is defined as the time, in days, from the time measurement criteria 
are first met for CR or PR  (whichever is first recorded) until the first date that recurrent or 
progressive disease  is objectively documented (taking as reference for progressive disease  the 
smallest measurements recorded since the treatment started). Only responses that were later 
confirmed, will be considered when calculating the DoR. For patients who were los t to follow -
up without progression or reached the time point of analysis without a known record of death 
or progression, the DoR  will be censored at the date of last tumo ur assessment.  
DoR wil l be listed, and may be summaris ed if there are sufficient respo nders.  
[IP_ADDRESS]  Duration of Stable Disease (SD)  
SD is defined for the subset of the EFR population categori sed as having neither sufficient 
shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease . Duration 
of SD  is defined as the time , in days, from the time measurement criteria are first met for  SD 
until the first date that recurrent or progressive disease  is objectively documented (taking as 
reference for progressive disease  the smallest measurements recorded since the treatment 
started). For patients who were lost to follow -up without progression or reached the time point 
NuTide:[ADDRESS_431217] tumo ur assessment.  
Duration  of SD will be listed , and may be summari sed if there are sufficient responders.  
[IP_ADDRESS]  Progression -Free Survival (PFS)  
PFS is defined as the time from first dose of study treatment until the date of objective disease 
progression or death (by [CONTACT_347054]) regardless of whether 
the patient withdraws from study therapy prior to progression. Patients who start another 
anti-cancer therapy prior to progression will be censored at the date of the last available 
RECIST v1.[ADDRESS_431218] v1.1 
assessment.   
The PFS time will always be derived based on the scan/assessme nt dates rather than visit dates 
and the following rules will be applied:  
• Date of disease progression will be determined based on the earliest of the dates of the 
component that triggered the disease progression, i.e., if both the target lesions and the 
non-target lesions indicate disease progression but were scanned on different days, the 
earlier of the 2 dates would be applied   
• When censoring a patient for PFS the patient will be censored at the latest of the dates 
contributing to a particular overall vi sit assessment  
PFS will be presented using all available data up until the earlier of progression and starting 
subsequent therapy, or last evaluable RECIST v1.1 assessment in the absence of progression.  
The number of overall censored patients, number of p atients with events and Kaplan -Meier 
estimates median time will be provided. In addition, the results will be presented graphically 
in Kaplan -Meier plots.   
[IP_ADDRESS]  Overall  Survival ( OS) 
OS is defined as the time from Screening  to the time of death due to any cause. For patients 
who are alive at the time of analysis,  or are permanently lost to follow -up, duration of OS will 
be censored at the date at which they were last known to be alive.  
The date at which the patient is last k nown to be alive is defined as the latest date of: (i) last 
site visit; (ii) last date at which the patient had a radiographic scan; and (iii) last date at which 
the patient, the study investigator, their other physicians, or a family member confirmed that  
the patient was alive.  
The number of overall censored patients, number of patients with events and Kaplan -Meier 
estimates  with 95% confidence interval s will be presented.  
13.5.6  Pharmacodynamic Endpoints  (Part 1 only)  
Baseline and post -dose PBMC marker data will be analysed using a paired t test. Full details 
will be provided in the SAP.  
Boxplots for the change from baseline over time in neutrophils, platelets, and lymphocytes  will 
also be produced.  
Full details of all planned analyses of PD endpoints will be  provided in the SAP.  
NuTide:[ADDRESS_431219] 3 evaluable patients 
are required for the analysis. The efficacy analysis of % change in tumo ur size will take place 
when all patients in a given cohort have undergone at least [ADDRESS_431220] withdraw n from 
treatment. To enable the DSMC  to make dose escalation decisions, safety and tolerability data 
will be reviewed on an ongoing basis. There will be no formal requirements for a database lock 
to support these ongoing reviews. Upon review of the safety and tolerability data from each 
cohort by [CONTACT_6802] , additional patients may be added to a cohort to further evaluate the safety 
profile of the combination.  
13.5.8  Changes to the Planned Statistical Methods  
Planned statistical analyses will be documented in the f inal SAP before database lock . Any 
changes to the planned statistical methods will be documented in the CSR .  
NuTide:[ADDRESS_431221] review each completed eCRF in a timely manner. The Investigator will 
be required to review and electronically sign and date the CRFs once the patient’s data is 
complete.  
14.2  Monitoring of the Study  
Monitoring and auditing procedures develop ed by [CONTACT_347055] -GCP guidelines . Before a study centre  can enter a patient into the 
study, a representative of the Sponsor  or designee will visit the study centre  to: 
• Determine  the adequacy of the facilities  
• Discuss with the Investigator(s) and other personnel their responsibilities with 
regard to protocol adherence, and the responsibilities of the Sponsor or its 
representatives. This will be documented in a Clinical Study Agreement between 
the Sponsor  and the  Investigator  
During the study, a monitor from the Sponsor  or appointed CRO will have regular contacts 
with the study centre , for the following:  
• Provide information a nd support to the Investigators  
• Confirm th at facilities remain acceptable  
• Confirm that the  investigational team is adhering to the protocol, that data are being 
accurately recorded in the source documents and eCRFs, and that drug 
accountabi lity checks are being performed  
• Perform source data verification. This includes a comparison of the data i n the 
eCRFs with the patient’s medical records at the hospi[INVESTIGATOR_7117], and other 
records relevant to the study. This will require direct access to all original  records 
for each patient ( e.g. clinic charts)  
• Record and report any protocol deviations not  previously sent to the Sponsor  
• Confirm AEs and SAEs have been properly documented in the eCRFs and confirm 
any SAEs have been forwarded to the Sponsor  or designee, and those SAEs that 
met criteria for reporting ha ve been forwarded to the IRB/EC  
The monito r will be available between visits if the Investigator or other staff needs information 
or guidance .  
Note : during the COVID -[ADDRESS_431222] on -site visits for as short a 
period of time as possible.  
NuTide:302                                                                                                                        Version 4.2, 10 Aug 2022 
 
Confidentia l                                                            NuCana  plc 147 14.3  Patie nt Confidentiality  
Personal data recorded on all documents will be regarded as highly confidential . To preserve 
each patient’s anonymity, only their patient study number and date of birth (or other identified 
as appropriate to country regulations and agreed wi th the Sponsor ) will be recorded on the 
eCRFs.  
The Investigator site must maintain the patient’s anonymity in all communications and reports 
related to the research .  The Investigator site team must keep a separate log of enrolled patients’ 
personal ident ification details as necessary to enable them to be tracked.   These documents 
must be retained securely, in strict confidence. They form part of the Investigator Site File and 
are not to be released externally.   
NuTide:[ADDRESS_431223] been delegated will undertake their assigned roles for this study in compliance 
with ICH-GCP, US 21 Code of Federal Regulations (CFR) 11, [ADDRESS_431224] s/ Ethics Committees  
The applicable IRBs/ECs will review all appropriate study documentation to safeguard the 
rights, safety, and well being  of the patients.  
The final study protocol  and ICF  must be approved in writing by [CONTACT_347056]/ECs for 
each site . Written IRB/EC approval must be received by  [CONTACT_347057] 
a study centre  can enrol  any patient s into the study . In addition, the IRB/EC must approve all 
advertising used to recruit patients for the study .  
In the US, t he protocol (and associated documents, including  amendments) must be 
re-approved by [CONTACT_1201]/EC s annually, as local regulations require . Progress reports will be 
provided to the IRB/EC according to loc al regulations and guidelines.  
15.[ADDRESS_431225] the study will be obtained from the applicable Regulatory Authorities 
prior to initiating the study in each participating country.  
15.4 Protocol  Amendments  
All protocol amendments (and amendments to related study documentation) will be  approved 
by [CONTACT_347058] s/ECs  and Regulatory Authorities  prior to implementation.  
15.[ADDRESS_431226] document and explain in the patient’s source 
documentation any deviat ion from the approved proto col. 
A deviation from the protocol is an unintended and/or unanticipated departure from the 
procedures and/or processes approved by [CONTACT_1035] /EC and ag reed to by [CONTACT_97734] -Investigator. Deviations usually have an impact on indiv idual patients or a 
small group of patients and do not involve inclusion/ or primary endpoint criteria . Deviations 
will be tracked by [CONTACT_347059] .  
A protocol violation occurs when there i s nonadherence to the protocol that results in a 
significant, additional risk to the patient, when  the patient o r Investigator  has failed to adhere 
to signific ant protocol requirements ( e.g., inclusion/ criteria and the patient was enrolled 
without prior Sponsor approval ), or when there is nonadherence to  the FDA or other applicable 
ICH-GCP guidelines . 
The clinical monitor will document protocol violations and deviations throughout the course 
of monitoring visits. The monitor wi ll notify the Investig ators during a visit and  in writing of 
all violations and deviations. The IRB /EC should be notified of all protocol violations and 
deviations in a timely manner.  
NuTide:[ADDRESS_431227] to a significant degree the:  
• Safety or physical or mental integrity of the patients of the study; or 
• Scientific value of the study  
Investigators will notify the CRO within one working day if any serious breach of ICH -GCP 
or the proto col is suspected . Upon confirmation of a serious breach, the CRO will notify the 
applicable Regulatory Authorities . Typi[INVESTIGATOR_897], serious breach notifications should be made 
within seven days of the CRO becoming aware; however, this timeline may differ as specified 
by [CONTACT_347060].  
15.7 Study Reporting Requirements  
The Investigator agrees to submit progress  reports to their IRB/EC as app ropriate . The 
Investigator also agrees to provide the Sponso r with an adequate report shortly after  completion 
of their participation in the study.  
15.[ADDRESS_431228] 
provide the sponsor  with a commitment to update this information promptly if any relevant 
changes occur during the investigation and for one year after study  comple tion. 
Neither the sponsor  nor the CRO is financially responsible for further testing/treatment of any 
medical condition which may be detected during the screening process. In addition, in the 
absence of specific arrangements, neither the sponsor  nor the CRO is financially responsi ble 
for further treatment of the patient’s disease.  
15.[ADDRESS_431229] been met . Retention and storage of central laboratory records supporting PK 
NuTide:[ADDRESS_431230] also comply with 
applicable legislation.  
15.11   Audit and Regulatory Inspection  
The Investigator, Sub-Investigators, and institutions involved in the study will permit 
study -related monitoring, audits, IRB/EC review, and regulatory inspection(s)  by [CONTACT_347061]. In the event of an audit, the Investigator or Sub -Investigator 
agrees to allow the sponsor  representatives of the sponsor , the FDA, or other regulatory agency 
access to all study records.  
The Investigator s hould promptly notify the sponsor  and the appointed CRO of any audits 
scheduled by [CONTACT_11781][INVESTIGATOR_346976] .  
NuTide:302                                                                                                                        Version 4.2, 10 Aug 2022 
 
Confidentia l                                                            NuCana  plc 151 16 PUBLICATION POLICY  
An ICH E3 -compliant CSR will be generated based on t he final data listings of this study . The 
final CSR will be submitted to Regulatory Authorities and IRBs/ECs in accordance with the 
stipulated timelines.  
16.1 Communication of Results by [CONTACT_347062].gov, the 
European Clinical Trials Database (EudraCT) and any other applicable public registries in 
accordance with local laws and regulations.  
Final study results may be submitted to ClinicalTrials.gov within one year of the primary 
completion date, which is defined as ‘the date that the final patient was examined or received 
an intervention for the purposes of final collection of data for the primary outcome, whether 
the clinical stud y concluded according to the pre -specified protocol or was terminated’ . Final 
study results may be posted to EudraCT within one year of the end of study .  
16.[ADDRESS_431231] contribution of 
evaluable patients to the study . Publication of study results may also be described in the 
agreement between the sponsor  and each Institution . In addition, the Sponsor  may form a 
publication committee to evaluate and give final approval of publication submission.  
The proposed publication (manuscript, abstract or poster) or presentation will be provided to 
the sponsor  by [CONTACT_347063] 60 d ays prior to the planned 
submission . The Investigator understands and agrees that participation in the study may involve 
a commitment to publish the study results in a cooperative publication with other Investigators . 
No publication of confidential informa tion shall be made without the sponsor ’s prior written 
approval .  
The Investigator agrees, upon sponsor ’s request, to delete any confidential information that 
may impact intellectual property protection from the proposed publication . Investigators will 
comply with recognis ed ethical publications and authorship standards, including Section II of 
the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work 
in Medical Journals  (http://www.icmje.org/icmje -recommendations.pdf ). 
  
NuTide:[ADDRESS_431232] c                                                             Confidential  152 17 REFERENCES  
Adjei AA.  A review of the pharmacology and clinical activity of new chemotherapy agents 
for the treatment of colorectal cancer.  J Clin Pharmacol  1999; 48:265 -277. 
Baek JH et al .  Unpredicted severe toxicity after 5 -fluorour acil treatment due to 
dihydropyrimidine dehydrogenase deficiency.  Korean J Intern Med  2006; 21:43 -45. 
Beck A et al.  A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour 
sensitivity to fluorouracil. Eur J Cancer  1994; 30A:1517 -1522. 
Bennouna J et al ; ML18147 Study Investigators. Continuation  of bevacizumab  after first 
progression in metastatic colorectal cancer  (ML18147): a randomised phase 3 trial. Lancet 
Oncol  2013;  14:29 -37. 
Bronckaers A et al .  The dual role of thymidine phosphorylase in cancer development and 
chemotherapy.  Med Res Rev  2009; 29:903 –953. 
Brutcher E et al. 5-Fluorouracil and capecitabine: Assessment and treatment of uncommon 
early -onset severe toxicities associated with adminis tration. Clin J Oncol Nurs  2018; 22:627 -
634. 
Chau I et al. A rand omised comparison between 6 months of bolus fluorouracil/leucovorin and 
12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer. 
Ann Oncol  2005; 16:549 -557. 
Chiara S et al .  Hand -foot syndrome induced by [CONTACT_5019] -dose, short term, continuous 5 -
fluorouracil infusion. Eur J Cancer  1997; 33:967 -969. 
Coveler AL, et al. NuTide:302: A phase Ib study of NUC -[ADDRESS_431233] 
therapi[INVESTIGATOR_346977]/met astatic colorectal cancer.  J Clin Oncol 2021; 39 (suppl 3): Poster 93.  
Deyme L et al.  Population pharmacokinetic model of irinotecan and its four main metabolites 
in patients treated with FOLFIRI or FOLFIRINOX regimen. Canc  Chemother  Pharmacol  
2021 ; 88:247–258. 
Diasio RB & Harris BE.  Clinical pharmacology of 5 -fluorouracil.  Clin Pharmacokinet 1999 , 
16: 215 –237. 
Deboever G et al .  Alternative treatment options in colorectal cancer patients with 5 -
fluorouracil - or capecitabine -induced cardiotoxicity.  Clin Colorectal Cancer  2013, 12: 8 –14. 
Eisenhauer EA et al . New response evaluation criteria in solid tumors: revised RECIST 
guidel ine (version 1.1) . Eur J Cancer  2009;  45: 228–247. 
EMA. G uideline on strategies to identify and mitigate risks for first -in-human and early clinical 
trials with investigational medicinal products . EMEA/CHMP/SWP/[ZIP_CODE]/07 Rev. 1 , EMA 01 
Feb 2018. Etienne MC et al.  Response to fluorouracil therapy in cancer patients: the role of 
tumoral dihydropyrimidine dehydrogenase activity.  J Clin Oncol  1995; 13:1663 -1670.  
Giantonio BJ  et al ; Eastern Cooperative Oncology  Group Study E3200. bevacizumab  in 
combination with oxaliplatin, fluorouracil,  and leucovorin (FOLFOX4) for previously treated 
metastatic colorectal cancer:  results from the Eastern Cooperative Oncology Group Study 
E3200. J Clin Oncol  2007;  25:1539 -1544.  
Goldberg RM et al .  Randomized c ontrolled trial of reduced -dose bolus fluorouracil plus 
leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients 
with previously untreated metastatic colorectal cancer: a North American Intergroup Trial.  J 
Clin Oncol  2006;24: 3347 -3353.  
NuTide:[ADDRESS_431234]  1996; 88:668 -674. 
Henricks LM et al.  DPYD genotype -guided dose individualisation of fluoro pyrimidine therapy 
in patients with cancer: a prospective safety analysis.  Lancet Oncol . 2018; 19:1459 -1467.  
Huang S et al .  Mycoplasma infections and different human carcinomas.  World J 
Gastroenterol  2001, 7: 266 –269. 
Ikoma N et al. An update on randomized clinical trials in metastatic colorectal carcinoma. Surg 
Oncol Clin N Am  2017; 26:[ADDRESS_431235] 5 -FU toxicity: the ultimate proof. J Natl Cancer Inst  
2014;106.  
Ishikawa Y et al.  Dihydropyrimidine dehydrogenase activity and messenger RNA level may 
be related to the antitumor effect of 5 -fluorouracil on human tumor xenografts in nude mice.  
Clin Cancer Res  1999; 5:883 -889. 
Jensen SA & Sorensen JB. Risk factors and prevention of cardiotoxicity induced  by 5 -
fluorouracil or capecitabine. Cancer Chemother Pharmacol  2006, 58: 487 –493. 
Jetté L et al.  Resistance of colorectal cancer cells to [ADDRESS_431236] and 5 -FU caused by [CONTACT_347064].  Anticancer Res  2008, 28: 2175 –2180. 
Jiang W et al .  Dihydropyrimidin e dehydrogenase activity in hepatocellular carcinoma: 
implication for fluorouracil -based chemotherapy.  Clin Cancer Res  1997; 3:395 -399. 
Komori S et al.  Predictive value of orotate phosphoribosyltransferase in colorectal cancer 
patients receiving 5 ‑FU‑based chemotherapy.  Mol Clin Oncol  2013, 1: 453 –460. 
Kwakman JJM et al. Management of cytotoxic chemotherapy -induced hand -foot syndrome. 
Oncol Rev  2020; 14:442.  
Lee JJ & Sun W. Options for second -line treatment in metastatic colorectal cancer. Clin Adv 
Hemat and Oncol  2016; 14.  
Liekens S et al .  Improvement of purine and pyrimidine antimetabolite -based anticancer 
treatment by [CONTACT_347065] -encoded catabolic enzymes.  Lancet Oncol  
2009 ; 10:628 –635. 
Lindskog E et al.  Thymidine phosphorylase expression is associated with time to progression 
in patients with metastatic colorectal cancer. BMC Clin Pathol  2014; 14: 25.  
Longley  DB et al. 5-fluorour acil: mechanisms of action and clinical strategies. Nat Rev Cancer 
2003, 3: 330 –338. 
Longley  DB & Johnston PG. Molecular mechanisms of drug resistance. J Pathol 2005 , 205: 
275–292. 
Ma H et al . Efficacy and safety of bevacizumab -based maintenance therapy in  metastatic 
colorectal cancer. Medicine  2019; 98:50.  
Mattison LK et al . Rapid identification of dihydropyrimidine dehydrogenase deficiency by 
[CONTACT_2329] a novel [ADDRESS_431237]. Clin Cancer Res  2004; 10:[ADDRESS_431238] successfully 
deliver the preformed bioactive monophosphate in cells and confer advantage over the parent 
nucleoside. J Med Chem 2011, 27: 7247 –7258.  
NuTide:[ADDRESS_431239] c                                                             Confidential  154 Meta Analysis Group in Cancer. Toxicity of fluorouracil in patients with advanced colorectal 
cancer: effect of administration schedule and pro gnostic factors. J Clin Oncol  1998; 16:3537 -
3541.  
MHRA Guidance: Managing clinical trials during coronavirus (COVID -19). March 2021. 
Available from: https://www.gov.uk/guidance/managing -clinical -trials -during -coronavirus -
covid -19 
Nikolaou V et al.  Inciden ce and implications of chemotherapy related hand foot syndrome.  
Expert  Opin Drug Saf 2016; 15:[ADDRESS_431240] 20 years. World J Gastroenterol  2014; 20: 9775 –9827. 
Pi[INVESTIGATOR_156633] G et al. Pyrimidine analogs. Holland -Frei Cancer Medicine . 6th edition. 2003.  
Ragnhammar P et al.  A systematic overview of chemotherapy effects in colorectal cancer.  
Acta Oncol  2001;40: [ADDRESS_431241] low gene expression 
levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine 
phosphorylase. Clin Cancer Res  2000, 6: 1322 –1327.  
Sayre RS et al. Accidental and experimentally induced 5 -fluorouracil toxicity in dogs. J Vet 
Emerg Crit Care 2012 , 22:545 –9. 
Scherf U et al. A gene expression database for the molecular pharmacology of cancer. Nat 
Genet 2000; 24:236 -244. 
Soong R et al . Prognostic signif icance of thymidylate synthase, dihydropyrimidine 
dehydrogenase and thymidine phosphorylase protein expression in colorectal cancer patients 
treated with or without 5 -fluorouracil -based chemotherapy. Ann Oncol  2008; 19: 915 –919. 
Spector T et al. Attenuatio n of the antitumor activity of 5 -fluorouracil by (R) -5-fluoro -5,6-
dihydrouracil. Cancer Res 1995 , 55: 1239 –1241.  
Takebe N et al. Retroviral transduction of human dihydropyrimidine dehydrogenase cDNA 
confers resistance to 5 -fluorouracil in murine hematopoie tic progenitor cells and human 
CD34+ - enriched peripheral blood progenitor cells. Cancer Gene Ther  2001, 8: 966 –973. 
Tsutani Y et al.  Decreased orotate phosphoribosyltransferase activity produces 5 -fluorouracil 
resistance in a human gastric cancer cell li ne.  Oncol Rep  2008, 20:1545 -1551.  
Vande Voorde J et al.  The cytostatic activity of NUC -3073, a phosphoramidate prodrug of 5 -
fluoro -2'-deoxyuridine, is independent of activation by [CONTACT_347066].  Biochem Pharmacol 2011, 82:441 –452. 
Woosley, RL and Romero, KA,  www.Crediblemeds.org , QT drugs List, [Accessed August  
2022], AZCERT, Inc. [ADDRESS_431242]., Oro Valley, AZ   [ZIP_CODE], [LOCATION_003].  
Yamashita K et al.  Neurotoxic effects of alpha -fluoro -beta-alanine (FBAL) and fluoroacetic 
acid (FA) on dogs.  J Toxicol Sci 2004 , 29: 155 –66. 
  
NuTide:302                                                                                                                        Version 4.2, 10 Aug 2022 
 
Confidentia l                                                            NuCana  plc 155 18 APPENDICES  
APPENDIX  1. RESPONSE EVALUATION CRITERIA IN SOLID 
TUMO URS (RECIST) VERSION 1.[ADDRESS_431243] criteria ( v1.1). The complete 
criteria are available at http://www.eortc.be/RECIST  and are included in the published RECIST 
document:  
Eisenhauer et al. New response evaluation criteria in solid tumour s: revised RECIST guideline 
(version 1.1) . Eur J Cancer  2009;  45: 228–247. 
 
Measurability of Tumo ur Lesions at Baseline  – Definitions  
Measurable disease  – the presence of at least one measurable lesion. If the measurable disease 
is restricted to a solitary lesion, its neoplastic nature should be confirmed by 
[CONTACT_3973]/histology.  
Measurable lesions  – tumo ur lesions  that can be accurately measured in at leas t one dimension 
(longest  diameter to be recorded) as ≥[ADDRESS_431244] x -ray, and as ≥[ADDRESS_431245] scan or 
clinical examination [using callipers] . Bone lesions are considered measurable only if assessed 
by [CONTACT_347067] (soft 
tissue component ≥[ADDRESS_431246] scan) . Malignant lymph nodes  must be ≥15 mm in the short  
axis to be considered measurable; only the short axis will be measured and followed . All 
tumo ur measurements must be  recorded in millimetres  (or decimal fractions of centimetres ) by 
[CONTACT_2363] a ruler or callipers. Tumo ur lesions situated in a previously irradiated area, or in an area 
subjected to other loco -regional therapy, are usually not considered measurable unless the re 
has been demonstrated progression in the lesion.  
Non-measurable lesions  – all other lesions (or sites of disease), including small lesions are 
considered non -measurable disease . Bone lesions without a measurable soft tissue component, 
leptomeningeal dis ease, ascites, pleural/pericardial effusions, lymphangitis cutis/pulmonis, 
inflammatory breast disease, lymphangitic involvement of lung or skin and abdominal masses 
followed by [CONTACT_347068] -measurable. Nodes that have a short axis <10 mm 
at baseline are considered non -pathological and should not be recorded or followed.  
Target lesions – when more than one measurable tumo ur lesion or malignant lymph node is 
present at baseline all lesions up to a maximum of 5  lesions total  (and a maximum  of 2 lesions 
per organ ) representative of all involved organs should be identified as target lesions and will 
be recorded and measured at baseline. Target lesions should be selected on the basis of their 
size (lesions with the longest diameter), be repres entative of all involved organs, but in addition 
should be those that lend themselves to reproducible repeated measurements . Note that 
pathological nodes must meet the criterion of a short axis of ≥[ADDRESS_431247] scan and only the 
short  axis of these nodes wi ll contribute to the baseline sum .  
At baseline, the sum of the target lesions (longest diameter of tumo ur lesions plus short axis of 
lymph nodes: overall maximum of 5) is to be calculated and recorded.  
Non-target lesions  – all non -measurable lesions (or s ites of disease) including pathological 
nodes (those with short axis ≥10 mm but <15 mm), plus any measurable lesions over and above 
those listed as target lesions are considered  non-target lesions . Measurements are not required 
but these lesions should be noted at baseline and should be followed as “present” or “absent”.  
NuTide:[ADDRESS_431248] 
their actual measurements recorded on the CRF at each subsequent evaluation, even when very 
small ( e.g., 2 mm) . If it is the opi[INVESTIGATOR_1101] t he radiologist that the lesion has likely disappeared, 
the measurement should be recorded as 0 mm . If the lesion is believed to be present and is 
faintly seen but too small to measure, a default value of 5 mm should be assigned . For lesions 
which fragment/ split add together the longest diameters of the fragmented portions; for lesions 
which coalesce, measure the maximal longest diameter for the “merged lesion”.  
Clinical lesions  – clinical lesions will only be considered measurable when they are superficial 
and ≥10 mm as assessed using callipers ( e.g., skin nodules) . For the case of skin lesions, 
documentation by [CONTACT_347069] a ruler to estimate the size of the lesion is 
recommended. If feasible, imaging is preferred.  
Chest X -ray – chest CT is  preferred over chest X -ray, particularly when progression is an 
important endpoint, since CT is more sensitive than X -ray, particularly in identifying new 
lesions . However, lesions ≥[ADDRESS_431249], MRI  – CT is the best currently available and reproducible method to measure lesions 
selected for response assessment. This guideline has defined measurability of lesions on CT 
scan based on the assumption that CT sl ice thickness is [ADDRESS_431250] 
slice thickness greater than 5 mm, the minimum size for a measurable lesion should be twice 
the slice thickness. MRI is also acceptable in certain situations ( e.g., for body scans) . While 
PET scans are not considered adequate to measure lesions, PET -CT scans may be used 
providing that the measures are obtained from the CT scan and the CT scan is of identical 
diagnostic quality to a diagnostic CT (with IV and oral contrast).  
Ultrasound  – ultrasound is not use ful in assessment of lesion size and should not be used as a 
method of measurement. If new lesions are identified by [CONTACT_12153], 
confirmation by [CONTACT_347070].  
Endoscopy, Laparoscopy  – the utilis ation of these techniques for objective tumo ur evaluation 
is not advised . However, they can be useful to confirm complete pathological response when 
biopsies are obtained or to determine relapse in studies where recurrence following complete 
response or surgical resectio n is an endpoint.  
Tumo ur markers  – tumo ur markers alone  cannot be used to assess objective tumo ur response . 
If markers are initially above the upper normal limit, however, they must normal ise for a patient 
to be considered in complete response.  
Cytology, H istology  – these techniques can be used to differentiate between PR and CR in rare 
cases if required by [CONTACT_990] (for example, residual lesions in tumo ur types such as germ cell 
tumo urs, where known residual benign tumo urs can remain) . When effusions are k nown to be 
a potential adverse effect of treatment ( e.g. with certain taxane compounds or angiogenesis 
inhibitors), the cytological confirmation of the neoplastic origin of any effusion that appears or 
worsens during treatment when the measurable tumo ur has met criteria for response or stable 
disease is advised to differentiate between response or stable disease and progressive disease.  
NuTide:[ADDRESS_431251] 4 weeks later . Refer to the Appendix 1 , 
Tables 1 and 2 below.  
Complete Response (CR)  – disappearance of all target  and non-target  lesions and 
normalis ation of tumo ur markers. Pathological lymph nodes must have short axis measures 
<10 mm ( Note : continue to record the measurement even if <10 mm and considered CR). 
Tumour markers must have n ormalis ed. Residual lesions (other than nodes <10 mm) thought 
to be non -malignant should be further investigated (by [CONTACT_347071]) before CR can 
be accepted.  
Partial Response (PR)  – at least a 30% decrease in the sum of measures (longest diameter  for 
tumo ur lesions and short axis measure for nodes) of target lesions, taking as reference the 
baseline sum of diameters . Non-target lesions must be non -PD.  
Stable Disease (SD) – neither sufficient shrinkage to qualify for PR nor sufficient increase to 
qualify for PD taking as reference the smallest sum of diameters on study.  
Progressive Disease (PD) – at least a 20% increase in the sum of diameters of measured lesions 
taking as references the smallest sum of diameters recorded on study (including baseli ne) AND 
an absolute increase of ≥5 mm . Appearance of new lesions will also constitute PD (including 
lesions in previously unassessed areas) . In exceptional circumstances, unequivocal progression 
of non -target disease may be accepted as evidence of disease progression, where the overall 
tumo ur burden has increased sufficiently to merit discontinuation of treatment, for example 
where the tumo ur burden appears to have increased by [CONTACT_2669] 73% in volume (which is the 
increase in volume when all dimensi ons of a single lesion increase by 20%) . Modest increases 
in the size of one or more non -target lesions are NOT considered unequivocal progression. If 
the evidence of PD is equivocal (target or non -target), treatment may continue until the next 
assessment,  but on further documentation, the earlier date must be used.  
  
NuTide:[ADDRESS_431252] Response for this 
Category Also Requires  
Patients with target lesions ± non -target lesions  
CR CR No CR Normali sation of tumo ur 
markers  
All tumo ur nodes <[ADDRESS_431253] once 
≥4 weeks from baseline  
CR Non-CR/Non -PD No PR 
Documented at least once 
≥4 weeks from baseline  CR Not all evaluated  No PR 
PR Non-PD/ not all evaluated  No PR 
SD Non-PD/ not all evaluated  No SD  
Not all 
evaluated  Non-PD No NE  
PD Any Any PD  
Any PD Any PD  
Any Any Yes PD  
Note : Patients with a global deterioration of health status requiring discontinuation of treatment 
without objective evidence of disease progression (or evidence of unequivocal disease progression) 
at that time should be reported as “ symptomatic deterioration” . This is a reason for stoppi[INVESTIGATOR_7374], 
but is NOT objective PD . Every effort should be made to document the objective progression even 
after discontinuation of treatment.  
 
Complete or partial responses may be claimed only if the criteria for each are met at a 
subsequent time point at least [ADDRESS_431254] overall response can be interpreted from 
Appendix 1 Table 2  on the next page . 
  
NuTide:302                                                                                                                        Version 4.2, 10 Aug 2022 
 
Confidentia l                                                            NuCana  plc 159 Appendix 1.  Table  2.  Response Assessment after Subsequent Scan  
Response: First 
Time Point  Subsequent 
Time Point  BEST Overall Response  Also Requires  
CR CR CR Normalis ation of tumo ur 
markers . All tumo ur nodes 
<10 mm.  
CR PR SD, PD or PR (see comment*)   
CR SD SD provided minimum criteria for SD 
duration met, otherwise, PD   
CR PD SD provided minimum criteria for SD 
duration met, otherwise, PD   
CR NE SD provided minimum criteria for SD 
duration met, otherwise NE   
PR CR PR  
PR PR PR  
PR SD SD  
PR PD SD provided minimum criteria for SD 
duration met, otherwise, PD   
PR NE SD provided minimum criteria for SD 
duration met, otherwise NE   
NE NE NE  
* may consider PR providing initial “CR” likely PR on subsequent review – then original CR should be 
corrected . Recurrence of lesion after true CR is PD.  
 
Frequency of Tumo ur Re-Evaluation  
Tumo urs should be assessed at the end of every 2nd cycle.  
Date of Progression  
This is defined as the first day when the RECIST ( v1.1) criteria for PD are met.  
Reporting of Tumo ur Response  
All patients included in the study must be assessed for response to treatment, even if there is a 
major protocol treatment deviation or if they are ineligible, or not followed/re -evaluated . Each 
patient will be assigned one of the following categories: complete response, partial response, 
stable disease, progressive disease, early death from malignant disease, early death from 
toxicity, early death from other cause or unknown (not assessable, insufficient data).  
‘Early death’ is defined as any death occurring before the first per protocol time point of tumo ur 
re-evaluation. The responsible Investigator  will decide if the cause of death is malignant 
disease, toxicity or other cause . Patients for whom response is not confirmed will be classified 
as "unknown", unless they meet the criteria for stable disease (or the criteria for partial response 
in case of an unconfirmed complete response) . Patients’ response will also be classified as 
"unknown" if insufficient data were collected to allow evaluation per these criteria.  
NuTide:[ADDRESS_431255] c                                                             Confidential  160 APPENDIX  2. ECOG PERFORMANCE SCALE  
 
Activity Performance Description  Score  
Fully active, able to carry out all on all pre -disease performance without 
restriction  0 
  
Restricted in physically strenuous activity but ambulatory and able to carry out work 
of a light or sedentary nature, e.g. light housework,  office work  1 
  
Ambulatory and capable of all self -care, but unable to carry out any work activities   
Up and abou t more than 50% of waking hours   2 
  
Capable of only limited self -care 
Confined to bed or chair  more than 50% of waking hours  3 
  
Completely disabled  
Cannot carry out any self -care 
Totally confined to bed or chair  4 
  
Dead  5 
 
  
NuTide:302                                                                                                                        Version 4.2, 10 Aug 2022 
 
Confidentia l                                                            NuCana  plc 161 APPENDIX  3. CONCOMITANT MEDICATIONS THAT MAY 
PROLONG QT c INTERVAL  
Medications with a known risk of torsade de pointes ( i.e., significant evidence they cause QT 
prolongation and are associated with a risk of causing torsade de pointes) are listed below.  
 
Appendix 3.  Table  1: Drugs known to prolong QT/QTc interval  
Generic Name  [CONTACT_342928] (Partial List)  
Aclarubicin (only on non -US market)  Aclacin®, Aclacinomycine®, Aclacinon®, Aclaplastin®, Jaclacin® 
Amiodarone  Cordarone®, Pacerone®, Nexterone® 
Anagrelide  Agrylin®, Xagrid® 
Arsenic trioxide  Trisenox® 
Astemizole (removed from market)  Hismanal® 
Azithromycin  Zithromax®, Zmax® 
Bepridil  Vascor® 
Cesium chloride  Energy catalyst  
Chloroquine  Aralen® 
Chlorpromazine  Thorazine®, Largactil®, Megaphen® 
Chlorprothixene (only on non -US 
market)  Truxal® 
Cilostazol  Pletal® 
Ciprofloxacin  Cipro®, Cipro -XR®, Neofloxin® 
Cisapride (removed from market)  Propulsid® 
Citalopram  Celexa®, Cipramil® 
Clarithromycin  Biaxin®, Prevpac® 
Cocaine  Cocaine  
Disopyramide  Norpace® 
Dofetilide  Tikosyn® 
Domperidone (only on non -US market)  Motilium®, Motillium®, Motinorm Costi®, Nomit® 
Donepezil  Aricept® 
Dronedarone  Multaq® 
Droperidol  Inapsine®, Droleptan®, Dridol®, Xomolix® 
Erythromycin  E.E.S.®, Robimycin®, EMycin®, Erymax®, Ery -Tab®, Eryc 
Ranbaxy®, Erypar®, Eryped®, Erythrocin Stearate Filmtab®, 
Erythrocot®, E-Base®, Erythroped®, Ilosone®, MY -E®, 
Pediamycin®, Zineryt®, Abboticin®, Abboticin -ES®, Erycin®, PCE 
Dispertab®, Stiemycine®, Acnasol®, Tiloryth® 
Escitalopram  Cipralex®, Lexapro®, Nexito®, Anxiset -E® (India), Exodus® 
(Brazil), Esto® (Israel), Seroplex®, Elicea®, Lexamil®, Lexam®, 
Entact® (Greece), Losita® (Bangladesh), Reposil® (Chile), 
Animaxen® (Colombia), Esitalo® (Australia), Lexamil® (South 
Africa)  
Flecainide  Tambocor®, Almarytm®, Apocard®, Ecrinal®, Flécaine® 
Fluconazole  Diflucan®, Trican® 
Gatifloxacin (removed from US 
market)  Tequin® 
NuTide:[ADDRESS_431256] c                                                             Confidential  162 Generic Name  [CONTACT_342928] (Partial List)  
Grepafloxacin  (removed from US 
market)  Raxar® 
Halofantrine  (only on non -US market)  Halfan® 
Haloperidol  Haldol® (US & [LOCATION_006]), Aloperidin®, Bioperidolo®, Brotopon®, 
Dozic®, Duraperidol® ([LOCATION_013]), Einalon S®, Eukystol®, 
Halosten®, Keselan®, Linton®, Peluces®, Serenace®, Serenase®, 
Sigaperidol® 
Hydoquinidine (Dihydroquinidine) 
(only on non -US market)  Serecor® 
Hydroxychloroquine  Plaquenil®, Quineprox® 
Ibogaine (only on non -US market)  None  
Ibutilide  Corvert® 
Levofloxacin  Levaquin®, Tavanic® 
Levomepromazine (only on non -US 
market)  Nosinan®, Nozinan®, Levoprome® 
Levomethadyl  acetate  (removed from 
US market)  Orlaam® 
Levosulpi[INVESTIGATOR_14956] (only on non -US market)  Lesuride®, Levazeo®, Enliva® (with rabeprazole)  
Meglumine antimoniate (only on non -
US market)  Glucantime® 
Mesoridazine (removed from US 
market)  Serentil® 
Methadone  Dolophine®, Symoron®, Amidone®, Methadose®, Physeptone®, 
Heptadon® 
Mobocertinib  Exkivity® 
Moxifloxacin  Avelox®, Avalox®, Avelon® 
Nifekalant (only on non -US market)  Shinbit® 
Ondansetron  Zofran®, Anset®, Ondemet®, Zuplenz®, Emetron®, Ondavell®, 
Emeset®, Ondisolv®, Setronax® 
Oxaliplatin * Eloxatin® 
Papaverine HCl  (intra -coronary)  None  
Pentamidine  Pentam® 
Pi[INVESTIGATOR_31930]® 
Probucol (removed from market)  Lorelco® 
Procainamide  Pronestyl®, Procan® 
Propofol  Diprivan®,  Propoven® 
Quinidine  Quinaglute®, Duraquin®, Quinact®, Quinidex®, Cin -Quin®, 
Quinora® 
Roxithromycin (only on non -US 
market)  Rulide®, Xthrocin®, Roxl -150®, Roxo®, Surlid®, Rulide®, 
Biaxsig®, Roxar®, Roximycinv®, Roxomycin®, Rulid®, Tirabicin®, 
Coroxin®  
Sertindole (only on non -US market)  Serdolect®, Serlect® 
Sevoflurane  Ulane®, Sojourn® 
Sotalol  Betapace®, Sotalex®, Sotacor® 
NuTide:302                                                                                                                        Version 4.2, 10 Aug 2022 
 
Confidentia l                                                            NuCana  plc 163 Generic Name  [CONTACT_342928] (Partial List)  
Sparfloxacin (removed from US 
market)  Zagam® 
Sulpi[INVESTIGATOR_14956] (only on non-US market)  Dogmatil®, Dolmatil®, Eglonyl®, Espi[INVESTIGATOR_14956]®, Modal®, Sulpor® 
Sultopride (only on non-US market)  Barnetil®, Barnotil®, Topral® 
 
Terfenadine (removed from US market)  Seldane® 
Terlipressin (only on non -US market)  
 Teripress®, Glypressin®, Terlipin®, Remestyp®, Tresil®, Teriss® 
and others  
 
Terodiline (only on non -US market)  Micturin®, Mictrol® (not bethanechol)  
 
Thioridazine  Mellaril®, Novoridazine®, Thioril® 
Vandetanib  Caprelsa® 
* Except as included in the specific arms and dosing regimens of this study . 
Note:  Medicines on this list are reviewed on an ongoing basis to assure that the available evidence supports their 
continued placement on this list. The list changes regularly and we recommend checking the website at 
crediblemeds.org for the most up -to-date inf ormation. There may be many additional brand names that are not 
listed on this table.  
 
If clinically relevant or urgent medical intervention is required with a drug known to  prolong 
the QT/QTc interval, study treatment must be paused and options for re -starting the study drugs 
should be discussed with the Medical Monitor.  
 
Disclaimer and Waiver:  The information presented is intended solely for the purpose of 
providing general information about health -related matters. It is not intended for any other 
purpose, including but not limited to medical advice and/or treatment, nor is it intended to 
subst itute for the users’ relationships with their own health care providers. To that extent, by 
[CONTACT_347072], the user affirms the understanding of the 
purpose and releases AZCERT, Inc. from any claims arising out of his/ her use of the website 
and its lists. The absence of drugs from these lists should not be considered an indication that 
they are free of risk of QT prolongation or torsades de pointes. Many medicines have not been 
tested for this risk in patients, especial ly those with congenital long QT syndrome.  
Woosley, RL and Romero, KA,  www.Crediblemeds.org , QT drugs List, [Accessed August  
2022], AZCERT, Inc. [ADDRESS_431257]., Oro Valley, AZ   [ZIP_CODE], [LOCATION_003].  
See more at:  https://www.crediblemeds.org/#sthash.vzyRSgay.dpuf   
  
  
NuTide:[ADDRESS_431258] often leads to 
delay in treatment, dose reduction or discontinuation of treatment.  There is a small but 
significant mortality associated with chemotherapy -induced diarrhoea (CID), especially when 
it occurs concomitantly with mucositis and neutropaenia.  
Classification  
Chemotherapy -induced diarrhoea is graded using the NCI criteria (Appendix 4 Table 1 ) which 
grades diarrhoea on a scale of 0 (normal) to 4 (severe) according to the number of loose 
stools/days, presence of nocturnal stools, incontinence, crampi[INVESTIGATOR_346978] i n stools.  
Appendix 4 Table 1.  NCI criteria for assessment of chemotherapy -induced diarrhoea  
Criteria  GRADE  
0 1 2 3 4 
Number  of 
stools  per day Normal  2–3 4-6 7-9 >10 
Symptom  - - Nocturnal stools  Incontinence  Bloody stool  
- - Moderate 
crampi[INVESTIGATOR_346979] a serious complication and requires prompt assessment. The steps in this 
assessment are as follows:  
1. Rule out other or concomitant causes of diarrhoea  
Other causes of diarrhoea must be ruled out.  These include medications (e.g. stool softeners, 
laxatives, antacids, etc), infection by C. difficile or Candida species, partial bowel obstruction, 
malabsorption, faecal  impaction, acute radiation reaction and  surgery (short bowel syndrome).   
Diets high in fibre  or lactose may aggravate diarrhoea.  
 
2. Dietary modifications during diarrohea  
Mild diarrhoea may be managed with diet to decrease the frequency of stools.  Patients should 
be advised to increase intak e of clear fluids ( e.g., water, sports drinks, broth, gelatin, clear 
juices, decaffeinated tea, caffeine -free soft drinks).  A BRAT (banana, rice, apples, toast) diet 
can be helpful.  
 
3. Medications  
• Loperamide  
Loperamide is indicated for Grade 1 diarrhoea that persists for more than 12 -24 hours 
or for moderate diarrhoea (Grade 2).  The standard dose of loperamide is 4 mg followed 
by 2 mg every 4 hours or after each unformed stool (maximum dose 16 mg/day).    Thi s 
dose may be increased in patients with mild to moderate diarrhoea (Grade 1 or 2) that  
NuTide:302                                                                                                                        Version 4.2, 10 Aug 2022 
 
Confidentia l                                                            NuCana  plc 165  
• persists for more than 24 hours.   The dose is 4 mg to start, followed by 2 mg every 2 
hours (or 4 mg every 4 hours at night to allow sleep). Loperamide should be con tinued 
for 12 hours following resolution of the diarrhoea and re -establishment of a normal diet.  
High -dose loperamide (4 mg followed by 2 mg every 2 hours) is also recommended at 
the onset of any diarrhoea in patients receiving irinotecan chemotherapy.  
• Atrophine -diphenoxylate  
At the discretion of the treating physician, it may be useful to add atropi[INVESTIGATOR_050] - 
diphenoxylate 1 to 2 tablets, every 6 -8 hours, to loperamide therapy for Grade 1 or 2 
diarrhoea.  It should not be expected that this would be sufficient f or the management 
of Grade 3 or 4 diarrhoea.  
 
• Octreotide  
For Grades 1 and 2 diarrhoea lasting more than 24 hours despi[INVESTIGATOR_287] -dose loperamide 
+ atrophine -diphenoxylate, octreotide 100 -150 mcg SC TID may be considered.  For 
Grades 3 and 4 diarrhoea, octreot ide 150 mcg SC TID is indicated; these pat ients 
usually require hospi[INVESTIGATOR_11956]. If there is no improvement in the diarrhoea after 24 
hours, the dose of octreotide should be increased to 300 -500 mcg SC TID. The duration 
of octreotid e therapy should be indi vidualis ed, but can be discontinued 24 hours after 
the end of diarrhoea and re -establishment of a normal diet.  Alternatively, octreotide 
may be administered  via a syring e driver with infusion over 24 hours of 600 mcg 
octreotide. If not controlled each day,  increase  the dose to 1200  mcg, then 1800  mcg, 
then 2400 mcg, but not beyond this daily dose. If diarrhoea is controlled , then octreotide 
can be de-escalate d. 
 
• Antibiotics  
In the presence of concomitant neutropaenia (granulocytes <1× 106/L), antibiotics ( e.g., 
ciprofloxacin 500 mg BID) should be considered until resolution of diarrhoea and 
recovery of the granulocyte counts.  In addition, o ral antibiotics (minocycline, 
doxycycline, or antibiotics covering skin flora) should be given to prevent or treat 
EGFR  inhibitor -related rash . 
 
Avoid the use of diuretics, laxatives and other agents know to exacerbate diarrhoea.  
 
 
 
